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Abstract
Voltage-dependent calcium channel (VDCC) y -subunits were first 
identified by their co-purification with VDCC ai-subunits from skeletal muscle. 
Since then a further seven y-subunits have been identified by their homology to 
y1 . Their role however is not limited to interaction with VDCCs. The second y- 
subunit identified, y2 (also known as Stargazin), along with y3, y4 and y8 have 
been shown to be involved in regulation of a-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid (AMPA) receptor trafficking. Also, recent work has 
shown that expression of the VDCC ai subunit, Cav2.2, is reduced when it is 
co-transfected with y7. The objectives of this study were to investigate the 
mechanism by which this reduction of Cav2.2 expression takes place and 
identify the role of y7.
Several truncated y7 subunits were made to examine if potential 
endoplasmic reticulum (ER) retention motifs, present in the C-terminal region of 
y7, are involved in the reduction of Cav2.2 expression. Truncation of y7 from 
Y217 (including both potential ER retention (RXR) motifs) did not alter its 
distribution compared to full length y7, both being localised in the ER in 
transiently transfected COS7 cells. This suggests that these ER retention 
motifs are not critical in the effect of y7 on Cav2.2 expression. However, 
western blotting experiments, also using transiently transfected COS7 cells, 
show that the C-terminal region of y7 is necessary and sufficient for the 
reduction of Cav2.2 expression. This was confirmed electrophysiologically 
using a Xenopus oocyte overexpression system
To aid in the elucidation of its role binding partners for y7 were sought.
PC 12 cells, a rat pheochromocytoma cell line, were used a potential source of 
binding partners. RT-PCR and immunocytochemistry were used to show that 
y7 is endogenously expressed in PC12 cells. Immunoprecipitation of HA tagged
2
y7 from a stably transfected PC 12 cell line identified three ribonucleotide binding 
proteins as potential binding partners.
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Chapter 1 - Introduction
1.1. Excitable Cells and Action Potentials
Excitable cells are cells that respond regeneratively to a small change in 
membrane potential. They are essential in a range of roles from movement (in 
the case of muscle cells) to conscious thought (in the case of neurons). Key to 
the functions of excitable cells are changes in ion concentrations across the 
plasma membrane. I will begin by explaining how the resting membrane 
potential is maintained and how changes in ion concentration can generate 
action potentials.
1.1.1. The Resting Membrane Potential
All cells have a resting membrane potential due to a local imbalance of 
charge across the membrane. In neurons the resting membrane potential is 
between -50 and -80 mV. This is maintained by several factors, most important 
of which is the electrogenic sodium/potassium pump. This pump, at the 
expense of energy in the from of ATP, moves two potassium ions into the cell 
and three sodium ions out thus creating a net negative charge inside the cell. 
This leads to a high potassium concentration within the cell compared to outside 
([K+] inside =100 mM, [K+] outside = 5 mM). The reverse is true for sodium 
concentration ([Na+] inside = 15 mM, [Na+] outside =150  mM). Using the 
Nernst equation one can find the equilibrium potential for each ion, EK = -80 mV 
and ENa = 62 mV.
In the absence of the sodium/potassium pump, if the membrane was 
impermeable to both K+ and Na+ ions then there could be no movement of ions 
and thus no membrane potential. If the membrane was only permeable to Na+ 
then the membrane potential would be equal to ENa (62 mV). Likewise if the 
membrane was only permeable to K+ then the membrane potential would be -80 
mV. This suggests that the resting membrane potential is due to a combination 
of permeability of both ions with K+ being the major contributor. Using the 
Constant Field Equation (also known as the Goldman-Hodgkin-Katz equation), 
which takes into account the permeability of the membrane, one can calculate 
the membrane potential. If the membrane was equally permeable to both ions 
then Vm = 7.97 mV. However, if the membrane is taken to be 40 times more
20
permeable to K+ than Na+ then Vm is approximately equal to the observed value 
of -65 mV. This calculation however is an oversimplification. It can be 
improved by taking into account other ions (most notably calcium and chloride 
ions). Anionic proteins, a common constituent of cells, also affect the resting 
membrane potential.
1.1.2. The Action Potential
The changes in membrane potential during an action potential can 
roughly be split into 4 stages (shown in Fig. 1.1.). Firstly, after stimulation, there 
is the rising phase during which there is rapid depolarisation of the membrane. 
At the peak of this depolarisation the membrane potential reaches about + 40 
mV. The point at which the membrane potential is greater than 0 mV is known 
as the overshoot. The falling phase of the action potential is a rapid 
repolarisation, past the resting membrane potential, until the membrane is 
actually more negative than the resting potential. The stage at which the 
membrane potential is less than the resting potential is known as the 
undershoot. There is then a relatively slow return to the resting membrane 
potential. Overall the action potential from beginning to end takes about 2 
msec.
Na equilibrium 
potential
Resting
potential
K equilibrium potential
Time — *
Fig. 1.1. Changes in membrane potential at a single point during an action potential.
After stimulation the membrane depolarises (1, rising phase), reaches a peak (2, 
overshoot) and begins to repolarise (3, falling phase) passing, and then slowing 
returning to the resting membrane potential (4 undershoot). Adapted from Lodish et al 
(1).
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A series of experiments by Hodgkin and Huxley in the 1950’s showed 
that the ionic current flow through the axon membrane was largely accounted 
for by changes in its conductance to Na+ and K+ ions. They went on to propose 
a model of the action potential in which sites for ionic flow were opened as a 
result of membrane potential change (2-5). During the rising phase the inside of 
the membrane has a negative electrical potential with a large driving force on 
Na+ ions. Na+ ions enter the cell causing rapid depolarisation of the membrane. 
During the overshoot phase the relative permeability of the membrane favours 
sodium and the membrane potential goes close to ENa- During the falling phase 
the membrane permeability to sodium reduces and the permeability to 
potassium increases. K+ ions leave, causing the membrane potential to 
become negative again. During the undershoot phase the membrane potential 
moves towards EK. The membrane then becomes less permeable to K+ and, 
due to the action of the electrogenic sodium/potassium pump, the resting 
potential is restored. These changes in ion permeability during the action 
potential are shown in Fig. 1.2. The sites of ionic flow proposed by Hodgkin and 
Huxley have now been shown to be voltage-dependent ion channels (VDICs).
Fig. 1.2. Changes in Na and IC ion permeability during the action potential. A)
Changes in membrane potential during an action potential. B) Corresponding changes 
in Na+ and K+ permeability. After stimulation the cell membrane transiently becomes
permeability and increase in K+ permeability results in hyperpolarisation. Adapted from 
Lodish et al (1).
Na equilibrium 
potential
Resting
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more permeable to Na+ resulting in depolarisation. The subsequent reduction in Na+
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1.2. Voltage-Dependent Ion Channels
All VDICs serve similar functions and there is a high degree of similarity 
between their structures. Firstly they required a voltage senor to detect 
changes in the membrane potential. Upon detecting a change they need to 
open to allow ions to flow across the membrane. It is also vital that they contain 
a specificity filter to ensure that only the required ions can pass through.
Finally, when required, they need to return to a closed state to prevent further 
ions passing through. Here I will try to describe common features shared 
between VDICs
1.2.1. The Molecular Structure of the Voltage-Dependent Ion Channels
All VDICs cloned thus far have a similar structure. They can be thought 
of as consisting of two main parts. Firstly, the pore, through which the ions 
pass. Secondly, the voltage sensor, the movement of which results in opening 
or closing of the channel depending on the membrane potential. All VDICs 
contain twenty four transmembrane a-helices separated into four domains (Fig.
1.3.). The six transmembrane a-helices are known as S1-S6 in each domain. 
Voltage-dependant sodium and calcium ion channels are single polypeptides of 
around 2000 amino acids. However, in potassium channels each of the four 
domains (approximately 600 amino acid each) are independent and come 
together to form an active channel (6;7). Between the 5th and 6th 
transmembrane a-helices in each domain is a subdomain that lines the pore of 
the channel (8-10). This is termed as H5 or the P loop. The 4th transmembrane 
a-helix in each domain has multiple positively charged amino acids and is 
thought to function as the voltage sensor (Fig. 1.3.).
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Fig. 1.3. A diagrammatic representation o f voltage-dependent ion channels.
Transmembrane domains are shown in blue. The S4 domain, thought to be the voltage 
sensor is shown in green. The P-loop, believed to line the pore o f the channel is shown 
in red. Dashed lines represent the intracellular loops that connect the individual 
domains in voltage-dependent sodium and calcium channels. These are absent in 
voltage-dependent potassium channels.
Recent work by Jiang et a/ (11) determined the crystal structure of a 
voltage-dependent potassium channel from the archaebacterial Aeropyrum 
pemix (Fig. 1.4).
1.2.2. Channel Opening and the Voltage Sensor
Hodgkin and Huxley had previously predicted ‘some component of the 
membrane which behaves as though it had a large charge or dipole moment’ 
(2). The movement of which should generate a small current during the gating 
of the channel. Detection of these “gating currents” was achieved and has 
proven useful in testing models of voltage dependent ion channel function (12).
Upon the deduction of the primary structure of a voltage-dependent 
sodium channel from Electrophorus electricus, Noda et a /(13) suggested the 
possible importance of the highly positively charged S4 segment in detecting 
changes in membrane potential and gating of the channel. Site directed 
mutagenesis experiments, in which these positively charged amino acids were 
replaced, confirmed a relationship between these charges and the membrane 
potential at which the channels opened (14; 15).
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Fig. 1.4. A diagrammatic representation o f the voltage-dependent potassium channel.
A. Structure o f the KvAP channel (blue, yellow, cyan and red helical structures) bound 
to four Fab fragments (green), viewed down the four-fold axis from the intracellular 
side. B. A schematic diagram o f the KvAP subunit topology is shown with an orange 
selectivity filter and an arrow to indicate the ion pathway. Adapted from Jiang et al 
(11).
There is an energetic problem of moving charged amino acids through 
the low dielectric environment of the membrane lipid bilayer. The conventional 
model of how this occurs places the majority of S4 charges in the gating pore, a 
highly solvated aqueous environment, formed largely by S1-S3 segments 
peripherally and the pore domain centrally. The positive charges on the S4 
segment are paired with negative charges on the other segments. Upon 
depolarisation of the membrane the S4 segment moves outwards exposing 
positive charges to the outside of the membrane and negative charges to the 
inside. Thus, the S4 charges cross the membrane with minimal contact with the 
hydrophobic core of the bilayer.
With the determination of a crystal structure of a voltage-dependent 
potassium channel a new model of how the voltage sensor works was 
proposed. Jiang et al (11) found that each S4 segment formed half of a 
cationic, helix-turn-helix structure. These were termed 'voltage-sensor
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paddles'. They went on to show that these voltage-sensor paddles are 
positioned inside the membrane, near the intracellular surface when the 
channel is closed (Fig. 1.4.B). When the channel opens the paddles move a 
large distance across the membrane from inside to outside (16). However, the 
possible distortion of the channel during the crystallisation process has led to 
this model being questioned (17;18). The process of gating remains 
controversial and is much debated (19-22).
1.2.3. The Pore and Selectivity Filter
VDICs are required to be highly specific for the ions which they allow 
through. The pore-region of potassium channels was first defined with pore- 
blocking scorpion toxins (23). Further detail was obtained with the generation of 
a crystal structure of a potassium channel from Streptomyces lividans, KcsA, a 
two transmembrane spanning protein with homology to the S5-S6 region of 
voltage-dependant potassium channels.
This crystal structure led to a model where the pore is constructed as an 
inverted cone, with the selectivity filter held at its base. The narrow selectivity 
filter is only 12 A long, whereas the remainder of the pore is wider and has a 
relatively inert hydrophobic lining. These structural and chemical properties 
favour a high K+ throughput by minimising the distance over which K+ interacts 
strongly with the channel. A large water-filled cavity and helix dipoles are 
thought to help to overcome the high electrostatic energy barrier facing a cation 
in the low dielectric membrane centre. The K+ selectivity filter is lined by 
carbonyl oxygen atoms, which provide multiple closely spaced sites. The filter 
is constrained in an optimal geometry so that a dehydrated K+ ion fits with 
proper coordination but the Na+ ion is too small. Two K+ ions at close proximity 
in the selectivity filter will repel each other. This repulsion overcomes the 
otherwise strong interaction between ion and protein and allows rapid 
conduction in the setting of high selectivity. These properties select for 
monovalent cations by providing a polar environment with a partial negative 
charge, and give just the right diameter to select for K+ over cations of different 
size.
26
The outer vestibule and selectivity region of the sodium and calcium 
channels must be different from the K+ channel structure to account for their 
different selectivity properties. In sodium channels mutation studies have 
revealed that the most important structural feature is the two rings of charged 
amino acids around the narrow selectivity filter, responsible for the channel's 
affinity for sodium ions (24-27). Specifically, four highly conserved amino acids 
in the same relative position in the Na+ channel P loops of domains l-IV 
participate in the formation of the selectivity filter, Asp-384, Glu-942, Lys-1422, 
and Ala-1714 (the DEKA motif), using the rat brain residue channel numbers.
The P loops of domains l-IV of high voltage activated (HVA) voltage- 
dependent calcium channels contain a highly conserved pattern in positions 
corresponding to those of the DEKA motif. These residues are Glu-393, Glu- 
736, Glu-1145, and Glu-1446 (the EEEE motif), using the numbers of the rabbit 
cardiac L-type channel (rabbit Cav1.2). In low voltage activated (LVA) calcium 
channels, there are two glutamates and two aspartates at the corresponding 
positions. The current model of calcium channel selectivity is that the pore acts 
like an ion exchange resin, with the four closely spaced negative charges 
attracting an equal number of positive charges (28). The high density of 
negative charge in the pore is crucial for selectivity for divalent cations. Indeed, 
in the absence of divalents, calcium channels are non-selective cation channels 
that allow even relatively large organic cations to permeate (29). Much work 
has been performed upon exactly how ions pass though the pore of ion 
channels. However, it is beyond the scope of this study and will not be 
discussed further here.
1.2.4. Inactivation
A further characteristic of voltage-dependent ion channels is that after 
maintained depolarisation of the membrane they inactivate. They 
spontaneously close and will not reopen until the membrane is repolarised. In 
potassium channels it was proposed that a “ball and chain” model of 
inactivation, in which a mobile part of the protein moves so as to block the pore, 
takes place (30). This is also known as N-type inactivation as the ball and chain 
are at the N-terminus of the protein. Support for this model was provided by
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Zagotta et al (31) who showed that 1) removal of the “ball” removed inactivation 
2) that shortening of the chain speed up inactivation and 3) that expression of 
the “ball” alone was sufficient to block the channel. There is also C-type 
inactivation involving the S6 and H5 regions which is likely to be associated with 
a change in the permeability characteristics of the pore (32;33). In addition, the 
(3-subunits of mammalian voltage-dependent potassium channels have also 
been shown to be involved in inactivation (34).
Inactivation of sodium and calcium channels involves different 
mechanisms. Stuhmer et al (14) and West et al (35) showed that in sodium 
channels a region of conserved positively charged and hydrophobic amino 
acids in the cytoplasmic section between domains III and IV was involved in 
inactivation. It is believed that this region works similarly to the ball in 
potassium channels. Both auxiliary (3-subunits (36) and the S4 segment (37) 
have also been shown to be involved. In calcium channels the S6 segment of 
Domain I has been shown to be involved in inactivation (38). The auxiliary 
subunits of voltage-dependent calcium channels have also been shown to be 
involved, as will be discussed later.
The kinetics of inactivation will not be extensively discussed here. A 
model based on the work of Kou and Bean (39) on voltage-dependent sodium 
channels and furthered by Serrano et al (40) working on voltage-dependent 
calcium channels (Cav3.1) channels is given in Fig. 1.5. They assume that all 
four voltage sensors must activate before the channel can open. However, 
inactivation can occur directly from closed states.
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Fig. 1.5. A model o f  gating o f  voltage dependent calcium channels. The gating o f 
VDCC channels is modelled by a number o f stages. They open (Co to O), inactivate (O 
to Io) and recover (back to Co). In the open state all four voltage sensors are activated.
C = closed, I = inactivated, O = Open. Adapted from Serrano et al (40)
1.3. Voltage-Dependent Calcium Channels
As a member of the VDIC family voltage-dependent calcium channels 
(VDCCs) are primarily composed of a pore forming subunit. However, when 
VDCC were first purified from the transverse tubule membranes of skeletal 
muscle (41) along with the pore forming (a) subunit additional proteins (p, y) 
were also identified.
More detailed biochemical analyses revealed an additional subunit 
co-migrating with the a1 subunit (42). These auxiliary proteins have been 
shown to be important in calcium channel function and will be discussed further 
in section 1.3.4. Biochemical analysis led to a model comprising a 190 kDa 
principal transmembrane ai subunit associated with a disulfide-linked a2§ 
hetrodimer of 170 kDa and a 33 kDa transmembrane y subunit. The 55 kDa p 
subunit was not predicted to have any transmembrane domains and was thus 
thought to be intracellular (Fig. 1.6).
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Fig. 1.6. A diagrammatic representation o f a voltage-dependent calcium channel.
The channel is primarily composed by the pore forming cti subunit. In addition to this 
there is an intracellular P subunit, an extracellular 012 subunit connected by disulphide 
bonds to a single transmembrane 5 subunit and a four transmembrane y subunit.
While no crystal structure of a VDCC has been obtained Wang et al 
(43;44) have used electron microscopy to obtain three-dimensional structures of 
skeletal and cardiac VDCCs. The skeletal muscle VDCCs were isolated as 
dimers composed of two arch-shaped monomers -210 A across and -75 A 
thick, that interact very tightly at each end of the arch. The roughly toroidal 
structure of the two monomers enclosed a cylindrical space of -80 A diameter, 
which is then closed on each side by two dome-shaped protein densities 
reaching over from each monomer arch. The dome-shaped domains had a 
length of -80-90 A and a maximum height of -45 A. Small orifices punctuated 
their exterior surface. The cardiac VDCC (Fig. 1.7) was found to have a similar 
structure with a major difference being apparent in the putative transmembrane 
region, which would be consistent with the absence of the y subunit.
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Fig. 1.7. A three-dimensional structure o f the cardiac voltage-dependant calcium 
channel. The complex has a total width o f 14.5 run with a central chamber that 
encloses a volume with a height and width 5 x 3  nm, respectively, and depth o f 4 nm. 
They can be thought o f as being comprised o f three regions 1) the monomer arches. 2) 
the finger domains, which are protein densities protruding from the monomer arches 
that surround a central aqueous compartment. 3) The nose region which is formed by 
the intimate association o f the monomer arches creating a narrow bridge, with some 
contribution from the tips o f the finger domains. Adapted from Wang et al (44).
1.3.1. Identification and Classification of Voltage-Dependent Calcium 
Channels
The first work on calcium channels was performed by Bernard Katz, Paul 
Fatt and Bernard Ginsborg in the 1950’s on the large muscle cells of crab (45) 
and crayfish (46). Due to their importance in many physiological processes 
much work has been performed on identifying VDCCs and attempting to 
elucidate their mechanisms of action. Now, in mammalian genomes, 10 
VDCCs have been identified and more than 20 putative genes have been 
identified which may encode functional calcium channel subunits (47;48).
t
The primary distinction between channel types is the voltage at which the 
channel operates. Low voltage-activated channels (LVA) are activated by weak 
depolarisation and rapidly inactivate, whereas high voltage-activated (HVA)
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channels require stronger depolarisation and have variable inactivation (49). 
HVA channels can be further classified as either L-, P/Q-, N-, R-type (LVA 
channels are classified as T-type) categorised by the kinetic and 
pharmacological properties of the channel.
Initially the distinction in HVA channels was between L-type channels 
(large and long lasting currents), and N-type channels (neither T- or L-type: T- 
type channels produced tiny and transient currents) (50). L-type channels are 
blocked by 1,4-dihydropyridines (DHPs). While insensitive to DHP’s, N-type 
channels are blocked potently by co-Conotoxin-GVIA (co-Ctx-GVIA), a peptide 
isolated from the venom of a cone snail Conus geographus (51).
Regan et al (52;53) discovered neuronal HVA channels that were not 
blocked by DHPs or by co-Ctx-GVIA, thus fitting into neither category. Named 
P-type channels (originally characterized in Purkinje neurons of the cerebellum 
(54)) they were found to be blocked by the toxin co-Agatoxin-IVA (co-Aga-IVA), a 
peptide from the venom of the funnel-web spider (Agelenopsis aperta) (55). 
Zhang et al (56) identified a further set of channels that were also resistant to 
DHP’s and co-Ctx-GVIA but were blocked less rapidly and/or potently by co-Aga- 
IVA. These were named Q-type channels. Due to the difficulty in determining a 
distinction between P- and Q-type channels they are often grouped together 
and termed P/Q-type channels. Also, there is HVA current that is resistant to 
DHP’s, co-Ctx-GVIA and co-Aga-IVA. Named R-type channels (resistant), they 
inactivate more rapidly than the other HVA currents and may activate at more 
negative voltages (56;57) and may include multiple channel subtypes (58).
The different types of VDCC currents are, primarily defined by different 
oti subunits. The first ai subunit to be cloned was the L-type channel of skeletal 
muscle. Six other HVA ai subunits were cloned by homology. Later three LVA 
ai subunits were cloned. The cloned ai subunits were originally designated 
classes A through I, with S used for the ai subunit from skeletal muscle. This 
single-letter notation for the oci subunits has now, for the most part, been 
superseded by the Cav classification proposed by Ertel et al (59). This scheme
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classified VDCCs by the structural relationship between the a1 subunits and 
splits them into three families Cav1, Cav2 and Cav3 (Fig. 1.8.).
 Cav1.1 (oc-is)
--------------  i Cav1.2 (a1G)
— Cav1.3 (a1D)
------------ Ca\/1.4 (oc-jp)
i—  Cav2.1 (a1A)
-------------------p—  Cav2.2 (a1B)
Cav2.3 (cx-jp)
j  Cav3.1 (oc^q)
__________________  Cav3.2 (cxipi)
Cay3.3 (oc-||)i______ i______ i______ i_____ i
20 40 60 80 100
Matching percentage using CLUSTAL
Fig. 1.8. Phytogeny o f  voltage-dependent calcium channel ctj subunits. Comparison 
o f all sequence pairs defined three families w ith intrafamilial sequence identities above 
80% (Cavl.x, Cay2.x, Cay3.x). A consensus sequence was defined for each family, and 
these three sequences were compared to one another, with interfamily sequence 
identities o f -52%  (Cavl x versus Cay2.x) and 28% (Cay3.x versus Cayl .x or Cay2.x). 
Only the membrane-spanning segments and the pore loops (-350 amino acids) were 
compared. Adapted from Ertel et al (59).
Expression of the cloned ai subunits in mammalian cells or Xenopus 
oocytes and analysis of their pharmacological and biophysical profiles has 
allowed the correlation between the ai subunits and the type of current they 
produce. The HVA channels are produced by the Cay1 .x and Cay2.x ai 
subunits. Cav1.1, Cay1.2, Cay1.3, and Cay1.4 are L-type channels (60-65). 
Cay2.1 is thought to encode both P- and Q-type channels by alternative splicing 
of the same gene (66-69). The N-type calcium channel is produced by Cay2.2 
(63;68;70;71). Cav2.3 likely constitutes a variant of the R-type calcium channel 
family (58;72-75). The LVA T-type channels are produced by Cav3.1, Cav3.2, 
and Cay3.3 (76-83) The various methods of classification of each of the ai 
subunits are given in Table 1.
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1.3.2. Calcium as a Signalling Molecule
Ca2+ ions are required for the proper functioning of many extracellular 
and intracellular processes, including muscle contraction, nerve conduction, 
hormone release, and blood coagulation. In addition, the Ca2+ ion plays a 
unique role in intracellular signalling and is involved in the regulation of many 
enzymes.
Both the extracellular and intracellular concentrations of Ca2+ are tightly 
regulated by bidirectional Ca2+ transport across the plasma membrane of cells 
and by the membranes of intracellular organelles such as the endoplasmic 
reticulum, the mitochondria, and the sarcoplasmic reticulum of muscle cells. 
This results in remarkably low intracellular Ca2+ concentration («10'7 M) 
compared to the extracellular concentration («10'3 M) and allows the opening of 
a relatively small number of calcium channels to cause a large transient change 
in intracellular Ca2+ concentration.
Upon opening of the channel the Ca2+ concentration in the area near the 
inner mouth of a calcium channel (“nanodomain”) can approach millimolar 
levels and near the membrane, but away from the channel (“microdomain”) it 
reaches micromolar levels. While these highly localised Ca2+ gradients cannot 
be measured directly they can be estimated from simulations of Ca2+ diffusion 
and binding (84-89).
1.3.3. The Function of Voltage-Dependent Calcium Channels
A range of cellular responses are triggered by the influx of Ca2+ through 
VDCCs including neurotransmitter release (90), neuronal excitability (91), 
neurite outgrowth (92) and Ca2+ release from cytoplasmic stores (93). It has 
also been implicated in synaptic plasticity, the regulation of calcium-dependent 
second messenger cascades (such as cyclic adenosine monophosphate and 
inositol 1,4,5-trisphosphate) and in the regulation of gene expression (94;95).
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Cav Classification Single-letter
Notation
Gene Name Physiological
Classification
Voltage
Activation
Cav11 « 1 S CACNA1S L HVA
Cav1 2 CC1C CACNA1C L HVA
Cav1 -3 «1 D CACNA1D L HVA
Cav1.4 a i F CACNA1F L HVA
Cav2.1 a iA CACNA1A P/Q HVA
Cav2.2 a i e CACNA1B N HVA
Cav2.3 a iE CACNA1E R HVA
Cav3.1 a iG CACNA1G T LVA
Cav3.2 a iH CACNA1H T LVA
Cav3.3 an CACNA1I T LVA
Table 1. Classification of the VDCC ai subunits
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As the structural relationship would suggest, the primary division in the 
roles of VDCCs is between HVA channels, crucial for muscle contraction and 
neurotransmitter release and LVA channels, involved in generation of repetitive 
electrical activity.
In skeletal muscle, Cav1.1 acts as a voltage sensor, coupling membrane 
depolarisation to release of calcium from the sarcoplasmic reticulum (SR). 
Franzini-Armstrong and Protasi (96) showed that this involves a direct physical 
interaction between the Cav1.1 channels and the ryanodine receptor of the SR. 
Cav1 2 is involved in excitation-contraction coupling in cardiac muscle. In 
contrast to Cav1.1, it is the influx of calcium through Cav1.2 which produces 
highly localised calcium influx, which triggers Ca2+-induced Ca2+ release from 
the cardiac SR (89;97).
L-type VDCCs are also widespread in neurons. They are typically 
confined to cell bodies (98) where they likely regulate calcium dependent 
enzymes, gene expression and integration of synaptic inputs (99). However, 
some specialized synapses use L-type channels (100) and there is some 
evidence for functional coupling of neuronal L-channels to ryanodine receptors 
(101). L-type VDCCs are also present in secretory cells such as endocrine cells 
where they initiate release of hormones (102).
Other HVA channels (notably N and P/Q channels) seem to be restricted 
to neurons and related endocrine cells, and are the primary calcium channels 
involved in the release of neurotransmitters at most synapses (90). N- and P/Q- 
type calcium channels show highest expression levels at presynaptic terminals 
and are directly coupled to neurotransmitter release (103-105). R-type calcium 
channels are expressed on proximal dendrites and may, in some neurons, 
participate in neurotransmitter release (106).
In addition to the effects of increasing the intracellular calcium 
concentration the inward current produced by VDCCs also contributes to the 
action potential. The electrical component of the calcium influx is especially 
important in the LVA VDCCs, which are involved in the generation of repetitive 
activity in several cell types, including cardiac pacemaker cells and thalamic
36
neurons (107). Briefly, hyperpolarisation removes the resting inactivation from 
LVA channels. This causes the channels to activate, producing a low-threshold 
spike, which in turn triggers a burst of sodium-dependent action potentials. 
Rapid inactivation of the LVA channels (and also activation of various 
potassium channels) leads to termination of this burst. Providing that the 
subsequent hyperpolarisation is sufficient to once again remove the inactivation 
from the channels, the cell can burst repetitively.
1.3.4. Auxiliary Subunits of Voltage-Dependent Calcium Channels
As mentioned previously, although the ai subunit is sufficient to form a 
functional channel (108) it is believed that endogenously it is associated with 
ancillary a2§, p and y subunits. These ancillary subunits have been shown to 
modulate various properties of the channel (such as activation and inactivation) 
and also are thought to be involved in the trafficking of the channel to the cell 
membrane (109-117). The structures and functions of the ot25 and p subunits 
will be briefly discussed here and with y subunits discussed later.
1.3.4.1. p subunits of Voltage-Dependent Calcium Channels
Ruth et al (118) were the first to clone a p subunit (the same p as purified 
by Takahashi et al (42)). A further three p subunit were identified by homology 
and subsequently cloned (81 ;111 ;112;119). The proteins encoded by these 
genes are further diversified by splice variants of each of these subunits. Their 
expression varies depending upon tissue type with all four genes being 
expressed within the brain. There does not appear to be an exclusive pairing 
between any one ai and p subunit (120).
All four p subunit genes encode intracellular proteins comprised of two 
domains connected by a flexible linker (121) (Fig. 1.9). These two domains 
were subsequently noted to be homologous to the SH3 and the guanylate 
kinase families (122; 123). Recent crystallographic analyses confirmed these 
findings and showed p subunits to be a members of the membrane-associated 
guanylate kinase (MAGUK) protein family (124-126).
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Pragnell et al (127) showed that p subunits bind with high affinity to the 
cytoplasmic intracellular linker between domains I and II of all HVA calcium 
channels, via an 18 amino acid motif called the a interaction domain (AID) on 
the l- ll linker. This interacts with the (3 subunit through a conserved 
hydrophobic cleft (named the a-binding pocket, ABP) in the guanylate kinase 
domain. Other, lower affinity, p subunit interaction sites have been identified on 
various a subunits (128-131). However, it has not yet been established whether 
the p subunit is an invariable stoichiometric subunit of the calcium channel, or 
whether it reversibly associates.
Fig. 1.9. The structure o f the VDCC p  subunit. Structure o f VDCC P functional core 
in complex with the AID ribbon. Domain I, domain II, and the A ID  are represented in 
red, blue, and green, respectively. Adapted from Opatowsky et al (125).
Lacerda et al (109) reported that co-expression of the p subunit with the 
skeletal Cav1.1 enhances the level of expression and confers gating properties 
more like endogenous channels. Co-expression of p subunits with the cardiac 
and neuronal ai subunits also had a large effect on the level of ai expression 
and the voltage dependence and kinetics of gating of the channel. Generally in 
expression systems co-expression of p subunits increases the level of 
expression of the ai subunit (reviewed in (132)), and in its absence the majority 
of the ai that remains is in the ER (133). These findings have led to the
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hypothesis that one role of the p subunit is to act as a chaperone assisting the 
trafficking of the channel to the plasma membrane. In addition to increased 
levels of ai expression the kinetics of the channel are also altered. Generally 
the voltage dependence of activation and inactivation is shifted to more 
negative membrane potentials, and the rate of inactivation is increased 
(reviewed in (120).
1.3.4.2. (X2S subunits of Voltage-dependent Calcium Channels
Thus far four genes encoding a 28 subunits (a28-1- a 28-4) have been 
identified (115; 134-136), further diversity is introduced by alternative splicing. 
Similarly to the p subunits a 28 expression varies depending upon tissue type 
and there does appear to be an exclusive pairing between any one 0^ and a 28 
subunit. All four a 28’s have been identified in heart and skeletal muscle and 
a 28-1 - a 28-3 have been shown to bd expressed in brain (115;135-138).
a 28 is a product of a single gene that is post-translationally cleaved into 
a 2 and 8 peptides, which are then linked by disulphide bridges (139-141). It is 
believed that the extracellular a2, rather than the transmembrane 8 subunit, 
interacts with the ai subunit (138). A region in the third domain of the ai 
subunit (in the first extracellular loop between the 5th and 6th transmembrane 
regions) is thought to be the corresponding primary site of interaction. The a 2 
subunit is extensively glycosylated (134) and these sugar residues have been 
shown to be important in maintaining the stability of the interaction with a! and 
in a 28’s effect on the channel kinetics (138).
The role of a 28 subunits is still unclear. Generally expression results in 
increasing the current through the channel and as with the p subunit co­
expression of a 28-1 was shown to increase the membrane trafficking of the ai 
subunit (142). Further effects on the kinetics of the channels have also be 
identified, but with no general trend between the four a28 subunits (reviewed in 
(143)).
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1.3.5. Channelopathies of Voltage-Dependent Calcium Channels
Mutations in VDCCs can cause a range of pathologies. These can be 
useful in discovering more about VDCC and will be briefly discussed here 
(reviewed in (144)).
Several pathologies have been linked to mutations in Cav2.1. For 
example familial hemiplegic migraine, which is associated with headaches 
accompanied by aura, ataxia and nystagmus, has been linked to numerous 
missense mutations causing defects in the Cav2.1 subunit (145). Further 
mutations have been found to be responsible for episodic ataxia-2, which is 
associated with ataxia, nystagmus, dysarthria, vertigo and cerebella atrophy 
and migraine are also common to this condition (146).
The presence of an expanded CAG repeat in the C-terminus of Cav2.1 
leads to autosomal dominant spinocerebellar ataxia 6. This is characterized by 
ataxia, nystagmus, dysarthria, and neuronal loss in the cerebellum, the dentate 
and inferior olivary nuclei (147). Two mouse models have also been identified, 
tottering (characterised by seizures and mild ataxia) and leaner (characterized 
by severe ataxia) both due to single nucleotide substitutions (148-150).
Missense mutation, deletions, and frameshifts with premature stop 
codons in Cav1.4 are thought to be responsible for human incomplete X-linked 
congenital stationary night blindness. This is a heterogeneous, non-progressive 
disorder with impairment of night vision and variably reduced day vision, which 
is thought to result from altered synaptic transmission from photoreceptor cells 
to second-order neurons (151; 152). Missense mutations in Cav1.1 result in 
hypokalemic periodic paralysis which presents as episodic weakness of the 
trunk and limbs, generally without myotonia, which can last hours to days (153- 
155).
Mutations in auxiliary subunits are also involved in pathologies. An 
insertion of four nucleotides into a splice donor site of the mouse gene encoding 
p4 results in the lethargic (ataxia and absence seizures, but without apparent
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neuronal degeneration (156)) phenotype (157). Mutations in the mouse a 28-2 
gene result in the ducky and ducky*J phenotypes (epilepsy and ataxia) (158) 
and also in the entla phenotype (ataxia, paroxysmal dyskinesia, and absence 
seizures) (159). Mutation of the y2 subunit results in the Stargazer phenotype, 
which will be discussed further below.
1.4. y Subunits of Voltage-Dependent Calcium Channels
It remains controversial as to whether y subunits form part of a functional 
VDCC or not. Compared to a 28 and p subunit their effect on VDCC expression 
and kinetics is slight (with the exception of the y7 subunit). Indeed it is accepted 
that a primary role of at least some of the y subunit family is involved in the 
trafficking of AMPA receptors (160).
Eight y subunits have thus far been identified ranging between 222 and 
426 amino acids in length. They are all part of the PMP-22/EMP/MP20/Claudin 
family. They share a conserved four transmembrane domain structure with 
amino- and carboxyl- termini located intracellularly. The first extracellular loop 
contains conserved sites for N-glycosylation and also a GLWXXC motif. The 
first extracellular loops also contain conserved cysteine residues which may 
form disulphide bonds. The carboxyl-term ini of y2, y3, y4 and y8 all contain a 
type I PDZ-binding motif (the consensus sequence for which is S/T-X-O, where 
O is any hydrophobic residue (161)). y5 and y7 share a similar SS/TSPC motif.
1.4.1. Identification of y Subunits
As mentioned previously y subunits were first identified as they were co­
purified with the Cav11 from skeletal muscle T-tubule membranes. This y 
subunit was subsequently cloned by Jay et al (162) from rabbit skeletal muscle 
cDNA revealing a 666 nucleotide sequence. This translates to a 222 amino 
acid protein with a calculated molecular weight of approximately 25 kDa. These 
finding were confirmed by Bosse et al (163).
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The human orthologue (CANCG1) was identified from cDNA library 
derived from foetal skeletal muscle. Both Powers et al (164) and lies et al (165) 
went on to map the gene to 17q11.2-q24. This is the same region which 
contains the gene for the p1 subunit (166). The rat orthologue was identified by 
Eberst et al (167) which encoded a 223 amino acid protein that shares 79% and 
84% identity to the rabbit and human y1 subunits respectively.
For sometime it was thought that there was only one y subunit which 
formed part of skeletal calcium channels. However, Letts et al (168) identified a 
second neuronal y subunit, the mutation of which was responsible for the 
“stargazer” phenotype in the stargazer mutant mouse strain. This protein was 
subsequently named stargazin (also known as y2).
Mouse y2 encodes a 323 amino acid protein with a molecular weight of 
approximately 36 kDa. The human orthologue of y2 (located on chromosome 
22q13.1) was identified by Black and Lennon (169) by a search of an EST 
database for sequences homologous to mouse y2 and subsequent (polymerase 
chain reaction (PCR) of a cerebellum cDNA library. Similarity between y1 and 
y2 is low (only 18% identity) but they do share similar hydrophobicity plots, gene 
structure and intron size (four exons with a large first intron). A third y subunit 
(y3) was also identified by Black and Lennon (169). They went on to map y3 to 
chromosome 16p12-p13.1. The deduced 315-amino acid transmembrane 
protein is 98% identical to y2, but only 17% identical to y1. Once again the gene 
contained four exons with a large first intron.
The mouse orthologue of y3 was identified by Klugbauer et al (170), who 
also identified 2 other potential y subunits, y4 and y5. However, this y5 had a 
different gene structure to the other members of the family, containing only 2 
exons. Additionally only one common sequence motif (GLWXXC) was shared 
between this protein and other members of the family. This motif is not 
exclusive to y subunits but is shared with other tetraspannin proteins. These 
differences led Chu et alto propose that this gene should be referred to as 
mouse protein distantly related to the y subunit Cancg genes (pr) (171).
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Burgess et al (172) mapped the human orthologue of y4 to chromosome 
17q24. They also identified a novel y subunit (y5) located on chromosome 
17q24. Subsequently, Burgess et al (173) went on to identify a further 3 y 
subunits (y6, y7 and y8) clustered on chromosome 19q13.4. Interestingly y8 
contains an unusual start codon, AXXCTGG (the consensus sequence for 
initiation of translation in vertebrates (also called Kozak sequence) is: 
ACCATGG). This is conserved in the rat, mouse and human genes.
y5, y6, y7 and y8 were independently identified by Chu et al (171) and y5 
and y7 were also independently identified by Moss et al (174). Furthermore 
both Chu et al and Moss et al suggested a different gene structure for y5 and y7 
from that proposed by Burgess et al. For both genes there was evidence of a 
five exon structure as opposed to the four exon structure originally purposed. A 
short form of y6 was also found by both Burgess et a / (173) and Chu eta l (171). 
They predicted that this short form is assembled by three exons rather than 
four, resulting in the encoded protein being shorter by 46 amino acids than the 
long isoform. Hydropathy analysis suggested that this short isoform would 
contain only two transmembrane domains (171).
The phylogenetic relationship between the y subunits is given in Fig. 1.10. 
Briefly, they can be grouped by homology into 3 sets: 1) y1 and y6; 2) y2, y3, y4 
and y8; 3) y5 and y7. There may also exist y subunits yet to be identified. By 
analysis of the mouse representative transcript and protein set for molecules 
involved in brain function Gustincich et al (175) identified two potential members 
of the y subunit family y9 and y10.
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Gene Name Chromosome/cytoband Exons Translation Length
y1 CACNG1 17q24 4 222
y2 (Stargazin) CACNG2 22 4 323
y3 CACNG3 16p12-p13.1 4 315
y4 CACNG4 17q24 4 327
y5 CACNG5 17q24 5 275
y6 CACNG6 19q13.4 4 260
y7 CACNG7 19q13.4 5 275
y8 CACNGQ 19q13.4 4 426
Table 2. y subunits genes
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Chu et al (171) proposed two possible models of the evolutionary 
pathway of the generation of the eight y subunits. The first contained four 
evolutionary steps in which following a single round of tandem gene duplication 
and chromosome duplication, an unequal crossing-over event led to a gene 
cluster with 3 paralogous y genes and an additional single y gene on another 
chromosome. This was followed by a final chromosome duplication event to 
generate a second homologous gene cluster as well as a second homologous y 
gene. The second model comprised five steps with two rounds of tandem 
duplications resulting in a gene cluster with three ancestral y subunit genes.
The first round of chromosome duplication generated another homologous gene 
cluster. The deletion of two genes from one of the gene clusters was followed 
by another round of chromosome duplication to give the eight y subunits. The 
lack of any y subunits in the Caenorhabditis elegans genome, which contains
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the other calcium channel subunits, led them to conclude an independent 
evolution of the y subunits from the other calcium channel subunits.
1.4.2. Tissue Expression of y Subunits
The tissue distribution of y subunits remains controversial with different 
results obtained between different groups (as detailed below). Overall at least 
one y subunit has been detected in almost all tissues. The brain has been 
shown to express all of the identified y subunits with the exception of y1.
Using RT-PCR Powers et al (164), Burgess et al (173)and Chu et al 
(171) all found y1 to be expressed in skeletal muscle. Chu et al also found 
expression at low levels in the aorta whereas Burgess et al found low levels of 
expression in bone marrow, thymus, foetal brain and trachea.
Using Northern blotting and in situ hybridization Letts et al (168) showed 
y2 mRNA to be expressed abundantly in adult mouse brain the with the highest 
expression in cerebellum, olfactory bulb, cerebral cortex, thalamus, and CA3 
and dentate gyrus of the hippocampus by in situ hybridisation. A similar 
expression profile was observed by Moss et al (176). This was confirmed by 
Klugbauer et al (170) who used Northern blotting and in situ hybridization 
detected y2 in the brain with high expression in the cerebellum and moderate 
expression in the hippocampus, cerebral cortex thalamus, and olfactory bulb. 
Tomita et al (177) also found y2 mRNA to be concentrated in the cerebellum 
and cerebral cortex. They went on to show that y2 mRNA is expressed in the 
neurons of cerebral cortex, granule cells of dentate gyrus, pyramidal cells of the 
hippocampus, interneurons of hilus of dentate gyrus and in stratum oriens and 
stratum radiatum.
y2 expression has also been investigated using various PCR techniques. 
Chu et al (171) and Green et al (178) only detected y2 expression in the brain. 
Further analysis by Green et al showed that y2 was expressed in all brain 
regions with higher expression in the cerebellum and nucleus accumbens.
Foetal brain also showed high expression. Burgess et al (173) also found
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expression of y2 in the brain, but in contrast to the previous results they also 
found y2 expression in the adrenal gland, spinal cord, foetal liver, foetal brain, 
testes, small intestine and liver.
Sharp et al (117) used western blotting and immunohistochemistry to 
investigate y2 expression at the protein level. They found expression in mouse 
forebrain and cerebellum but not the thymus, heart, lung, skeletal muscle, liver 
or kidney. y2 expression was highest in the cerebellum and cortex; moderate in 
midbrain thalamus hippocampus and striatum and low in pons and brain stem. 
This was confirmed by Tomita et al (177), who also identified low levels of 
expression in the olfactory bulb. Immunoblotting for y2 in rat pups showed 
expression was first detectable at postnatal day 4 and increased until 
adulthood.
Northern blotting and in situ hybridization showed y3 expression only in 
the brain (restricted to the forebrain) with strong expression in the hippocampus 
and cerebral cortex and moderate expression in the olfactory bulb and caudate 
putamen (170; 177). PCR techniques also found y3 expression in both adult and 
foetal brain (171; 173; 178). At the protein level the highest levels of y3 
expression was found in the cortex, with moderate expression in the midbrain, 
hippocampus and striatum and low expression in thalamus and hippocampus 
(117; 177). Expression was first detectable in rat pups at postnatal day 16 and 
increased until adulthood.
Northern blotting showed y4 to be only expressed in the brain (170). In 
situ hybridization showed y4 mRNA to be diffusely expressed throughout the 
brain with higher levels of expression in the caudate putamen, olfactory bulb, 
habenula and moderate expression in the cerebellum and thalamus (177). PCR 
techniques confirmed the expression of y4 in the brain with high expression in 
the caudate nucleus, putamen and thalamus. y4 was found to be expressed 
strongly in foetal brain. Lower levels of expression were also found in a range 
of tissues including lung, heart, prostate, pancreas, placenta, small intestine, 
stomach, testes and uterus (171; 173; 178). At the protein level y4 expression 
was found in the olfactory bulb, cortex midbrain, hippocampus, striatum and at
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lower levels in the thalamus, pons brainstem and cerebellum (117; 176; 177). In 
rat pups expression was detectable from embryonic day 20 and increased to a 
peak at postnatal day 6 then reduced again to low levels at adulthood. Kious et 
al (179) found y4 to be expressed early in the cranial neural plate, and later in 
the cranial and dorsal root ganglia in developing chick embryos. The timing of 
this expression correlated precisely with the onset of neuronal differentiation 
and led them to suggest that y4 may promote differentiation via regulation of 
intracellular calcium levels.
Expression of y5 has of yet only been examined by RT-PCR. Chu et al 
(171) only found y5 mRNA in the brain. Burgess eta l (173) also found 
expression in kidney, thymus, prostrate, testes, foetal brain and spinal cord.
The two splice variants of y6 show different expression profiles. Burgess 
et al (173) found that in skeletal muscle, bone marrow, salivary gland and 
adrenal gland the long (four exon) isoform predominates whereas expression of 
the short (three exon) isoform is found in the small intestine, spleen and spinal 
cord. Chu et al (171) found expression of the long isoform in skeletal muscle, 
and the short isoform in aorta, brain and lung. Both isoforms were expressed in 
both the atrium and ventricle.
Burgess et al (173) found y7 mRNA to be expressed in a range of tissues 
with high level of expression in the brain, foetal brain, spinal cord, testis and 
foetal liver. Lower level of expression were found in kidney, liver, lung, colon, 
small intestine, spleen, stomach, thymus, prostrate skeletal muscle, trachea, 
adrenal and mammary tissue. Chu et al (171) also found y7 mRNA to be 
expressed in the brain and also found high expression in the lung and testes 
with lower levels of expression in the atrium, ventricle and skeletal muscle.
Using Northern blotting Moss et al found y7 mRNA to be only expressed in the 
brain (174). Two transcripts (~2.4 and 3.0 kb) were found in all regions probed 
with the short transcript expressed at greater levels in the cerebellum, 
amygdala, hippocampus and thalamus.
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Unpublished data from experiments performed in our laboratory by Dr.
M. Niteo-Rostro found widespread expression of y7 mRNA in mouse brain with 
stronger expression in the olfactory bulb, cerebellum and CA1, CA3 and dentate 
gyrus regions of the hippocampus. Within the cerebellum y7 mRNA was 
strongly expressed in the Purkinje cell layer and also in the granule cell layer. 
Immunohistochemical studies of mouse cerebellum found y7 localisation in 
individual Purkinje cells and their dendrites (Appendix A.4.2. Fig. A.1).
Finally y8 mRNA was detected in brain, foetal brain and testes (171; 173). 
In situ hybridization detected high levels of expression in the hippocampus and 
moderate expression in the cortex and olfactory bulb. In rat pups protein was 
detectable from postnatal day 4 increasing until adulthood. The highest level of 
expression was found in the hippocampus with lower levels in the cerebral 
cortex and olfactory bulb (177).
1.4.3. Effects of y Subunits on Voltage-Dependent Calcium Channels
1.4.3.1. Effects on Calcium Current Properties
y1 Subunits
Wei et al (180) showed that in Xenopus oocytes co-expression of y1 did 
not have a significant effect on currents elicited by Cav1.2. However, when the 
subunit was co-expressed with Cav1.2 and p i, both peak currents and rates of 
activation at more negative potentials were increased. They suggested that 
rather than simply amplifying expression of ai subunits, heterologous skeletal 
muscle p and y subunits could modulate the biophysical properties of Cav1.2.
Lerche eta l (181) showed that in mammalian HEK 293 cells co­
transfection of the y1 with Cav1.2 shifted the inactivation curves by -20 mV. 
Similarly Eberst et al (167) showed that co-expression of y1 with the Cav1.2, 
p2a and a 26-1 complex in HEK 293 cells shifted the inactivation curve to 
negative potentials and accelerated current inactivation without changing other
49
voltage-dependent properties of the channel. Again in HEK293 cells Klugbauer 
et al (170) showed that co-expression of y1 with Cav1.2, P2a and a 25-1 resulted 
in a -30 mV shift in the steady-state inactivation curve with accelerated current 
inactivation. Using a Xenopus oocyte expression system Kang et al (182) 
showed co- expression of y1 with Cav2.2, p3 and a 28 resulted in decelerated 
activation kinetics.
Mice that lack y1 by targeted deletion are viable, fertile and show no 
obvious phenotype. The other components of skeletal muscle VDCCs are 
expressed at normal levels (183) and the channel is maintained as a complex 
(184). There is a increase in L-type current density, deceleration of the 
inactivation, and a shift in the steady state inactivation to more positive 
potentials. However, there was no observed effect on skeletal excitation- 
contraction coupling (185). Transient expression of the y1 subunit, but not the 
y2 subunit, in primary cultured muscle cells from y1-deficient mice shifted the 
steady-state inactivation approximately -15 mV, thereby restoring wild type 
steady-state inactivation and current amplitude (186).
y2 Subunits
In the initial experiments performed by Letts et al (168) co-expression of 
y2 in a BHK cell line stably transfected with Cav2.1, p1a and a25-1 resulted in 
current amplitudes that were decreased as the channels became increasing 
inactivated. y2 accentuated inhibition by shifting the voltage-dependence of 
channel availability towards more negative potentials. Also, the midpoint 
voltage was more negative in cells transfected with y2 resulting in a 
hyperpolarising shift of approximately 7 mV. However, the peak current-voltage 
relationship was unchanged.
Klugbauer et al (170) showed that co-expression of y2 with Cav2.1, pia
and a25-1 in HEK293 cells resulted in a small, but significant, shift of the
voltage-dependent activation to more positive potentials and also shifted the
steady state inactivation curve towards a more hyperpolarised potential.
Substitution of the p ia  subunit (skeletal) with the p2a subunit (cardiac) resulted
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in the negative shift in voltage-dependence of inactivation which only occurred 
when Ca2+ was used as the charge carrier. If Ba2+ was used as the charge 
carrier a shift to more positive potentials was observed. Co-expression of y2 
with Cav1.2, p2a and a26-1 resulted in small shifts of the voltage-dependence of 
activation and inactivation. Co-expression of y2 with the LVA VDCC Cav3.1 
slowed the speed of recovery from voltage-dependent inactivation.
Rousset et al (116) found that co-expression of y2 with Cav2.1 and oc25-1 
induced a small negative shift in the inactivation curve and an acceleration of 
the inactivation kinetics. When p subunits were co-expressed these effects 
were still generally present (116). They also observed that y2 increased the 
proportion of p expressing oocytes that displayed unusually slow inactivation. 
Also in a Xenopus oocyte expression system Kang et al showed co-expression 
of y2 with Cav2.2, P3 and a 28-1 resulted in decelerated activation kinetics (182). 
A decrease in current amplitude was observed, though this effect was 
dependent upon the presence of the ot25 subunit.
Green et al (178) observed no effect on current amplitude, current 
activation, steady-state inactivation or the rate of inactivation upon the co­
expression of y2 with Cav3.3 in HEK293 cells. However, deactivation was 
significantly slowed. When co-expressed in Xenopus oocytes with a Cav2.1/p4 
VDCC complex, either in the absence or presence of an a 28-2 subunit y2 did not 
significantly modulate the VDCC peak current amplitude, voltage-dependence 
of activation or voltage-dependence of steady-state inactivation (176).
y3 Subunits
As with y2, Rousset et al (116), found that co-expression of y3 with 
Cav2.1and a 25 induced a small negative shift of the inactivation curve and an 
acceleration of the inactivation kinetics. When p subunits were co-expressed 
these effects were still generally present. They also observed that y3 increased 
the proportion of p expressing oocytes that displayed unusually slow 
inactivation.
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Green et al (178) found co-expression of y3 with Cav3.3 in HEK 293 cells 
had no effect on current amplitude, current activation, steady-state inactivation 
or the rate of inactivation. Unlike the case for y2, deactivation was not 
significantly slowed by y3.
y4 Subunits
Klugbauer et al (170) showed that co-expression of y4 with Cav2.1 ,p1a 
and a28-1 shifted the steady state inactivation curve towards a more 
hyperpolarised potential. Co- expression y4 with Cav3.1 resulted in a significant 
shift of steady state inactivation curves to more positive voltages and slowed 
the speed of recovery from voltage-dependent inactivation.
In contrast Green et al (178), also using HEK293 cells found no effect on 
current amplitude, current activation, steady-state inactivation or the rate of 
inactivation, when y4 was co-expressed with Cav3.3. Co-expression of y4 with 
a Cav2.1/(34 VDCC complex, either in the absence or presence of an a25-2 
subunit in Xenopus oocytes did not significantly modulate the VDCC peak 
current amplitude, voltage-dependence of activation or voltage-dependence of 
steady-state inactivation (176). y4 was also found to have no significant effect 
on Cav3.1 current (187).
y6 subunits
Hansen et al (187) observed that co-expression of both the long and 
short isoforms of y6 with Cav3.1 in HEK293 cells significantly decreased the 
current density by 49% and 69% respectively. Neither the long nor the short 
isoform significantly affected the voltage dependency of activation or 
inactivation or the kinetics of Cav3.1 current. Expression of the long isoform of 
y6 was shown not to affect the level of Cav3.1 mRNA or the total protein 
expressed in HEK 293 cells. Transient expression of the long isoform of y6 was 
also found to reduce the endogenous low voltage-activated current by 63% in 
HL-1 cells, an immortalised arterial cell line (187).
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y7 subunits
In our laboratory Moss et al (174) showed that co-expression of y7 with 
Cav2.2, (31B and a25-2 resulted in almost complete abolition of N-type current in 
both Xenopus oocytes and mammalian cell expression system. This effect was 
shown to be not dependent upon co-expression of a28-2. y7 was also shown to 
significantly reduce the current through both Cav1.2 and Cav2.1 by 48% and 
52% respectively with no significant effects of y7 on the voltage dependence of 
activation. However, endogenous N-type currents in sympathetic neurones of 
the rat superior cervical ganglion were unaffected by the transient transfection 
of y7. They went on to show that co-expression of y7 resulted in a large 
reduction of expression of Cav2.2 rather than interfering with trafficking or 
biophysical properties of the channel. Hansen et al (187) found that y7 had no 
significant effect on the voltage dependency of activation or inactivation or the 
kinetics of Cav3.1 when co-expressed in HEK293 cells.
1.4.3.2. Biochemical Interactions
Biochemical association between y subunits and the other VDCC 
subunits has been less widely examined than the biophysical effects. As 
mentioned previously y1 subunits were found to co-purify with Cav1.1, P1a and 
a 25-1 . Arikkath et al (184) showed that Cav1.1, P1a and a 25-1 subunits are still 
associated in y1 null mice. Transiently transfected y1 subunits (but not y2 
subunits) incorporated into y1 null L-type channels in skeletal muscle of y1 null 
mice. In addition Cav1.1 and y1 were found to form a complex when transiently 
transfected in tsA-201 cells. They went on to identify that it is the first half of y1, 
including the first two transmembrane domains, that is important for subunit 
interaction.
y2 and y3 have also been shown to associate with other neuronal VDCC 
subunits. Using sucrose gradient fractionation of rabbit cerebellum Cav2.1,
Cav2.2, ot25-2, p3 and p4 were found to co-sediment with both y2 and y3 (182).
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These interactions were confirmed by co-immunoprecipitation. Sharp et al 
(117) also found interaction between y subunits and ai subunits. Using 
antibodies against a highly conserved C-terminal epitope present in y2, y3 and 
y4 they immunoprecipitated Cav2.2 on subunits from mouse brain.
1.4.4. Non-Voltage-Dependant Calcium Channel Roles of y Subunits
Along with their effects on VDCCs there is increasing evidence that y 
subunits have other roles. It has been proposed that y2, y3, y4 and y8 are all 
involved in the trafficking of AMPA type glutamate receptors and should be 
defined as transmembrane AMPA receptor regulatory proteins (TARP's) (177). 
AMPA receptors are of fundamental importance in the brain. They are 
responsible for the majority of fast excitatory synaptic transmission. They are 
hetero-tetramers composed of variable combinations of four subunits, glutamate 
receptor 1 (GluRI-GluR4) (188; 189). Glutamate is the primary excitatory 
neurotransmitter in the central nervous system, regulating numerous cellular 
signalling pathways and controlling the excitability of central synapses both pre- 
and postsynaptically. AMPA receptors have been shown to be involved in 
synapse formation and stabilisation, and regulation of functional AMPA 
receptors is the principal mechanism underlying synaptic plasticity (reviewed 
Palmer et al (190)). The interaction between y subunits and AMPA receptors 
was revealed through investigation of the Stargazer mutant mouse strain which 
will now be discussed.
1.4.4.1. The Stargazer Mutant Mouse Line
The stargazer mutation in mice arose spontaneously in the A/J Mouse 
strain in the Animal Resources colony of the Jackson Laboratory in the 1980s.
It was originally identified by its distinctive head-tossing activity, ataxic gait spike 
wave seizures and behavioural arrest (191). This phenotype is characteristic of 
absence epilepsy in humans.
As mentioned previously Letts et al found this phenotype is due to a 
mutation in the cacng2 gene which encodes for y2. Stargazer mice harbour a
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transposon insertion in the second intron of cacng2, disrupting transcription of 
the gene (117;168;182;192). Subsequently, two allelic variants of stargazer 
have arisen, Wagglerand Stargazer 3J. All three mutations affect the cacng2 
mRNA levels as they all arise from disruptions within the introns of this gene. 
The mutations cause reduced cacng2 mRNA and protein levels. Stargazer and 
Waggler mice have the least amount of mRNA and undetectable protein, 
whereas Stargazer^ appears to be the mildest allele, both in terms of the 
phenotype and protein expression (192).
Electroencephalography (EEG) studies demonstrated frequent polyspike 
discharges and staring spells that could be suppressed with anticonvulsants 
effective against absence epilepsy (191-193). Electrophysiological studies have 
shown hyperexcitability of thalamic and cortical neurons as a potential source of 
the absence spells (194; 195), and anatomical studies have suggested that the 
frequent seizures result in aberrant sprouting of mossy fibres and loss of hilar 
interneurons in the hippocampus(196).
The anatomy of the stargazer cerebellum is normal, except for a 14% 
reduction in cerebellar size (191; 197). However, there is a loss of brain-derived 
neurotrophic factor during development, and delayed disappearance of external 
granule cells (197; 198). In addition, there is a loss of y-aminobutyric acid 
(GABA) synapses among Purkinje and Golgi cells (199;200) and an impairment 
of AMPA-mediated glutamate transmission onto cerebellar granule cells 
(201 ,202).
1.4.4.2. The Role of /Subunits in AMPA Receptor Trafficking
Using immunocytochemical staining and immunogold electron 
microscopic analysis Chen et al (202) revealed a lack of synaptic labelling of 
AMPA receptor subunits despite the presence of cytoplasmic staining in 
cerebellar granule cells of Stargazer mice. They went on to show that y2 co- 
immunoprecipitates with GluR1, 2, and 4 in co-transfected COS cells. Sharp et 
al (117) also confirmed the co-immunoprecipitation of y2 with GluR1 from 
solubilised mouse brain homogenates. Interestingly GluR1 could also be co-
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immunoprecipitated with Cav2.2. Furthermore, Chen et al (202) showed that 
transfection of y2 into stargazin mutant granule cells led to recovery of AMPA 
receptor mediated synaptic currents.
In addition to binding to AM PA receptors y2 was also found to bind to 
synaptic PDZ proteins, such as PSD-95, SAP-97 and SAP-102 through its C- 
terminal PDZ binding motif. Chen et al (202) proposed a model in which the 
interaction of y2 with AM PA receptor subunits was essential for delivering 
functional receptors to the surface membrane of granule cells, whereas its 
binding with PSD-95 and related PDZ proteins is required for targeting AM PA  
receptors to synapses.
Using phosphorylation site-specific y2 antibodies Choi et al (203) showed 
that the C terminus of y2 is phosphorylated within the PDZ binding motif at the 
Thr-321 residue in heterologous cells and in vivo. y2 phosphorylation was 
enhanced by the catalytic subunit of cAMP-dependent protein kinase A (PKA). 
Mutations mimicking stargazin phosphorylation (T321E and T321D) resulted in 
elimination of yeast two-hybrid interactions, in vitro co-immunoprecipitation, and 
co-clustering between y2 and PSD-95. Phosphorylated y2 showed a selective 
loss of co-immunoprecipitation with PSD-95 in heterologous cells and limited 
enrichment in postsynaptic density fractions of rat brain.
Similar experiments were performed by Chetkovich et al (204). In vitro 
peptide phosphorylation assays and western blot analysis with phospho- 
stargazin-specific antibodies confirmed phosphorylation of Thr-321 by protein 
kinase A. These results led both groups to suggest that phosphorylation of the 
y2 C-terminus by PKA regulates its interaction with PSD-95 and synaptic 
targeting of AMPA receptors. Furthermore NMDA receptor activity can induce 
both stargazin phosphorylation, via activation of CaMKII and PKC, and y2 
dephosphorylation, by activation of PP1 downstream of PP2B (205).
Schnell et al (206) used hippocampal slice cultures and biolistic gene 
transfections to study the targeting of the AMPA receptor to synapses. They 
showed that AMPA receptors are localised to synapses through direct binding
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of the first two PDZ domains of synaptic PSD-95 to y2. Increasing the level of 
synaptic PSD-95 caused the recruitment of new AMPA receptors to synapses 
without changing the number of surface AMPA receptors. Additionally y2 over 
expression drastically increased the number of extra-synaptic AMPA receptors, 
but did not alter synaptic currents if synaptic PSD-95 levels were kept constant. 
Chen et al (207) showed that surface delivery of kainate receptors, which are 
structurally very similar to AMPA receptors, was independent of y2.
Tomita et al (177) showed that other y subunits (y3, y4 and y8) are also 
involved in AMPA receptor trafficking and proposed that this group of proteins 
should be defined as TARP’s. y1, y5 and the related protein claudin-1 were all 
shown not to be involved in AMPA trafficking. TARPs interact with AMPA 
receptors at the postsynaptic density, and surface expression of mature AMPA 
receptors requires a TARP. In a further series of experiments Tomita et al (160) 
showed that TARPs were stable at the plasma membrane, whereas AMPA 
receptors were internalized in a glutamate-regulated manner. Upon binding to 
glutamate, AMPA receptors detached from TARPs. This did not require ion flux 
or intracellular second messengers. They proposed that this allosteric 
mechanism for AMPA receptor dissociation from TARPs may participate in 
glutamate-mediated internalisation of receptors in synaptic plasticity.
Interaction between y2 and AMPA receptors involved both extra- and 
intracellular determinants of TARPs. Cuadra et al (208) identified a novel 
domain corresponding to residues 243-283 within the cytoplasmic C terminus of 
y2 that is also required for y2 and AMPA receptor synaptic clustering. Using a 
yeast two-hybrid assay they showed that this domain binds to nPIST (neuronal 
isoform of protein-interacting specifically with TC10), a Golgi-enriched protein 
implicated in trafficking of transmembrane proteins. Using a range of techniques 
they confirmed this interaction in the brain. Interestingly over expression of 
nPIST in hippocampal neurons enhances AMPA receptor clustering, whereas 
transfection of a dominant-negative nPIST construct attenuates AMPA receptor 
synaptic clustering. These led them to propose the model of AMPA receptor 
trafficking below (Fig 1.11)
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Fig. 1.11. A mode o f the regulation o f AMPA Recptors at synapses. y2-AMPA 
receptor complexes interact with nPIST in the Golgi and exit the Golgi in vesicles (A). 
The vesicles fuse at extrasynaptic sites (B), and nPIST chaperones the y2- AMPA 
recptor complex to the PSD, where it interacts with synaptic proteins such as GluR82, 
NR2A, or directly with PSD-95, allowing the y2 C terminus to bind PSD-95 and 
stabilize the AMPA recptor at the synapse (C). nPIST is recycled to the Golgi to repeat 
the cycle (D). Adapted from Cuadra et al (208)
Furthermore, Ives et al (209) identified a series of proteins that interact 
with y2 including the non-PDZ domain containing protein light chain 2 of 
microtubule-associated protein 1 (LC2). They went on to show that LC2 co­
associates with y2 as part of a tripartite complex comprising LC2-y2-GluR2. As 
the extracted complex was found to be devoid of PSD95, SAP97, and actin they 
proposed that LC2 is involved in trafficking of AMPA receptors before they are 
anchored at the synapse.
1.4.4.3. TARPs as Modulators of AMPA Receptor Activity
Yamazaki et al (210) showed that in addition to the importance of TARPs 
in the trafficking of AMPA receptors they also directly modulated AMPA receptor 
activity. Co-expression of any of the TARPs with GluR 1 in HEK293 cells and
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Xenopus oocytes markedly enhanced glutamate-induced currents. The effect 
was not just due to the increase of AMPA receptor surface expression. The 
enhancing effect by y2 co-expression was further observed for homomeric 
GluR2 channels, which, when expressed alone, are known to produce only a 
small or negligible current response.
Subsequently it was shown that co-expression of y2 with AMPA receptor 
subunits, either in Xenopus oocytes or in human embryonic kidney 293 cells, 
significantly reduced receptor desensitization in response to glutamate. 
Receptor deactivation rates were also slowed, and the recovery from 
desensitization was accelerated (211). Tomita et al (212) showed that y2 can 
alter AMPA receptor kinetics by increasing the rate of channel opening. This 
effect of y2 requires the first and second transmembrane domains and the first 
extracellular loop.
1.5. The Role of y7
As mentioned previously Moss et al (174) showed that co-expression of 
y7 with Cav2.2 resulted in almost complete abolition of N-type current in both 
Xenopus oocyte and mammalian cell expression systems. This was found to 
be due to y7 causing a reduction in Cav2.2 expression. The aim of the work 
presented here is to try is to determine the mechanism by which y7 causes the 
reduction of Cav2.2 expression and go on to identify the role of y7.
The expression of a VDCC is a multi step process (Fig. 1.12). Firstly the 
RNA message for each of the subunits has to be transcribed from the 
corresponding gene on the chromosome (for endogenous expression) or from 
the vector (for transfected subunits). During (and post) transcription a range of 
ribonucleotide binding proteins (RNPs) bind to the mRNA. These proteins have 
a range of roles including mRNA export, localisation and stability (213).
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Fig. 1.12. A diagrammatic representation o f  the process o f expression o f a VDCC. 
The synthesis o f a VDCC from DNA to a functional channel in the plasma membrane 
can be simplified into 3 stages. Transcription o f DNA to RNA, translation o f the RNA 
to protein (and subsequent modification o f these proteins and their coming together to 
form a multi subunit protein) and finally trafficking o f the proteins to the plasma 
membrane.
The mRNA is then translated on ribosomes with the transmembrane 
containing proteins being translated into the membrane of the ER. Proteins are 
then modified (e.g. disulphide bonds are formed and glycosylation takes place) 
in the ER and Golgi network. The individual subunits also assemble to form the 
multi-subunit complex. Finally the multi-subunit complex is trafficked to the 
plasma membrane. The VDCC complex is then localised to specific regions 
within the plasma membrane, such as the pre-synaptic terminal.
There are many points upon this pathway that y7 could be having its 
effect on the expression of Cav2.2, a few of which are mentioned here. For 
example, at the transcription stage, promoter competition between y7 and 
Cav2.2 (when expressed from plasmids) could result in a reduction of Cav2.2 
mRNA being produced. Also, y7 could interact with RNPs present on Cay2.2 
mRNA resulting in the Cav2.2 mRNA becoming less stable. At the translation 
stage y7 could be causing stress upon the ER resulting in reduced protein
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synthesis or it could be preventing the formation of the multi-subunit complex 
and thus negating the increased expression of ai subunits observed when p 
subunits are co-expressed (132). y7 could also have its effect at the trafficking 
stage, for example by trafficking Cav2.2 to lysosomes for degradation. 
Determining the mechanism by which y7 reduces the expression of Cav2.2 will 
hopefully provide an insight into the role of y7.
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Chapter 2 -  General Methods
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2.1. cDNA’s Constructs
The following cDNAs were used: human y7(Moss), rabbit Cav2.2 A3’UTR 
(D14175), rat p1b (X61394, except R417S, V435A, V449A, W492R and 
V511A), a gift from Dr. T. P. Snutch, mouse a28-2 (AF247139, common brain 
splice variant), rat Kv3.1b (M68880). All were used in the pMT2 expression 
vector (214) with the exception of KV3.1b which was used in the pRC-CMV 
expression vector.
2.2. Cel! Culture
2.2.1. Culture of PC12 Cells
Rat pheochromocytoma cells (PC 12) were a gift from Dr T. Shafer. They 
were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 7.5% horse serum and 7.5% foetal bovine serum (FBS) in a 
5% C 0 2 humidified atmosphere. Cells were passaged weekly. Three days 
after passaging 50% of the media was removed and replaced with fresh media. 
Before use PC12 cells were replated in DMEM supplemented with 10% FBS on 
to collagen coated 3.5 cm dishes or 3.5 cm dishes containing poly-L-lysine 
coated coverslips. To induce differentiation two hours after replating media was 
removed and replaced with serum free DMEM containing 100ng/ml Nerve 
Growth Factor (NGF)7S fragment (murine, natural). During differentiation 
medium was changed every other day and cells were left for at least 5 days 
before use.
2.2.2. Culture of tsA-201 Cells
tsA-201 cells (obtained from ECACC) are a SV40-transformed variant of 
the HEK293 human embryonic kidney cell line. They were maintained in 
Minimum Essential Medium supplemented with 10% FBS and 1% non-essential 
amino acids in a 5% C 0 2 humidified atmosphere. Cells were passaged twice 
weekly. For transfection cells were used at 60-80% confluency and, unless 
otherwise stated, plated on to 3.5 cm dishes.
2.2.3. Culture of COS7 cells
C0S7 cells are SV40 transformed african green monkey kidney cells 
(obtained from ECACC). They were maintained in DMEM supplemented with 
10% FBS and in a 5% CO2 humidified atmosphere. Cells were passaged twice 
weekly. For transfection cells were used at 60-80% confluency and, unless 
otherwise stated, plated on to 3.5 cm dishes.
2.3 Transfection
2.3.1. GenePORTER
Transient transfection of COS7 cells was performed using 
GenePORTER transfection reagent following the manufactures guidelines. 
Briefly, the DNA and GenePORTER reagent (2 pg:10 pi ratio -  all DNA at 1 
pg/pl) were each diluted in 500 pi of serum-free medium, mixed, incubated at 
room temperature for 1.5 hours, then applied to the cells. Transfections were 
stopped after 4 hours by the addition of 1ml of medium containing 20% serum. 
Unless otherwise stated a total of 2 pg of DNA was used to transfect one 3.5 cm 
dish of cells. All cells were incubated for 3 days at 37°C in a 5% C 02 humidified 
atmosphere before use.
2.3.2. FuGENE
Transient transfection of tsA-201 and PC12 cells was performed using 
FuGENE 6 transfection reagent, following the manufactures guidelines. Briefly, 
for a 3.5 cm dish of cells, 3 pi of FuGENE was added to 97 pi of serum-free 
medium (MEM or DMEM for tsA201 and PC12 cells respectively) in a small, 
sterile tube and gently mixed. To this 2 pg of DNA solution (all DNA at 1 pg/pl) 
was added and gently mixed. Transfection mixes were then left to incubate for 
between 15 and 45 minutes at room temperature before being added to cells. 
Unless otherwise stated a total of 2 pg of DNA was used to transfect one 3.5 cm
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dish of cells. All cells were incubated for 3 days at 37°C in a 5% C 0 2 humidified 
atmosphere before use.
2.3.3. Nucleofection
Transient nucleofection of tsA201 was carried out using Amaxa’s 
Nucleofector™ Device and Cell Line Nucleofector™ Kit V (Solution V). 
Nucleofection was performed according to manufactures guidelines for HEK- 
293 cells. Briefly, one T-75 flask of cells was used per nucleofection condition. 
Cells were harvested by incubating them in 5 ml of PBS and tapping the flask. 
Cells from all flasks were pooled and pelleted by centrifugation at 200 xg for 10 
min at room temperature. This was done to remove and variability between 
individual flasks of cells. Pelleted cells were resuspended in 1ml of PBS per 
nucleofection condition and aliquoted into 15 ml Flacon tubes. Cells were then 
pelleted once again by centrifugation at 200 xg for 10 min at room temperature.
For each condition, the supernatant was discarded and pellet 
resuspended in 100 pi of Solution V to which 5 pg DNA (1 pg/pl) was added. 
The resuspended cells were then transferred into a cuvette and program A-23 
used to nucleofect cells. 500 pi of pre-warmed (37°C) Roswell Park Memorial 
Institute 1640 (RPMI) medium supplemented with 10% FBS was added. For 
each condition two 6 cm plates containing 4 ml of RPMI supplemented with 
10% FBS (pre-warmed to 37°C) were seeded with 250 pi of the nucleofected 
cell solution. Cells were cells were incubated at 37°C in a 5% C 0 2 humidified 
atmosphere for 24 hours before use.
2.4. Generation of Constructs
During this study many constructs were generated. As the techniques 
used to generate each construct are very similar for brevity only the generation 
of y7(i .217) will be detailed here.
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2.4.1, PCR to generate y7(i.2i7)
The following primers were designed to amplify the first 651 bases 
(corresponding to amino acids 1-217) of human y7:
Forward 5’-GACGAATTCACCATGAGTCACTGCAG-3’;
Reverse 5’-ATAGAATTCCTCAGTAGAAGGCCGGGTGTGG-3’.
An EcoRI site was incorporated into each primer to allow cloning into the 
pMT2 expression vector.
The PCR reaction consisted of 25 mM dNTPs, 0.1 pg of y7 in pMT2, 0.4 
pmol/pl of each primer, 2.5 U of PfuTurbo® DNA Polymerase (Pfu), 20 mM Tris- 
HCI (pH 8.8).2 mM MgSO4.10 mM KCI.10 mM (NH4) 2S04 0.1% Triton® X-100 
and 0.1 mg/ml nuclease-free BSA in a total volume of 50pl. 0.1 pg of full length 
human y7 in pMT2 was used as a template. PCR was performed using a 
Techne thermocylcer as follows:
Cycle 1 (1x): 
Cycle 2 (25x):
98°C for 3 min
Cycle 3 (1 x) 
Cycle 4 (1x)
Step 1 
Step 2 
Step 3
98°C for 30 sec 
50°C for 40 sec 
75°C for 2 min 30sec
75°C for 5 min 
4°C fo r00
Initial denaturation step 
Denaturation step 
Annealing step 
Extension step
Final extension step 
Cooling
A sample of the PCR reaction was combined with DNA sample loading 
buffer and separated by agarose gel electrophoresis on a 1% agarose gel using 
TAE as the running buffer. The gel was stained using ethidium bromide and 
DNA visualized under UV light using a UV transilluminator. An amplicon was 
identified corresponding to the expected size of y7(1.2i7). Unincorporated 
dNTP’s and Pfu were removed from PCR reaction using a PCR clean up kit 
(following the manufacturer’s guidelines) and the PCR product eluted in water.
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2.4.2. Sub-cloning of y7(1.2i7) into the pMT2 Expression Vector
y7(i-2i7) was subcloned into the mammalian expression vector pMT2 by 
the following method. Complementary sticky ends were produced for both the 
PCR product and pMT2 vector by incubation at 37°C for 1 hour with the 
restriction endonuclease EcoRI. pMT2 has a unique EcoRI site in the multiple 
cloning site upstream of the promoter sequence. The products of each of the 
restriction digests were combined with DNA sample loading buffer and 
separated by agarose gel electrophoresis on a 1% agarose gel. The gel was 
stained using ethidium bromide and DNA visualized under low UV light. Bands 
corresponding to y7(i_2i7) and linearised pMT2 were excised from the gel and 
purified using an Invitrogen gel extraction kit (following the manufacture’s 
guidelines). To reduce contamination by empty vector linearised pMT2 was 
dephosphorylated by incubation for 2 hours at 37°C with Calf Intestinal Alkaline 
Phosphatase (CIAP). CIAP was removed using an Invitrogen PCR clean up kit 
and dephosphorylated linearised pMT2 eluted in water. y7(1.2i7) and pMT2 were 
ligated together using T4 ligase. An approximate ratio of 3 y7(1.217) : 1 pMT2 was 
used and incubation was carried out for 2 hours at room temperature. A control 
ligation was also set up in which was y7(1.2i7)was replaced with water. This 
provided an indication to the amount of pMT2 remaining that was either uncut or 
remained phosphorylated.
2.4.3. Transformation
Products of the ligation reactions were then used to transform Library
efficiency DH5a competent bacteria (Invitrogen) by the following protocol. Cells
were thawed from storage at -80°C on wet ice, the products of the ligation
reactions added and mixed gently. A further control in which no DNA was
added to the cells was also performed to ensure that antibiotic selection took
place. The cells were then incubated on ice for 30 minutes. Heat-shock was
performed by placing the cells in a 42°C water bath for 45 seconds then
returning them to ice for a further 2 minutes. S.O.C. medium, pre-warmed to
37°C, was added to the cells which were then incubated for 1 hour at 37°C with
constant shaking. Cells were then spread onto LB agar plates containing 100
pg/ml ampicillin and left to incubate overnight at 37°C. Plates were then stored
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at 4°C until required. Aseptic technique used through out to minimize the 
possible contamination.
2.4.4. Purification of y7(1.2i7) in pMT2 DNA
Individual colonies were picked from the plate and used to seed 5 ml of 
LB broth containing 100 pg/rnl ampicillin. Cultures were grown overnight at 
37°C with constant shaking. Plasmid DNA was purified from 1.5 ml (the 
remainder was stored at 4°C) of each culture using an Invitrogen miniprep kit 
following the manufactures guidelines. Briefly, bacteria were harvested by 
centrifugation. Bacteria are lysed under alkaline conditions, and the lysate is 
subsequently neutralized and adjusted to high-salt binding conditions before 
loading onto a spin column. The columns contain a silica-gel membrane that 
binds DNA under high salt conditions and allows it to be eluted under low salt 
conditions. RNA, cellular proteins, and metabolites are not retained on the 
membrane and are removed in the flow-through during the wash steps. A short 
lysis time allows maximum release of plasmid DNA without release of 
chromosomal DNA, while minimizing the exposure of the plasmid to denaturing 
conditions. DNA was eluted in water. A sample of each plasmid was 
restriction digested with Ncol for 1 hour at 37°C to examine if y7<1_2i7) was 
present and inserted in the correct orientation. Products of the restriction 
digests were mixed with DNA sample loading buffer and separated by 
electrophoresis on a 1% agarose gel. The gel was stained with ethidium 
bromide and visualised under UV.
The remaining culture from one of the clones identified as containing y7(1. 
217) in the correct orientation was used to seed 200ml of LB broth containing 100 
pg/ml ampicillin. This culture was incubated overnight at 37°C with constant 
shaking. A sample of the culture was taken to make a glycerol stock which was 
subsequently frozen and stored at -80°C. The remainder of the cells were then 
pelleted by centrifugation and plasmid DNA purified using a Invitrogen 
megaprep kit following the manufactures guidelines. DNA was taken up in TE 
and DNA concentration estimated by absorbance at 260 nm using a DU 800 
spectrophotometer. DNA concentration was adjusted to 1 pg/fil by the addition
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of TE. The test restriction digests detailed above were repeated to confirm that 
the correct plasmid had been purified. Purified plasmid was stored at -20°C.
2.4.5. Sequencing
y7(i-2i7) in pMT2 was sequenced using the Big Dye Kit v3.1, using the 
primers complementary to the vector both upstream and downstream of the 
expected insert, by the following method. Each reaction consisted of 2 pi of 
DNA at 1 pg/pl, 2pl of water, 2pl of 5X BigDye sequencing buffer 2pl of primer 
at 2 pmol/pl and 2pl of BigDye v3.1 and the following PCR reaction performed 
on a Techne thermocyler:
Cyclel (1x): 96°C for 2 min 30 sec Initial denaturation step
Cycle 2 (25x): Step 1: 96°C for 20 sec Denaturation step
Step 2: 50°C for 30 sec Annealing step
Step 3: 60°C for 4 min Extension step
Cycle 3 (1x) 4°C fo r» Cooling
PCR products were then precipitated with isopropanol taken up in 
sequencing loading buffer run on an Avant-3100 sequencer. Chromatograms 
were analysed using Chromas and sequence aliments performed using Omega.
Standard molecular biology methods were also used to make the 
following constructs y7(1.238) in pMT2; y7(i.27p in pMT2; y7(20i-275) in pMT2; y7(20i- 
275) in pcDNA3; y7_CFP in pECFP-N1; y7_HA in pMT2; y7_HA in pcDNA3;
HA_y7 in pMT2; y7(20i-275) _HA in pMT2; y7_STOP in pMT2; y2TM y7Tail in pMT2; 
y7_PDZ in pMT2 and y7N45A in pMT2. The primer pairs to design these 
constructs are given in the Appendix (A.3.1).
2.5. Immunocytochemistry
PC12 and COS7 cells were fixed and permeabilised for 
immunocytochemistry as follows. Coverslips were removed from 3.5 cm dishes 
and washed twice with TBS (Tris buffered saline: 20 mM Tris, 150 mM NaCI, pH
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7.4) to remove any remaining media. Cells were fixed by treatment with 4% 
paraformaldehyde for 15 minutes at room temperature. Cells were then 
permeablised by incubation for 15 minutes at room temperature with TBS 
containing 0.02% Triton-X 100. Prior to incubation with antibodies the 
coverslips were incubated for 30 minutes at room temperature with blocking 
buffer (20% (v/v) goat serum, 4% (w/v) bovine serum albumin (BSA), and 0.1% 
D,L-lysine in TBS) to reduce the amount of non-specific binding. Cells were 
then incubated overnight at 4°C with the primary antibody in antibody diluent 
buffer (10% (v/v) goat serum, 2% (w/v) BSA, and 0.5% D,L-lysine in TBS).
After 4 washes with blocking buffer, 5 minutes per wash, biotin-conjugated goat 
anti-rabbit or anti-mouse antibody was applied at 5 pg/ml in antibody diluent 
buffer and incubated for 2 hours at 4°C. Cells were then washed 4 times with 
TBS, 5 minutes per wash, before fluorescein isothiocyanate (FITC)-conjugated 
streptavidin in TBS was applied at 3.33pg/ml and incubated for 1 hour at room 
temperature. After washing once with TBS the cells were incubated with the 
nuclear dye 4',6-diamidino-2-phenylindole at 300 nM DAPI) in TBS for 5 
minutes at room temperature. In experiments with differentiated PC12 cells 
actin was visualised by incubating the cells for 20 min with 6.6 pM TexasRed- 
phalloidin. Finally cells were extensively washed with TBS and mounted in 
VectorShield to reduce photobleaching.
2.6. Immunoprecipitation
Cells were washed with ice cold PBS and harvested in PBS with 
protease inhibitor cocktail. Cells were lysed and protein solublised by the 
addition of extraction buffer (1% (v/V) Igepal, 20mM Tris, 150mM NaCI, 1mM 
EDTA 0.5% (w/v) Cholic Acid, 0.1% (w/v) SDS, protease inhibitor cocktail (pH
7.4) and constant agitation maintained for 30 minutes at 4°C. Insoluble material 
was removed by centrifugation at 40,000 xg 4°C for 1 hour. The supernatant 
was cleared by the addition of Protein G linked to agarose beads and constant 
agitation maintained for 2 hours at 4°C. Beads were removed by centrifugation 
for 12,000 xg for 30 seconds. 2pg of High Affinity Anti-HA was added to the 
supernatant and left to incubate overnight at 4°C with constant agitation.
Further Protein G linked to agarose beads was added and left to incubate for 2 
hours at 4°C with constant agitation. Beads were washed twice with a high
detergent buffer (1% (v/v) Igepal, 20mM Tris, 150mM NaCI, 1mM EDTA, 
Complete™ protease inhibitor cocktail pH 7.4); twice with a high salt buffer 
(0.1% (v/v) Igepal, 20mM Tris, 500mM NaCI, 1mM EDTA protease inhibitor 
cocktail (pH 7.4)) and twice with a low salt buffer (0.1% (v/v) Igepal, 20mM Tris, 
1mM EDTA, protease inhibitor cocktail (pH 7.4)). Protein was freed from the 
beads by the addition of SDS sample buffer containing reducing agent and 
heating to 70°C for 10 minutes. Samples were then run on 4-12% Bis-Tris gels 
and either coomassie or silver stained or analysed by western blotting.
Samples not used immediately were stored at -20°C until required.
2.7. RNA Isolation and Reverse Transcription
2.7.1. RNA Purification
RNA was isolated from tsA-201 or PC12 cells using the Qiagen RNeasy 
kit following the manufactures guidelines. Briefly, the media was removed and 
cells washed with PBS prior to lysis. Lysed material was then homogenised 
using QIAshredder columns. Ethanol was added to the homogenised lysate 
prior to loading onto the spin-column to provide the correct binding conditions. 
On column DNase digestion, using RNase-free DNase (Qiagen), was 
performed to prevent DNA contamination. Columns were extensively washed 
to remove all contaminants and RNA was eluted in water. If RNA was not 
immediately used for cDNA synthesis it was stored at -80°C. RNA 
concentration was determined from absorbance at 260nm using a DU 800 
spectrophotometer.
2.7.2. Reverse Transcription
First-strand cDNAs were generated from 2pg of RNA by using Moloney 
Murine Leukemia Virus Reverse Transcriptase (MMLRTV) in the presence of 
random hexamer primers and RNasin.
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2.8. Quantitative PCR
cDNA generated from the RT reaction described previously were diluted 
100 fold and combined with iQ SYBR supermix and primers to give QPCR 
reactions with a final concentration of each primer of 8 pmol/pl For every 
experiment a standard curve was generated from a serial dilution (4 fold (1'1 to 
9.8'5) or 10 fold (11 to 1-6)) of a mix of all cDNAs used within that experiment. 
Each sample and standard reaction was set up in triplicate. QPCR was 
performed using an iCycler using the following protocol:
Cyclel (1x): 98°Cfor3m ins Initial denaturation step
Cycle 2 (50x): Step 1: 98°C for 30 sec Denaturation step
50°C for 40 sec Annealing step
A melt curve was generated by raising the temperature from 54°C to 
94°C over 80 30s cycles the temperature increasing 0.5 °C per cycle and the 
fluorescence measured at the end of each cycle.
2.9. Stable Cell Lines
PC12 cell lines stably transfected with y7_HA or y7_CFP were
established as follows. Before transfection the minimum concentration of
Geneticin required to ensure death of untransfected cells within 14 days was
determined to be 400 pg/ml. To decrease the likelihood of the vector integrating
into the genome in a way that would have disrupted the gene of interest or other
elements required for expression in mammalian cells the expression vectors
containing y7_HA and y7_CFP were linearised prior to transfection using Pvul.
Cells were transfected with y7_HA in pcDNA3 or y7_CFP in pECFP-N1 using
FuGENE as previously described. Cells transfected with empty pCDNA3 and
untransfected cells were used as positive and negative controls respectively.
24 hours post transfection the cells were washed fresh media added. Cells
were split 48 hours post transfection to 25% confluency into DMEM
supplemented with 7.5% horse serum, 7.5% fetal bovine serum and 400pg/ml
Geneticin. Selective medium was replaced every 3-4 days until foci of resistant
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cells could be identified and no cells remained in untransfected cell control. To 
obtain clonally selected cell lines both y7_HA and y7_CFP cells were 
resuspended, counted then transferred to 96-well plates at a dilution so as to 
give 1 cell per well. Wells in which more than one cell could be identified were 
not used further. After sufficient growth clones were transferred to 6-well plates 
and finally to T-75 flasks. Expression of y7_HA and y7_CFP was confirmed by 
western blotting and epifluorescence microscopy respectively. Stably 
transfected cell lines were maintained as previously described for untransfected 
PC 12 except that media is further supplemented with 400pg/ml of Geneticin
2.10. Western Blotting
2.10.1. Preparation of Samples
Cells were washed with ice cold PBS and harvested in PBS with 
Complete™ protease inhibitor cocktail. A BCA assay was carried out to 
determine the protein concentration of each sample. Samples were then taken 
up in SDS sample loading (50 mM Tris-HCI (pH 7.4), 2% (w/v) SDS, 0.1% 
bromophenol blue, 10 % (v/v) glycerol and 2% (v/v) p-mercaptoethanol) to give 
a final protein concentration for each sample of 50 pg/30 pi. Samples were 
then sonicated briefly (3 10 second pulses, on ice) and, unless otherwise 
stated, heated to 70°C for 10 minutes. Samples not used immediately were 
stored at -20°C until required. Prior to loading on the gel protein samples were 
warmed for several minutes in a 37°C water bath and then any insoluble 
material pelleted by centrifugation.
2.10.2. SDS-PAGE
Samples were separated by SDS-PAGE using 4-12% Bis-Tris gels 
(Invitrogen) with a running buffer consisting of 50 mM MOPS 50 mM Tris base, 
0.1% (w/v) SDS 1 mM EDTA (pH 7.7). The anti-oxidant thioglycolic acid was 
added to the upper reservoir at a final concentration of 0.01% to prevent 
disulphide bond formation during the run and thus improve protein resolution. 
Gels were run under for 1 hour at 200 V with mA limiting using a Novex Minicell
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gel apparatus. Unless otherwise stated 50 pg of protein per lane was loaded 
and 12 pi of rainbow molecular weight markers were used.
2.10.3 Electrotransfer
Separated protein was transferred electrophoretically to polyvinylidene 
fluoride (PVDF) membranes using a semi-dry transfer system. The transfer 
buffer consisted of 10% (v/v) methanol, 0.01% (v/v) thioglycolic acid, 25 mM 
Bicine, Bis-tris (free base), 0.1% (w/v) SDS 1mM EDTA (pH 7.2). PVDF 
membranes were cut to size and pre-incubated in methanol and then transfer 
buffer before use. Transfer conditions of 15V and 400 mA (voltage limiting) for 
30 minutes were used.
2.10.4. Western blotting
After transfer the membranes were blocked with 3% BSA for 3 hours at 
room temperature and then incubated overnight at room temperature with 
primary antibody in antibody diluent buffer (3% (w/v) BSA, 0.5% (w/v) 
Ovalbumin, 10% (v/v) goat serum, 0.5% (v/v) Igepal). Membranes were then 
extensively washed with TBS containing 0.5% (v/v) Igepal. Secondary antibody 
(Anti-Rabbit-HRP) was added (1pg/ml in antibody diluent), and the membranes 
were incubated at room temperature for 2 hours. After extensive washing with 
TBS containing 0.5% (v/v) Igepal, bound antibodies were detected using 
enhanced chemiluminescence plus reagents. Chemiluminescence or 
fluorescence was detected using a Typhoon phosphoimager and resulting 
images were analysed using ImageQuant.
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Chapter 3 -  Confirmation of Previous 
Observations and Generation of 
Stable Cell Lines
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3.1. Introduction
3.1.1. Cay2.2, But Not Kv3.1b, Expression is Suppressed by Co-expression 
of y7
As mentioned earlier, Moss et al (174) showed that expression of Cav2.2 
was suppressed by the co-expression of y7. This was shown as both a 
reduction in N-type current in both mammalian cells and Xenopus oocyte 
overexpression systems and also by immunocytochemistry and western 
blotting. They went on to show that there was no change in currents through a 
control protein, the Shaw-like voltage dependent potassium channel Kv3.1b. 
There was also no reduction in Kv3.1b expression when y7 was co-transfected, 
as judged by immunocytochemistry.
3.1.2. Green Fluorescent Protein (GFP) and Influenza Hemagglutinin (HA) 
Tagged Proteins
Green fluorescent protein (GFP) was discovered by Shimomura et al 
(215), as a companion protein to aequorin, in the Aquorea jellyfish. Its role is to 
transduce, by energy transfer, the blue chemiluminescence (around 475 nm) 
from aequorin into green fluorescent light (around 509 nm) (216). Cloning of 
the GFP gene (217) allowed the generation of chimeric proteins containing a 
GFP tag. Such proteins have been of great use in investigating the cellular and 
subcellular distribution of proteins (218). Mutations of GFP have resulted in 
variants with differing excitation and emission profiles such as cyan fluorescent 
protein (CFP) and yellow fluorescent protein (YFP).
Influenza virus hemagglutinin (HA) is a type I transmembrane 
glycoprotein that is well characterized in terms of structure, function and 
intracellular transport. Amino acids 99-107 (YPYDVPDYA) have been shown to 
exceptionally antigenic (219) and they are often added to proteins as an epitope 
tag (220-222). There are many commercially available antibodies to the HA tag 
and high-specificity, high-affinity antibodies can be used. These properties 
allow immunoprecipitation of the tagged protein with minimum contamination.
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3.1.3. Sub-cellular Distribution of y7
Moss et al showed that y7 transfected into COS7 cells was distributed 
throughout the cytoplasm but not specifically localised to the plasma membrane 
(174). This pattern of distribution was also shown by Hansen et al using a GFP 
tagged y7 (187). Hansen et al also used differential centrifugation to show that 
y7 is found within membranes, but did not show if these were internal or plasma 
membranes.
3.2. Aims
The aims of the work described in this chapter were firstly to confirm the 
suppression of Cav2.2 expression previously obtained with y7. Secondly I 
wished to investigate the potential glycosylation of y7, and thirdly I wanted to 
examine y7’s sub-cellular distribution.
3.3. Additional Methods
Experiments were performed as described in Chapter 2 with the following 
differences and additions.
3.3.1. Generation of Constructs
HA_y7, y7_HA, y7N45A and y7_CFP were made by standard molecular 
biological techniques using the primer pairs detailed in the Appendix (A.3.1). 
HA_y7 and y7_HA were cloned into the pMT2 expression vector. y7_HA was 
also cloned into the pcDNA 3.1 expression vector, which contains a neomycin 
resistance gene, for generation of a stably transfected PC12 cell line. y7_CFP  
was generated by cloning y7 into pECFP-N1 expression vector.
3.3.2. Imaging
Confocal images were obtained using a LeicaTCS SP confocal scanning
laser microscope, except PDI co-localisation experiments which were obtained
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using a Zeiss LSM 510 confocal microscope. In all experiments photomultiplier 
settings were kept constant in each experiment and all images were scanned 
sequentially. All images shown, except where stated, are single 0.5 pm 
sections through the cell. PC12 cells stably transfected with y7_CFP were 
examined using a Zeiss LSM 510 microscope and an Improvision live cell 
imaging system. When examining co-localisation of y7_CFP with PDI the PDI 
antibody was used at 1:200. In the comparison of y7 in fixed PC 12 cells and 
y7_CFP in live PC 12 cells, cultures were treated with 100ng/ml NGF for 24 hr 
before fixing or imaging to initiate process outgrowth.
3.3.3. Western Blotting
Protein samples for Western blotting were separated using 4-12% Bis- 
Tris gels except in the experiments examining expression of Cav2.2 which were 
run on 4-12% Tris-Glycine gels. Anti-y7(Taii), anti-HA and Anti-Cav2.2 antibodies 
were used at 0.4 pg/ml, 0.8 pg/ml and 1.2 pg/ml respectively.
3.4. Results
3.4.1. The Expression of Cav2.2 is Suppressed by the Co-Expression of y7
Previous work had shown that co-transfection of y7 suppressed the 
expression of Cav2.2. It was decided to repeat experiments performed by 
Moss et al (174) to confirm the effect of y7 on Cav2.2 expression at a protein 
level by western blotting with an antibody raised against the I I/I 11 loop of rabbit 
Cav2.2.
The suppression of Cav2.2 expression by y7 at the protein level is shown 
in Fig. 3.1. A. There is a clear reduction in Cav2.2 expressed when y7 is co­
transfected with it. As a control the effect of y7 on the six potassium channel 
Kv3.1b was investigated. Western blotting with an antibody raised against 
Kv3.1b showed that expression of Kv3.1b was found to not to be suppressed by 
co-expression of y7 (Fig. 3.1.B).
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Fig. 3.1. Cay2.2 expression but not Ky3.1b expression is suppressed by co-expression
o f y7. Extracts o f tsA-201 cells transfected with A. Cay2.2 ± y7 or B. Kv3.lb  ± y7 were 
western blotted with antibodies raised against Cay2.2 and Ky3.1b respectively.
3.4.2. y7 is a Glycoprotein and is Glycosylated at N45
Glycosylation of the first extracellular loop is believed to be a conserved 
feature between the y subunits (223). The asparagine at position 45 of y7 has 
been predicted to be glycosylated and the following experiment was performed 
to confirm this. Primers were designed to generate a construct in which the 
asparagine at position 45 was converted to alanine thus preventing 
glycosylation taking place. Western blotting with the y7(Taii) antibody showed a 
shift in molecular weight from a diffuse band between 32 and 37 kDa to a sharp 
band at the predicted molecular weight of around 31 kDa (Fig. 3.2).
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Fig. 3.2. Introduction o f the mutation N45A in f7 results in f7 running at the 
expected molecular weight o f 31 kDa. Extracts o f tsA-201 cells transfected with y7 or 
y7 N45A were western blotted with the y7(raii) antibody.
It was considered that y7 may have to be glycosylated to suppress the 
expression of Cav2.2. To investigate this, tsA-201 cells were transiently with 
Cav2.2, a25-2 and p1b with or without y7 and N-type current was recorded. 
Experiments were performed by Dr. J. Leroy and are detailed in the Appendix 
(A.4.3. Fig. A.2.). Briefly, the N45A mutant was equally as effective as wild type 
y7 in suppressing Cav2.2 expression.
3.4.3. Generation and Characterisation of HA Tagged y7 Constructs
Primers were designed to generate y7 incorporating an HA tag at either 
the N or C-terminus. Expression of these constructs was confirmed by their 
transfection into tsA-201 cells and subsequent western blotting with the anti- 
y7(Tail) antibody. Both the HA_y7 and y7_HA were detectable as can be seen 
in Fig. 3.3.A. However, western blotting with an antibody raised against the HA 
epitope only detected the y7_HA construct (Fig. 3.3.B).
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Fig. 3.3. N-terminally HA tagged y7 is detected with the y7(Taii) antibody but not the 
Anti-HA antibody. Extracts o f tsA-201 cells transiently transfected with y7, HA_y7 or 
y7_HA were western blotted with A. y7(Taii) antibody B. Anti-HA antibody. Multiple 
bands seen may represent different glycosylation states.
Electrophysiological experiments in both Xenopus oocytes and tsA-201 
cells, by Dr. J. Leroy and Prof. A. Dolphin respectively, were performed to 
confirm that the addition of a HA tag did not alter the suppression of Cav2.2 
expression. Briefly Xenopus oocyte or tsA-201 cells were injected or transiently
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transfected respectively with Cav2.2, p1b and either y7_HA or a 
corresponding amount of empty vector. In both model systems y7_HA was as 
effective as untagged y7 in suppression of N-type current through Cav2.2.
3.4.4. Generation and Characterisation of a CFP Tagged y7 Construct
Primers were designed to generate y7 that could be cloned into pECFP- 
N1 to express y7 with a C-terminal CFP tag. To confirm expression this 
construct was transiently transfected into COS7 cells and visualised by confocal 
microscopy (Fig. 3.4).
Fig. 3.4. Expression o f y7_CFP. y7_CFP was transiently transfected into COS7 cells 
and three days post transfection its expression was examined by confocal microscopy.
N indicates nucleus. The white arrow indicates the predominant perinuclear expression 
o f y7_CFP. Scale bar = 10 pm
y7 showed a similar distribution to that previously described for untagged 
y7 (174). Both showed perinuclear location with a weaker diffuse localisation 
throughout the cell. However, no discernable plasma membrane localisation 
was seen with either untagged or CFP-tagged y7.
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Electrophysiological experiments were performed by Dr. J. Leroy to 
confirm that y7_CFP still suppressed Cav2.2 expression. Briefly tsA-201 cells 
were transiently transfected with Cav2.2, a25-2 and p ib  either plus y7 or a 
corresponding amount of empty vector. y7_CFP was as efficient as untagged 
y7 in suppressing N-type current through Cav2.2 (Appendix. A.4.3. Fig. A.2.).
3.4.5. Generation of y7_HA and y7_CFP Stably Transfected PC12 Cell Lines
During the course of this study PC 12 cell lines that stably expressed 
either y7_HA or y7_CFP were generated. The use of PC12 cells and their 
expression of y subunits will be detailed Chapters 5 and 7. However, 
generation of these cell lines will be discussed here.
Briefly PC12 cells were transfected with either y7_HA or y7_CFP, and 
stably expressing cells were selected by addition of Geneticin, a neomycin 
analogue. Clones were selected and expression of y7_HA detected by western 
blotting and immunodetection with the anti-HA antibody (Fig. 3.5) or by 
epifluorescence microscopy for y7_CFP (Fig. 3.6). In both cases the majority of 
clonal cell lines that were tested did not express a y7 construct at detectable 
levels despite being resistant to Geneticin.
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Fig. 3.5. Selection o f y7_HA expressing stably transfected PC 12 cells. PC 12 cells 
were transfected with y7_HA. Cells were treated with neomycin and resistant cells 
clonally selected. y7_HA expression was determined by western blotting with a anti- 
HA antibody. Extracts from tsA-201 cells transiently transfected with y7_HA were 
used as a control.
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Fig. 3.6. Expression o f  / /  CFP in expressing stably transfected PC 12 cells. PC 12 
cells were transfected with y7_CFP. Cells were treated with neomycin and resistant 
cells clonally selected. y7_CFP expression was determined by epifluoresence 
microscopy. A. Bright field. B. CFP fluorescence. Scale Bar = 20 pm
3.4.6. Sub-cellular Distribution of y7_CFP in PC12 Cells
The sub-cellular distribution of y7_CFP was similar in fixed transiently 
transfected PC12 cells, live stably transfected PC12 cells and transiently 
transfected COS7 cells. All showed a predominantly perinuclear expression 
which was suggestive of localisation of y7 to the ER and/or Golgi. In addition in 
PC12 cells which had extended processes y7 often appeared to be 
concentrated at the end of the process (Fig. 3.7. White arrows).
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Fig. 3 .7. Expression o f  y7and y7_CFP PC 12 cells. A. PC 12 cells were transiently 
transfected with y7 and its cellular distribution detected by the y7(Taii) antibody (Green). 
Texas-Red phalloidin was used to reveal F-actin. B. PCI2 cells stably transfected with 
y7_CFP I. Bright field. II. CFP fluorescence. White arrows indicate y7 and y7_CFP 
localised at the end o f processes. Scale bars = 20 pm.
To investigate if the perinuclear distribution seen was due to y7_CFP 
being present in the ER, y7_CFP stably transfected PC12 cells were fixed and 
then probed with an antibody to Protein Disulphide Isomerase (PDI) as a
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marker of ER (Fig. 3.8) (224). y7 largely co-localises with the ER marker PDI 
(yellow).
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Fig. 3.8. Co-localisation o f y7_CFP with PDI, at marker o f  ER. PCI 2 cells stably transfected with y7_CFP (Green) were fixed and probed with an 
antibody to PDI (Red). Yellow indicates where staining overlaps. Scale bar = 20 pm
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3.5. Discussion
In agreement with the work previously performed by Moss et al (174) 
western blotting experiments here showed expression of Cav2.2 is suppressed 
when y7 is co-transfected. This occurs even in the absence of p and 0126 
subunits. Western blotting also showed that expression of Kv3.1b was not 
reduced by the co-transfection of y7. The lack of suppression of Kv3.1b, also a 
voltage gated ion channel suggests a degree of specificity of the action of y7.
N-glycosylation has been shown for y2, y3 and y4 (117) and all y subunits 
have been predicted to have a glycosylation site at a preserved asparagine in 
the extracellular loop, N45 in y7. Mutation of this asparagine to alanine resulted 
in a reduction in the apparent molecular weight of y7 when separated by SDS 
PAGE. This would suggest that N45 is indeed glycosylated in native y7. 
Treatment of wild type y7 with endoglycosidases F or H could be performed in 
order to confirm this hypothesis.
Glycosylation is known to alter the running of proteins on SDS PAGE.
The carbohydrate moiety alters the profile of the protein resulting in it being 
retarded differently by the gel and not running at the true weight of the protein. 
This may in part explain the broad range of molecular weights observed y7 after 
SDS PAGE.
Electrophysiological experiments showed that glycosylation of y7 is not 
important for the suppression of Cav2.2 expression. The N45A mutant was 
found to be as efficient as y7 at suppressing N-type current through Cav2.2 in 
tsA-201 cells.
In agreement with other studies on the subcellular distribution of y7 
(174; 187) these experiments show that y7 appears to be located mainly on 
intracellular membranes. Subcellular distribution of y7 and y7_CFP appears to 
be identical in both COS7 and PC 12 cells. In the stably transfected PC 12 cells 
much of the y7 co-locates with PDI, a marker of ER. However, due to the 
diffuse staining given by the PDI antibody it is hard to determine if y7 is also
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present outside the ER. The distribution of y7_CFP in PC 12 cells would 
suggest that y7 moves from a perinuclear location to the end of the processes. 
However, the increased fluorescence seen at the end of the processes could be 
due to the increased volume of the cell there compared to the processes 
themselves. The movement of y7_CFP could be further studied by live cell 
imaging of the stably transfected PC12 cell line.
It is possible that the N-terminal tail of y7 is cleaved or modified. An HA 
tag placed at the N-terminius of y7 was not detectable with an antibody to HA 
but was detectable with an antibody to an epitope in the C-terminal tail of y7 
(Fig.3.3B). This could be due to the N-terminal tag being not accessible to the 
Anti-HA antibody, not translated or cleaved from the protein. Sequencing 
revealed no problems with the construct that could account for the HA tag being 
missing.
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Chapter 4 - y 7  and ER Stress
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4.1. Introduction
4.1.1. Mechanisms of ER Stress
The ER is the principal site for synthesis, folding and maturation of 
transmembrane and secreted proteins. Perturbations that alter ER 
homeostasis, brought about by for example pathogenic infection, chemical 
insult, genetic mutation and nutrient deprivation can lead to accumulation of 
unfolded proteins.
The cellular response to ER stress is the activation of an intracellular 
signalling pathway -  the unfolded protein response (UPR). The UPR is an 
integrated intracellular signalling pathway that transmits information about the 
protein folding status in the ER lumen to the cytoplasm and the nucleus. The 
UPR includes transcriptional induction of UPR genes, translational attenuation 
of global protein synthesis and ER-associated degradation (ERAD). If the 
protein-folding defect is not corrected, cells undergo apoptosis. The three major 
transducers of the UPR are PERK, ATF6  and IRE1 (225).
The ER chaperone BiP (immunoglobulin heavy chain-binding protein) is 
the regulator of the activation of the three major ER stress transducers -  PERK, 
ATF6 and IRE. All three proteins contain a luminal domain that interacts with 
BiP. Under normal conditions, BiP serves as a negative regulator of PERK, 
ATF6  and I RE 1 activation. During ER stress, BiP binds to unfolded proteins, 
resulting in BiP release from the transducers. Upon BiP release from PERK 
and IRE1, they both undergo homodimerization and activation. BiP release 
from ATF6 permits its transport to the Golgi compartment for regulated 
intramembrane proteolysis. This BiP-regulated activation provides a direct 
mechanism to sense the folding capacity of the ER (225).
PERK is an ER transmembrane protein kinase that phosphorylates the a 
subunit of translation initiation factor 2 (elF2) in response to ER stress (226). 
Phosphorylation of elF-2a results in inhibition of the guanine nucleotide 
exchange factor elF-2p, thereby reducing the rate of the GDP to GTP exchange 
that is required for elF2 to carry out additional rounds of translation initiation
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(227). This translational control provides an efficient mechanism to reduce the 
number of proteins entering into the ER.
ATF6 is an ER transmembrane-activating transcription factor. Upon ER 
stress, ATF6 and ATF6 G transit to the Golgi compartment where they are 
cleaved by S1P and S2P proteases to yield a cytosolic fragment (228). The free 
ATF6  fragment migrates to the nucleus to activate transcription.
IRE1 is an ER transmembrane glycoprotein which contains both kinase 
and RNase activities in the cytoplasmic domain (229). ER stress leads to its 
autophosphorylation and the subsequent activation of its RNase activity. The 
substrate of IRE1, XBP mRNA, encodes a basic leucine-zipper-containing 
transcription factor. Splicing of XBP mRNA is initiated by the RNase activity of 
IRE1 to generate mature XBP mRNA. Thus initiation of the UPR results in both 
an upregulation, and an increase in the amount, of mature, edited, XBP (230).
The signalling from downstream effectors of IRE1, PERK and ATF6 
merges in the nucleus to activate transcription of UPR target genes. The 
mammalian ER stress element (ERSE) is present in the promoter regions of 
many, but not all, UPR target genes. XBP, ATF6 and the CAAT-binding factor 
(CBF), all of which bind to ERSE, along with ATF4, activate transcriptional 
induction of target genes (231). Generally these genes encode molecular 
chaperones and folding catalysts. Their upregulation increases the folding 
capacity of the ER.
The UPR also induces transcription of genes encoding proteins that 
mediate ERAD (232). This important component of the UPR stimulates the 
degradation and clearance of unfolded proteins in the ER lumen. This removal 
of these unfolded proteins further reduce stress upon the ER.
Prolonged UPR activation leads to apoptotic cell death, in which IRE1 
serves a proapoptotic function. Activated IRE1 recruits Jun N-terminal inhibitory 
kinase (JIK) and TNF Receptor-Associated Factor 2 to activate apoptosis- 
signalling kinase 1 (ASK1), which in turn activates JNK and mitochondria/Apafl- 
dependent caspases (233). In addition, UPR activation induces CHOP(C/EBP-
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homologous protein ) expression through the PERK and ATF6 pathways 
(234;235). CHOP is a proapoptotic transcription factor that potentiates 
apoptosis.
An overview of the cellular response is shown in Fig 4.1 (236)) and ER 
stress and the unfolded protein response has recently been comprehensively 
reviewed by Schroder & Kaufman. (225).
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Fig. 4.1. ER stress signalling pathways. An accumulation o f misfolded proteins or an 
excessive accumulation o f normal proteins activate a number o f signalling pathways. 
Chaperones within the ER lumen are responsible for folding newly synthesized proteins 
into their tertiary structures prior to their export to the Golgi. A variety o f stress factors, 
including a decline in the luminal level o f Ca2+, results in dysfunctional chaperones and 
an accumulation o f misfolded proteins that can activate a number o f signalling 
pathways:
1. Oligomerization and autophosphorylation o f PERK which sets o ff a phosphorylation 
cascade that culminates in the phosphorylation and inactivation o f the translation 
initiation factor elF-2 resulting in protein synthesis being switched off.
2. Oligomerization and autophosphorylation o f IRE 1 initiates one o f the transcriptional 
signalling pathways responsible for the up regulation o f the various chaperones.
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3. Another o f the transcriptional pathways depends upon the activation o f the ER 
membrane-bound transcription factor ATF6, which is released from the ER to enter the 
nucleus where it interacts with the ER stress response element o f the CHOP gene.
4. The various chaperones are then expressed within the ER where they participate in 
protein folding.
5. One o f the genes activated during the stress response is CHOP, which acts as a 
transcription factor and can contribute to apoptosis.
6. The caspase-12, which is associated with the ER membrane is also activated and 
contributes to ER stress-induced apoptosis.
7. An excessive accumulation o f proteins w ithin the ER results in the activation o f the 
transcription factor NF-KB, which acts to increase the production o f interferons and 
cytokines so contributing to an inflammatory response.
Adapted from Berridge MJ (236)
4.1.2. Suppression of Cav2.2 Expression by the Co-Expression of 
Truncated Cav2.2 Constructs
Raghib et al (237) showed that functional expression of full-length Cav2.2 
was significantly reduced by the co-expression of constructs which expressed 
domain I, domain l-ll or domain lll-IV of Cav2.2. Recording at the current level 
showed that this suppression was not due to differences in the biophysical 
properties of the channel. However, microscopy and western blotting were 
used to show that there was a decrease in Cav2.2 protein upon co-transfection 
with any of the truncated constructs. From these results they proposed that the 
mechanism of suppression of Cav2.2 by truncated constructs containing domain 
I involved inhibition of channel synthesis.
Page et al (238) went on to show that the UPR was involved in 
mechanism of Cav2.2 suppression of expression. They showed that co­
transfection of a dominant negative PERK significantly reduced the suppression
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of expression induced by domain I of Cav2.2. In addition treatment with 
thapsigargin, which induces ER stress, resulted in a similar reduction in N-type 
current and Cav2.2 protein as co-transfection of domain I of Cav2.2.
4.1.3. Measurement of Markers of ER Stress by QPCR
Recently QPCR has become an increasing popular method for 
quantifying changes in gene expression. In this study it was used to measure 
XBP editing and the expression of XBP and CHOP all of which are indicators of 
ER stress. A brief description of QPCR will be given here. An in depth review 
of QPCR experiments has recently been written by Bustin & Nolan (239).
QPCR follows the same methodology as standard PCR, with the 
exception that in addition one measures the binding of a fluorescent marker to 
the PCR product generated. At the start of a PCR reaction, reagents are in 
excess, and the template and product are at low enough concentrations that 
product renaturation does not compete with primer binding, so that amplification 
proceeds at a constant, exponential rate. As the point at which the reaction rate 
ceases to be exponential and enters a linear phase of amplification is variable, it 
is necessary to collect quantitative data at a point in which every sample is in 
the exponential phase of amplification. A threshold value, at which the PCR 
reaction is progressing exponentially, is set and the point at which the PCR 
reaction passes reaches this level is known as the Ct value. The lower the 
starting amount of mRNA the higher the Ct value will be. A typical QPCR graph 
is shown in Fig 4.2
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Fig. 4.2. An example o f data generated by QPCR. Standards are shown by black 
lines. A sample with a high amount o f target mRNA is shown by the red line and a 
sample with a lower amount o f target mRNA is shown by the blue line. The threshold 
value is shown by the orange horizontal line. A t this point the PCR is in the exponential 
phase. It is worth noting that the end point fluorescence varies greatly. The red circle 
highlights the point at which the fluorescence passes the threshold. This is termed the 
Ct value. Samples and standards are usually performed in triplicate but only one o f the 
three reactions has been shown for clarity.
SYBR Green binding was used for detecting and quantifying PCR 
products. SYBR Green is a fluorophore that binds to double-stranded DNA.
The amount of light emitted is far higher when bound to double stranded DNA 
then when unbound. Thus, as a PCR product accumulates, fluorescence 
increases. The advantages of SYBR Green are that it is inexpensive, easy to 
use, and sensitive. However, SYBR Green will bind to any double-stranded 
DNA in the reaction, including non-specific reaction products and primer-dimers. 
Therefore it is necessary to perform a melt curve after completion of the PCR 
run to confirm that only one product has been produced. Molecular beacons 
and Taqman probes, which bind specifically to the PCR product generated, can 
also be used but will not be discussed here.
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4.2. Aims
The aims of the work described in this chapter were first to investigate if 
the suppressive effect of y7 on Cav2.2 expression is mediated by y7 mRNA 
rather than y7 protein. Secondly, to examine if the UPR pathway, shown to be 
involved in the suppression of Cav2.2 expression by truncated Cav2.2 
constructs, was involved in the suppression of expression of Cav2.2 by y7
4.3. Additional Methods
Experiments were performed as described in Chapter 2 with the following 
differences and additions.
4.3.1. y7_STOP
y7_STOP was made by standard molecular biological techniques using 
the primer pairs detailed in the Appendix (A.3.1.) and subcloned into the pMT2 
expression vector. y7_STOP mRNA was identified by RT-PCR using the 
y7_STOP RT primer pairs detailed in the Appendix (A.3.2.).
Electrophysiological experiments on tsA-201 cells were performed by Dr J.
Leroy.
4.3.2. QPCR
tsA-201 cells were transfected or nucleofected with 2 pg or 5 pg 
respectively of a mix of Cav2.2, pib, a28-2 and y7 constructs at a 1:1:1:1 ratio. 
Where subunits were omitted they were replaced with empty pMT2 vector.
RNA was harvested 24 hours post transfection. Inducers of ER stress were 
applied at a level shown previously to induce ER stress (230;240). Where 
tunicamycin was applied it was added to the growth medium of the cells to give 
a final concentration of 2.5 pg/ml six hours prior to harvesting RNA. Similarly in 
experiments where DTT was used it was added to the growth medium to give a 
final concentration of 10 mM 30 minutes prior to harvesting RNA. Primer pairs 
for CHOP, XBP(Totai) and XBP(Unedited) are detailed in the Appendix (A.3.2.).
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Preliminary experiments were performed to define the optimum PCR 
conditions for each primer pair and accordingly step two of the second PCR 
cycle was set to a temperature of 61 °C, 56.7°C and 61.1°C for primer pairs for 
CHOP, XBP(Totai) and XBP(Unedited). respectively.
Percentage XBP Edited was calculated as follows:
^^Total “ ^ U^nedited X 100
SQlotal
4.4. Results
4.4.1 Suppression of Cav2.2 by y7 Requires y7 Protein
To investigate if y7 protein was required for the suppression of Cay2.2 
expression a construct was made which would produce a y7 mRNA that would 
not be translated to y7 protein. To make this construct primers were designed 
to generate y7 in which the codon for cystine at position 4 was mutated to a stop 
codon (y7_STOP).
tsA-201 cells were transiently transfected with y7 or y7_STOP. Three 
days post transfection total protein was harvested and separated by SDS 
PAGE. Expression of y7 was determined by western blotting using the y7(jaii) 
antibody. No y7 protein was detected in cells transfected with y7_STOP (Fig.
4.3.A). It is worth noting that the next possible start codon is in frame. If 
translation was starting from this start codon the protein produced would still be 
detected by the y7(Taii) antibody. As there were no reactive lower molecular 
weight bands it would appear that this is not occurring.
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Fig. 4.3 Mutation o f the codon fo r  cysteine at position four o f y7 to a stop codon 
produces mRNA but not protein. Protein and mRNA were harvested from tsA-201 
cells three days post transfection with either y7 or y7_STOP. A. Extracts o f cells 
transfected with y l  or y7_STOP were western blotted with the y7(Taii) antibody. B. RT- 
PCR o f mRNA from tsA-201 cells transiently transfected with y7_STOP gives the 
expected product (750 bp). First lane -  molecular weight markers.
To confirm of transcription of y7 RNA tsA-201 cells were transiently 
transfected with y7_STOP and three days post transfection RNA was harvested 
and reverse transcribed. PCR was performed on the resulting cDNA with a 
primer pair to y7 (Fig 4.3.B). A band of expected size (approximately 750 bp) 
was obtained confirming that y l  mRNA was produced.
Experiments with this construct, performed by Dr J. Leroy, showed that it 
did not suppress N-type current through Cav2.2 channels in a tsA-201 cell 
expression system. These experiments are detailed in the Appendix (A.4.3.
Fig. A.2.).
4.4.3. QPCR of the Markers of ER Stress, CHOP and Edited XBP
It has previously been reported that ER stress can lead to a suppression 
of protein expression. It was hypothesised that expression of y7, or co- 
expression of Cav2.2 and y7, would lead to ER stress. To test this hypothesis 
experiments were performed to quantify expression of CHOP and XBP editing, 
two markers of the activation of the ER stress pathway cells.
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Primers were designed to allow QPCR of CHOP and XBP. Primers were also 
designed to quantify XB P editing. Fig. 4.4 shows the location of primers in 
relation to the edited section of XBP. The X B P (T0tai) primer pair will pick up all 
XBP cDNA. The reverse primer of the X B P (Unedited) pair was designed to be 
within the edited region of XBP thus only amplifying unedited XBP. QPCR is 
dependent upon the PCR efficiency. Preliminary experiments were performed 
to ensure that the PCR reactions with the CHOP XBP(Totai) and X B P (Unedited) were 
sufficiently efficient.
XBP
X B P (U n«*»d ) F  XBP(Tott0F
Edited Region
XBPW R
X B P ( Unedited) P
Fig. 4.4. Diagrammatic representation o f the positions o f  the XBP (Total) and 
XBP(unedited) primer pairs. The region edited out by IRE1 is shown as a red box. 
XBP(Totai) primer pairs are shown in green and XBP(Unedited) primer pairs are shown in 
blue.
PCR efficiency is obtained by comparing the values obtained for the 
standard curve to that of an ideal PCR reaction in which a difference of 3.3 
cycles would be equivalent to a 10 fold difference in the starting quantity of 
cDNA. Fig 4.5 shows the PCR efficiency using the (A) CHOP, (B) XBP(Totai) and 
(C) XBP(unedited) primer sets. All primer sets were of high efficiency (97.4%, 
98.6% and 98.2% respectively), which is sufficient for use in QPCR. Fig. 4.6. 
shows the melt curves obtained for each construct. For each primer pair the 
PCR product obtained melts as a single, narrow peak. This suggests that only 
one PCR product was produced for each primer set.
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PCR Efficiency: 97.S % Standards
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PCR Efficiency: 99.0 %
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Fig. 4.5. PCR reactions using the CHOP XBP (Total) and XBP (Unedited) primer sets 
are o f high efficiency and can be used fo r  QPCR. A cDNA library derived from 
mRNA from tsA-201 cells treated with Tunicamycin was serially diluted and PCR 
performed using CHOP; XBP(xotai) and XBP(unedited) primer sets to obtain the PCR 
efficiency for each primer set.
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Fig. 4.6. Melt curves o f the PCR products generated using the CHOP, XBP (Total) and 
XBP(i]nedite(t) primer sets show specificity o f the PCR products in each reaction. The
PCR products obtained using the CHOP XBP(T0tai) and XBP(Unedited) primer pairs were 
heated from 54-94 °C in 80 steps increasing 0.5°C per step. The temperature at which 
there is the greatest change in fluorescence corresponds to the release o f the SYBR dye 
and thus the melting o f the PCR product.
4.4.4. Regulation of CHOP Expression and XBP Editing by the ER stress 
Inducers DTT and Tunicamycin
To confirm that the expression of CHOP and editing of XBP could be 
used as markers of ER stress in this system tsA-201 cells were treated with the
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inducers of ER stress, Dithiothretiol (DTT) or tunicamycin. Fig. 4.7 shows that 
the addition of 2.5 pg/ml of tunicamycin six hours prior to harvesting RNA 
increased XBP and CHOP expression to 193 ± 27% (n=5) and 1620 ± 437% 
(n=5) compared to untreated cells, respectively. Addition of DTT to a final 
concentration of 10mM 30 minutes prior to harvesting produced no change in 
XBP expression (106 ± 3% (n=3)) and a slight increase in CHOP expression 
(163% (n=1)). However, XBP editing is increased by treatment with both DTT 
and tunicamycin as shown in Fig. 4.8. In experiments in which cells were 
treated with 10mM DTT the amount of edited XBP rose from 16 ± 6% in 
untreated cells to 95 ± 3% (n=3). Similarly the amount of edited XBP in cells 
treated with tunicamycin rose to 88 ± 4%, from 26 ± 9% in untreated cells (n=5)
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Fig. 4 .7. XBP and CHOP levels during ER stress. tsA-201 cells were treated with the 
inducers o f ER stress, DTT or Tunicamycin. The expression o f XBP and CHOP were 
assessed by QPCR and normalized with respected to the expression measured in 
untreated cells. Where present bars represent S.E.M.
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Fig. 4.8. The inducers o f ER stress DTT and tunicamycin both increase the 
percentage o f XBP that is edited. tsA-201 cells were treated with the inducers o f ER 
stress, DTT or Tunicamycin. The percentage o f XBP that was edited was assessed by 
QCPR. Bars represent S.E.M.
4.4.5 CHOP Expression and XBP Editing Are Not Regulated by 
Transfection of y7 or Co-Transfection y7 and Cav2.2.
To examine if ER stress is induced by transfection of y7, or the co­
transfection of y7 and Cav2.2, cells were transfected with y7, Cav2.2 (plus the 
auxiliary subunits Pib and ct25-2), Cav2.2 (plus the auxiliary subunits Pib and 
a25-2) plus y7, or as a control, empty pMT2 vector. After 24 hours mRNA was 
harvested from the cells and reverse transcribed. Expression of CHOP and 
XBP, were measured by QPCR. Fig 4.9 and Fig 4.10 show that neither CHOP 
nor XBP expression is regulated by the expression of Cav2.2, y7 or Cav2.2 co­
transfected with. y7.
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Fig. 4.9. CHOP expression is not increased by transient transfection o f Cay2.2, y7 or 
both Cay2.2 and y7. tsA-201 cells were transiently transfected with Cay2.2, y7 or 
Cay2.2 and y7 co-transfected. Expression o f the indicator o f ER stress, CHOP, was 
assessed by QCPR and normalized by the expression measured in untreated cells. Bars 
represent S.E.M. (n = 5).
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Fig. 4.10. XBP expression is not increased by transient transfection o f Cay2.2, y7 or 
both Cay2.2 and yl. tsA-201 cells were transiently transfected with Cay2.2, y7, or 
Cay2.2 and y l  co-transfected. Expression o f the indicator o f ER stress, XBP, was 
assessed by QCPR and normalized by the expression measured in untreated cells. Bars 
represent S.E.M. (n =5)
A further indicator of ER stress, editing of XBP, was also examined using 
QPCR. XBP editing was not significantly increased when cells were transfected 
with Cav2.2 alone, ory7 or with both Cav2.2 and y l  (the highest p value 
obtained was 0.08 for untreated cells compared to y l  transfected cells) (Fig 
4.11).
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Fig. 4.11. XBP editing is not increased by transient transfection o f Cay2.2, y7 or both 
Cay2.2 and y l  co-transfected. tsA-201 cells were transiently transfected with Cay2.2, 
y7, or Cay2.2 and y7. Editing o f XBP, an indicator o f ER stress, was assessed by 
QPCR. Bars represent S.E.M. (n = 5).
The level of XBP expression and the percentage of XBP editing are 
positively correlated with an R value of 0.84 in both transfected cells and cells 
treated with Tunicamycin, as a positive control (Fig. 4.12)
106
250.00
7n 200.00
150.00
100.00
50.00
0.00
vP0s
co
' ( / )  cn
CL
X
LU
■o
0
.N
"TO
E
o
100.00
90.00
-  80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
"O
01
1C
LU
f l ­
ea
X
■  Expression — Edited
Fig. 4.12. Comparison o f XBP expression and XBP Editing. XBP expression and 
XBP editing in cells transfected with Cav2.2, y7, co-transfected with Cay2.2 and y7, or 
treated with tunicamycin. Bars represent S.E.M. (n = 5).
It was possible that y l  or y7 co-transfected with Cav2.2 was inducing ER 
stress but that too few cells were transfected for the effect to be detected. To 
investigate this, the same experiment with the cells transfected using an Amaxa 
Nucleofector. Nucleofection gives a very high level of plasmid take up and 
protein expression. Once again, even with a very high rate of transfection, 
CHOP expression was not increased when transfected with y7 or with Cav2.2 
and y l  (Fig 4.13). These values correlate well with the previous experiments 
with an R value of 0.95.
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F/g. 4.13. CHOP expression is not increased in cells transfected by nucleofection o f  
Cay2.2, y7 or both Cay2.2 and y7 co-nucleofected. tsA-201 cells were transiently 
transfected with Cay2.2, y l  or Cav2.2 and y7 co-transfected. Expression o f the indicator 
o f ER stress, CHOP, was assessed by QCPR. Bars represent range (n=2).
4.5. Discussion
The experiments using y7_STOP, which produces y7 mRNA that is not 
translated to y7 protein, show that the production of y7 mRNA alone is 
insufficient to cause a suppression of Cav2.2 expression. Therefore, the 
suppression of Cav2.2 expression by y7 requires y7 protein and is not due to an 
RNA-RNA interaction between Cav2.2 and y7 mRNA. As promoter usage 
between y7 and y7_STOP should be identical these experiments also provide 
further evidence that the suppression of Cay2.2 is not due to promoter 
competition between plasmids.
Previous work by Page et al (238) has shown that suppression of Cav2.2 
expression by truncated Cav2.2 expression involves the UPR pathway. It has
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also been shown that the UPR pathway leads to suppression of translation of 
mRNA (225). To investigate if the UPR pathway was involved in the 
suppression of Cav2.2 by y7 QPCR assays were designed to quantify CHOP 
and XBP expression and XBP editing in tsA-201 cells transiently transfected 
with y7 or y7 co-transfected with Cav2.2. CHOP was chosen as it has been 
shown to be regulated by both the PERK and ATF6 pathways whereas XBP 
editing and expression is affected by all three pathways of the UPR.
The functionality of the assays was confirmed by treating cells with 
inducers of ER stress DTT and tunicamycin. It is interesting that while DTT had 
little effect on CHOP expression, it strongly increased the percentage of XBP 
that was edited. A possible reason for this is that short incubation time with 
DTT (30 minutes) was insufficient for large changes in gene expression to take 
place but sufficient for the enzymatic editing of XBP to take place.
Transient transfection of tsA-201 cells with Cav2.2, plus auxiliary 
subunits, with or without y7 or transfection with y7 alone did not result in 
significant upregulation of expression of CHOP or XBP or increased editing of 
XBP. Despite the much higher rate of transfection, cells transfected by 
nucleofection also did not show a significant increase in CHOP expression with 
any of these combinations.
In both transiently transfected and nucleofected cells Cav2.2 expression 
resulted in a small, but not significant, increase in CHOP expression. While 
neither of these results was statistically significant when taken alone, together 
they suggest that overexpression of Cav2.2 cause significant stress upon the 
ER. This is perhaps to be expected as calcium channels are large multi­
transmembrane, multi-subunits proteins. It may be that y7, by reducing Cav2.2 
expression, reduces the stress upon the ER, but in no case was there a 
significant reduction compared to Cav2.2 alone.
These results suggest that the UPR pathway is not induced and that this 
pathway is not involved in the suppression of Cav2.2 expression by y7. 
Therefore, while the observed effects on Cav2.2 expression by the co­
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transfection of y7 are similar to those of co-transfection of truncated Cav2.2 
constructs the mechanism of their action appears to be different.
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Chapter 5 - y7 and PC12 cells
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5.1. Introduction
5.1.1. Generation of the PC12 Cell Line
The PC 12 cell line was generated by Greene and Tischler from a 
transplantable rat adrenal pheochromocytoma (neuroendocrine tumours of 
adrenal chromaffin cells) line (241). It is a clonal line which upon treatment with 
NGF undergoes mitotic arrest and begins to put out branching processes similar 
to those seen in sympathetic neurons. This change in morphology is 
accompanied by a change in biochemistry to resemble neuronal cells. These 
properties have made PC 12 cells a useful model system for the study of neural 
differentiation (242)
5.1.2. Voltage-Dependent Calcium Channels in PC12 Cells
PC 12 cells have been shown to express N- L- P- and T-type currents 
(243-246). Differentiation induced by treatment with NGF leads to an increase 
in N-type current (243). This increase in N-type current has been shown to be 
accompanied by an increase in Cav2.2 mRNA (247;248).
5.2. Aims
The aims of the work described in this chapter were firstly to investigate if 
y7 suppressed the expression of endogenous Cav2.2 in differentiating PC12 
cells and secondly to investigate the endogenous expression of yl  in PC 12 
cells.
5.3. Additional Methods
Experiments were performed as described in Chapter 2 with the following 
differences and additions.
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5.3.1. QPCR
PC 12 cells were cultured as described in Methods. NGF was applied at 
100 ng/ml and every second day medium was removed and replaced with NGF 
containing media. RNA was harvested after seven days of treatment with NGF. 
Primer pairs y7(QpcR), Cav2.2(QpcR) and Cav1.2(QPCR) are detailed in the Appendix 
(A.3.2.). Preliminary experiments were performed to define the optimum PCR 
conditions for each primer pair and accordingly step two of the second PCR 
cycle was set to temperatures of 56.7°C, 53°C and 53°C for primer pairs for 
y7(qpcr), Cav2.2(QpcR) and Cav1.2(QPcR), respectively. Significance was 
determined using a one-sampled t-test.
5.3.2. RT-PCR
Primer pairs y1(Rat), y2(Rat), yVat). y 6 (Rat), y 7 (Rat), and Actin(Rat) are detailed 
in the Appendix (A.3.2). cDNA libraries were generated from undifferentiated 
PC 12 cells.
5.3.3. Immunocytochemistry
In experiments with differentiated PC12 cells, actin was visualised by 
incubating the cells for 20 minutes at room temperature with 6.6 pM TexasRed- 
phalloidin. All cells were examined on a LeicaTCS SP confocal laser scanning 
microscope. Photomultiplier settings were kept constant in each experiment.
All images shown are single 0.5 pm sections through the cell. Anti-y7(Taii) Anti- 
and y7(Loop) antibodies were used at 0.8 pg/ml
5.3.4. Western Blotting
PC 12 cells were taken up in PBS plus Complete™ protease inhibitors. 
Cells were lysed on ice by sonication for 3 x 10s second bursts. Unlysed cells 
and other material were removed by centrifugation at 3,000 x g for 3 minutes. 
The supernatant was decanted and spun at 50,000 x g for 4 hrs (4°C). The 
pellet was taken up in PBS plus Complete™ protease inhibitors and the protein
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concentration determined by BCA assay. 200 jig of protein (along with 30 \ig of 
whole cell lysate from y7 transiently transfected tsA-201 cells) were run on 
NuPAGE 4-12% Bis-Tris gels. Western blotting was then performed with the 
anti-Y7(Taii) antibody at 0.4 pg/ml.
5.4. Results
5.4.1. Transient Transfection of y7 into Undifferentiated PC12 Cells Does 
Not Suppress N-type Current Through Cay2.2 After Differentiation
NGF-induced differentiation of PC12 cells is accompanied by an increase 
of N-type current through Cav2.2 channels after about 3 days. It was 
hypothesised that transient transfection of y7 into undifferentiated cells might 
inhibit Cav2.2 expression, thus preventing expression of N-type current in 
differentiated cells. To test this hypothesis PC 12 cells were transiently 
transfected with y7 and then differentiated by application of 100 ng/ml NGF. N- 
type current was recorded from cells five to seven days post transfection and 
subsequent treatment with NGF. These experiments were performed by Dr J. 
Leroy and are detailed are in Appendix (A.4.4. Fig. A.3.). Briefly, transient 
transfection with y7 did not suppress the expression of N-type current in 
differentiated PC12 cells.
5.4.2. Suppression of Cav2.2 Expression by y7 Still Occurs in Transiently 
Transfected PC 12 cells.
As transient transfection of y7 did not suppress endogenous N-type 
current in differentiated PC 12 cells it was hypothesised that there may be a 
component which is endogenously expressed in PC12 cells, but not tsA-201 
cells, COS7 cells or Xenopus oocytes, that prevented this effect of y7. PC 12 
cells were transiently transfected with Cav2.2 and auxiliary subunits with or 
without y7. Three days post transfection N-type current was recorded. These 
experiments were performed by Dr J. Leroy and are detailed in the Appendix 
(A.4.4. Fig. A.3.). Briefly, as in other cell types, N-type current through
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transiently transfected Cay2.2 channels was suppressed by co-transfection with
y7.
5.4.3. y7 is Endogenously Expressed in PC12 Cells
Previous work has shown that transient transfection of y7 into SCG cells 
results in an altered morphology of the cell (174). Processes put out by SCG 
cells transiently transfected with y7 were much finer than those of untransfected 
controls. Experiments were performed to examine if transient transfection with 
y7 would also alter the morphology of PC 12 cells. Although there were no 
obvious changes in morphology in PC 12 transfected with y7 compared to 
untransfected cells, it was observed that all PC 12 cells were reactive to the 
y7(Tail) antibody. y7 was detected in both undifferentiated cells (Fig 5.1.A) and 
differentiated cells (Fig. 5.1.B).
In both differentiated and undifferentiated PC12 cells y7 was found 
throughout the cell without the perinuclear concentration seen in transiently 
transfected cells. In differentiated cells y7 was found along the process and 
appeared to localise with actin at the ends of the processes (Fig 5.1 B. Arrows). 
A similar spatial organization was observed when y7 was detected with the 
y7(LooP) antibody (Fig. 5.1 C).
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Fig. 5.1. y7 is endogenously expressed in both undifferentiated and differentiated PC 12 cells. Immunofluorescence for y7 (green) was 
detected in undifferentiated (A I) and differentiated (B) PC 12 cells. Immunofluorescence for y7 was not detected i f  the y7 antibody was pre­
incubated with a 10-fold molar excess o f the peptide it was raised against (A II) or when the y7 antibody was omitted (A III). Co-location o f 
y7 and actin (red) at the ends o f process is indicated by arrows. C) Expression was also detected with and antibody raised against a different 
epitope in y7. The nuclear stain DAPI (blue) was used as a marker in all experiments. Texas-Red phalloidin was used to reveal F-actin in 
experiments B and C. Scale bar = 20 pm
To confirm expression of y7 in PC 12 cells RT-PCR with primer pairs for 
y7 was performed on a cDNA library generated from undifferentiated PC 12 cells 
(Fig. 5.2.A). A band of the expected size of 828 bp for y7 was obtained. This 
band was confirmed to be y7 by DNA sequencing. PC12 cells from an 
alternative source were also tested using RT-PCR and were found to express 
y7. Western blotting with the y7(Taii) with cell lysate from undifferentiated PC12 
cells detected a faint band of the same molecular weight as y7 transiently 
expressed in tsA-201 cells (Fig. 5.2 B).
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Fig. 5.2 RT-PCR and western blotting confirm endogenous expression o f y7 in 
undifferentiated PCI2 cells. A) RTPCR o f y7 from a cDNA library generated from 
undifferentiated PC 12 cells. Primers for actin were used as a positive control. B) 
Extracts from tsA-201 cells transiently transfected with y7 (1) and undifferentiated 
PC 12 cells. PC 12 cells were sonicated and insoluble material (2) removed by 
centrifugation. The resulting supernatant was centrifuged at 50,000 x g for 4 hours and 
samples o f the supernatant (3) and pellet (4) taken. A ll samples were western blotted 
with the y7(Taii) antibody.
5.4.4. y7 expression Does Not Significantly Change After Treatment of 
Cells with NGF
To examine if expression of y7 in PC12 cells changed in response to 
NGF treatment, QPCR was performed using primer pairs to y7. Expression of 
y7 in PC 12 cells after seven days treatment with NGF was compared to 
untreated cells. Cav1.2 and Cav2.2 expression were used as controls.
Previous work by Colston et al (248) had shown a slight increase in Cav2.2 and 
a decrease in Cav1.2 expression in PC12 in response to NGF. Primer pairs for
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Cav1.2, Cav2.2 and y7 were tested to ensure that they were of sufficient 
efficiency for QPCR (Fig 5.3).
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Fig. 5.3. PCR reactions using primer sets C o v 2 . 2 ( q p c r ) ,  Cayl.2(QPCR) and y7 (q p c r) are 
o f high efficiency and can be used fo r  QPCR.. A cDNA library derived from mRNA 
from undifferentiated PC 12 cells was serially diluted and PCR performed using the 
Cay2.2(QPCR), Cavl.2(QPCR) and y7(qpcr) primer sets to obtain the PCR efficiency for 
each primer set.
As previously reported, exposure to NGF for seven days evoked a 
significant decrease of Cav1.2 expression (248). However, neither expression 
of y7 nor Cav2.2 was affected.
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Fig. 5.4 y7 expression does not change in PC 12 in response to NGF treatment. PC 12
were treated for 7 days with lOOng/ml NGF. Expression o f Cay2.2, Cay 1.2 and y7 were 
assessed by QPCR and compared to their respective expression in untreated cells. Bars 
represent S.E.M (n = 4).
5.4.5 Expression of Other y Subunits in PC12 Cells
Previous work has shown expression of several gamma subunits (y1, y2, 
y4, y6 and y7) in the adrenal gland (173). RT-PCR was used to examine if any 
other y subunits found in the adrenal gland, in addition to y7, were expressed in 
PC12 cells. Primer pairs were designed to detect y1, y2, y4 and y6 giving bands 
of 95, 114, 131 and 76 bp respectively. RT-PCR using these primer pairs on a 
cDNA library generated from undifferentiated PC12 detected y2 but notyl, y4 or 
y6 (Fig 5.5).
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Fig. 5.5. mRNA fo r  y2, but not yl, y4 and y6, is endogenously expressed in PC 12 
cells. RT-PCR for y l, y2, y4 and y6 on a cDNA library generated from undifferentiated 
PC 12 cells.
To investigate if y2 expression in PC 12 cells changed upon treatment 
with NGF QPCR was performed on the cDNA libraries from undifferentiated and 
NGF treated cells generated previously. The primer pair for y2 was tested and 
found to be suitable for QPCR (Fig. 5.6.A). Preliminary experiments showed a 
reduced expression of y2 in NGF differentiated PC12 cells, but the effect was 
not statistically significantly (p = 0.06)(Fig. 5.6.B). Further experiments would 
need to be performed to confirm this result.
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Fig. 5.6. Effect o f NGF treatment on y2 expression in PC 12 cells A) Efficiency o f 
PCR using the y2 primer pair is sufficient for QPCR. B) PC 12 were treated for 7 days 
with lOOng/ml NGF. Expression o f y2 was accessed by QPCR and compared to its 
expression in untreated cells. Cav2.2 expression obtained previously is shown as a 
comparison. Error bars represent S.E.M. (n = 4).
5.5. Discussion
Transient transfection of y7 into undifferentiated PC12 cells did not 
suppress the expression of N-type current through Cav2.2 channels upon 
differentiation. However, in undifferentiated PC12 cells expression, of 
transiently transfected Cav2.2 was still suppressed by co-transfection of y7.
This would suggest that the failure of transfected y7 to suppress expression of 
endogenous Cav2.2 is not due to another factor expressed in PC12 cells. A 
result similar to the present finding in differentiated PC12 cells was reported by 
Moss et at who showed that transient transfection of primary sympathetic 
neurons with y7 did not suppress N-type current through Cav2.2 channels (174).
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One possible explanation of these results is Cav2.2 is only suppressed 
when it is expressed from a plasmid. However, previous work by Sher et al 
(249) suggests that the expression of N-type current following differentiation of 
PC12 cells is due to an existing pool of Cav2.2 channels rather than an increase 
in expression of Cav2.2. Therefore it is possible that transient transfection of y7 
does not affect endogenous N-type current in PC12 cells as the Cav2.2 
channels are already present or have at least past the step in their expression 
at which y7 exerts its effect.
In support of Cav2.2 channels being expressed before differentiation, 
QPCR experiments performed here showed that Cav2.2 mRNA levels do not 
change significantly during differentiation. Colston et al (248) showed a slight 
but significant increase in Cav2.2 mRNA in PC 12 cells by treatment with 100 
ng/ml NGF for 7 and 14 days. However, before 7 days there was no significant 
difference in Cav2.2 mRNA. The differences seen between those experiments 
and those performed here could be explained by the sensitivity of using real 
time QPCR compared to measuring ethidium bromide binding used by Colston 
et al or due to the differences between PC12 cells from different sources. The 
larger and more significant decrease of Cav1.2 expression was detected in both 
sets of experiments.
If y7 acts as a regulator of Cav2.2 expression then it would be expected 
that NGF treatment would reduce y7 expression as N-type current through 
Cav2.2 channels increased. However, there was no significant change in the 
mRNA level of endogenous y7 in NGF-treated cells compared to untreated 
cells.
y7 is endogenously expressed in PC 12 cells. It was detected at a mRNA 
level by RTPCR and at protein level by immunocytochemistry and western 
blotting. y7 has been shown to be mainly neuronal (174) but has also been 
found at the mRNA level in a range of tissues (171; 173). The adrenal gland, 
from which PC12 cells are derived, has been to shown express y1, y2, y4, y6 
and y7 (173). In addition to y7, y2 was also found in PC12 cells. The presence
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of y2, shown to be a TARP, in PC12 is surprising as PC12 cells have been 
shown not to express glutamate receptors of the AMPA type, although they do 
express NMDA type glutamate receptors (250).
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Chapter 6 -  The C-terminus of y7
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6.1. Introduction
Multi-subunit proteins require the correct folding and stoichiometry of the 
individual subunits to function correctly. One of the ways in which the cell 
prevents individual subunits from leaving the ER before they assemble correctly 
is by the use of RXR motifs. RXR motifs were first discovered by Zerangue et 
al (251). They showed that an RXR motif was involved at multiple stages of the 
assembly of the ion channel K a tp  and restricted surface expression to fully 
assembled and correctly regulated channels.
The presence of a RXR motif in the subunit resulted in the immature K Atp  
subunits being retained within the ER in the absence an auxiliary subunit. 
Mutation of the RXR motif to alanines resulted in surface expression of the 
subunit even in the absence of an auxiliary subunit. Furthermore, addition of 
the RXR motif to IRK1, another potassium channel that is normally trafficked to 
the cell surface, resulted in this protein being retained within the ER. Further 
work by Ma et al went on to confirm the importance of RXR motifs in the 
regulation of surface potassium channel numbers (252;253).
RXR motifs are located cytoplasmically and it is believed that when they 
are exposed the protein is retained within the ER. Upon the correct assembly of 
the multi-subunit complex the RXR motif is masked allowing the protein 
complex to leave the ER.
RXR motifs have also been shown to be important in the regulation of 
trafficking of other proteins to the plasma membrane including GABA(B), 
kainite, 5HT3 and NMDA receptors (253;254).
6.2. Aims
The aims of this study were to investigate if RXR motifs, present in the C- 
terminal tail of y7, are involved in the knockdown of Cav2.2 expression. To do 
this a series of truncated y7 mutations were made and their effect on Cav2.2
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expression measured by western blotting. The effect of the C-terminal tail of y7 
alone on Cav2.2 expression was also investigated.
6.3. Additional Methods
Experiments were performed as described in Chapter 2 with the following 
differences and additions.
6.3.1. Generation of Constructs
77(1-217), y7(i-238). y7(i-27i). y7(2oi-275), y7(2oi-275) _HA, y2TM y7Tail and 
y7_PDZ were made by standard molecular biological techniques using the 
primer pairs detailed in the Appendix (A.3.1). All constructs used in these 
experiments were subcloned into the pMT2 expression vector.
6.3.2. Western blotting
To determine the level of expression of the truncated y7 constructs they 
were transfected into tsA-201 cells and three days post transfection cells were 
harvested and taken up in 200 pi of SDS buffer. Samples were then sonicated 
briefly (3 10 second pulses, on ice) and heated to 70°C for 10 minutes. A 15 pi 
aliquot of each sample was separated on 4-12% Bis-Tris gels using MES 
running buffer. Using MES as a running buffer provides better resolution of 
lower molecular weight proteins. SigmaMarker™LowRange makers were used. 
Anti-y7(Loop) and anti- y7(jaii) antibodies were both used at 1 pg/ml.
In quantification of Cay2.2 expression by western blotting experiments, 4- 
12% Tris-Glycine gels, which provide better resolution and more favourable 
transfer conditions, were used instead of 4-12% Bis-Tris gels. Transfer 
conditions of 25V and 400 mA (current limiting) for 1 hour were used. An 
antibody to Cay2.2 was used as the primary antibody at a concentration of 
1.2pg/ml. Quantitative analysis of western blots was performed using 
ImageQuant software. The intensity of the Cav2.2 band from cells co­
transfected with a y7 construct was measured and given as a percentage of the
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intensity of the band obtained for cells transfected with Cav2.2 and empty 
vector. Significance was determined by a one sample t-test.
6.3.3. Imaging
In sub-cellular localisation experiments cells were examined on a Leica 
TCS SP confocal scanning laser microscope. Photomultiplier settings were 
kept constant in each experiment and all images were scanned sequentially. All 
images shown are single 0.5 pm optical sections through the cell. Anti-y7(L0op) 
was used at 0.8 pg/ml.
6.4. Results
6.4.1. Expression of Truncated y7 Subunits
The C-terminal region of y7 contains two putative ER retention motifs 
RPR (218-220) and RGR (239-241). To investigate if these were involved in 
the knockdown of Cav2.2 expression, two truncated y7 constructs were made. 
Primers were designed to replace either R218 or R239 with a stop codon to 
give y7(i-2i7) and y7(1.238) respectively. A third truncated y7 construct y7(1_27i) was 
also made in which the last four amino acids were deleted. It has been 
hypothesised that these four amino acids may be similar to a PDZ binding motif 
shown to be important in TARPs (177). These three constructs are shown 
diagrammatically in Fig. 6.1. and their expression confirmed by western blotting 
(Fig. 6.2.) using antibodies raised against epitopes in either the predicted 
extracellular loop (y7(LOop)) or the C-terminal tail (y7(Taii)) as appropriate.
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Fig. 6.1. Diagrammatic representation o f truncated y l  constructs. Putative RXR 
motifs are highlighted in bold. y7(i_2i7) is underlined in green, y7(i_238) underlined in 
yellow and y7(i_27i) underlined in orange. y7(2oi-275) is underlined in light blue. In 
y7_PDZ the last 4 amino acids were mutated from TSPC to TTPV.
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Fig. 6.2. Western blotting and immunodetection o f truncated y7 constructs, y l  and
truncated y l  constructs were expressed in tsA-201 cells. Three days post transfection 
cells were harvested and whole cell lysate separated by SDS PAGE. Upper panel: 
Immunodetection using the y7(Loop) antibody. The upper arrow indicates y7(i_238) and the 
lower arrow indicates y7(i_2i7). Lower panel: Immunodetection using the y7(iaii) 
antibody.
All constructs appear as doublets with the majority of the protein being 
found in the lower of the two bands. This band corresponds to the expected 
molecular weight of each protein, assuming the protein is unmodified (y7, y7(i.
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217), 7*7(1-238) and y7(1.27i) are 31kDa, 24 kDa, 27 kDa and 31kDa respectively). 
The upper band seen may be the glycosylated form of each protein. y7(1.2i7) 
and y7(i_238) lack the epitope to which the C-terminal antibody was raised and 
are consequently not detected with the y7(Taii> antibody.
6.4.2. Removal of the C-terminal Region of y7 Negates the Knockdown of 
Cay2.2 Expression
COS7 cells were transiently transfected with Cav2.2, co-transfected with 
either empty pMT2 or full length y7 or one of the truncated y7 constructs. In 
control experiments the non-related six transmembrane domain voltage- 
dependant potassium channel (Kv3.1b) replaced a y7 construct. Three days 
post transfection the cells were harvested, total protein concentration was 
measured by BCA assay and all samples were standardised to a protein 
concentration of 1.67 pg/pl. 30 pg of each sample was separated by SDS 
PAGE. The amount of Cav2.2 expressed in each sample was estimated by 
Western blotting and immunodetection with an antibody raised against an 
epitope in the ll-lll loop of Cav2.2. In these experiments no auxiliary calcium 
channel subunits were co-transfected. The suppression of Cav2.2 expression 
by y7 was found to be independent of other auxiliary subunits (as shown in 
Chapter 3) and omitting them removes a potential source of variation.
Example blots of the effect of each construct on Cav2.2 expression are 
shown in Fig. 6.3. A. Cav2.2 was detected as a discrete band just above the 
205 kDa marker (Cav2.2 expected molecular weight 261 kDa). The intensities 
of the bands representing Cav2.2 in both control and experimental lanes were 
measured using ImageQuant. In each experiment Cav2.2 co-transfected with 
empty pMT2 was designated as100% and Cav2.2 co-transfected with other 
constructs given as a corresponding percentage. The mean data from 5 to 12 
experiments is given in Fig. 6.3.B.
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Fig. 6.3. The effect o f y7, the truncated y l  constructs and Ky3.1b on the co­
expression o f Cav2.2. A) C0S7 cells were transfected with Cav2.2 plus y7, one o f the 
truncated y7 constructs, Ky3.1b or empty pMT2 vector. The expression o f Cay2.2 was 
measured by western blotting and immunodetection using an antibody raised against 
Cay2.2. Cay2.2 is indicated by an arrow in each blot. B) Quantitative analysis o f 
suppression o f expression o f Cay2.2 by y7 and truncated y7 constructs. Cay2.2 co­
transfected with pMT2 alone was designated to be 100% and other co-transfected 
constructs are given as corresponding percentages. Bars represent S.E.M. ** p<0.01, * 
p<0.05.
Cay2.2 expression was reduced to 38% ± 7% (n = 12) when co­
transfected with y7 compared to Cav2.2 co-transfected with control empty pMT2 
vector. Co-transfection of Kv3.1b with Cav2.2 did not significantly alter Cav2.2 
expression. The effect of co-transfecting the truncated y7 constructs was also 
examined. y7(1.27i) reduced Cav2.2 expression to the same extent as full-length
y7 (to 28% ± 3% (n = 6) of Cav2.2 expressed alone). y7(1.238), which contains 
one RXR motif, also reduced Cav2.2 expression, though to a lesser extent (to 
56% ± 4% (n = 5) of Cav2.2 expressed alone). y7(i_2i7). in which both RXR 
motifs have been removed, did not significantly alter Cav2.2 expression (Fig. 
6.3B).
These results show that removal of the whole of the C-terminal tail of y7, 
including both RXR motifs, negates the suppression of Cav2.2 expression seen 
with full length y7. Removal of the C-terminal tail of y7, up to and including the 
first RXR motif, results in only a partial effect on Cav2.2 expression compared to 
full length y7. Removing only the last four amino acids did not alter y7’s ability 
to suppress Cav2.2 expression. A further construct in which the last four amino 
acids were converted to a PDZ binding domain was also found to be as 
effective as y7 in suppressing Cav2.2 expression (data not shown).
6.4.3. Sub-cellular Localisation of the Truncated y7(i.2i7) Subunit is 
Unaltered From That of Full Length y7
It was hypothesised that removal of the RXR motifs in y7 would result in 
a change in its location to the plasma membrane, as is common in other y 
subunits (177; 187). To investigate this y7 and the truncated y7(1.2i7) construct 
were transiently expressed in COS7 cells. Three days post transfection cells 
were fixed, permeablised and stained with the nuclear marker DAPI. The 
cellular distribution of the y7 and y7(1.2i7) was detected using an antibody raised 
against the predicted first extracellular loop of y7 (y7{LOop)) and imaged by 
confocal microscopy (Fig. 6.4 A).
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Fig. 6.4. Removal o f  the C-terminal tail o f  y7 does not alter its sub-cellular location.
A. Immunofluoresence for y l  or y7(i_2i7) with an antibody raised against an epitope in 
the predicted first extracellular loop o f y l  (green), y l  was only detectable i f  the cells 
were permeablised by treatment with 0.02 % Triton for 15mins at room temperature 
following fixation. B. Immunofluoresence for y7(2oi-275) with an antibody raised against 
an epitope in the C-terminal tail o f y l  (green). In both experiments the nuclear stain 
DAPI (blue) was used as a marker. Bars = 50 pm.
y l  was found to be present throughout the cytoplasm and often showed 
mainly perinuclear location, characteristic of it being present in the ER. y7(i_2i7) 
was all also located throughout the cytoplasm with the strongest staining often 
being perinuclear. Neither y7 nory7(i-2i7) localised to the plasma membrane. 
This is supported by the observation that no y l  could be detected if the cells
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were not permeablised. Similar patterns of location were seen for the yl^.2zs) 
and y7(i-27i) constructs.
6.4.4. The C-terminal Region of yl is Sufficient to Cause a Knockdown of 
Cav2.2 Expression
As removal of the C-terminal tail of y l negated the suppression of 
expression of Cav2.2 it was decided to investigate the effect of the C-terminal 
tail alone. Primers were designed to generate a construct that would express 
the C-terminal region of y7 (amino acids 201-275) (y7(2oi-275))-
Three days post-transfection into COS7 cells y7(20i-275) was not 
detectable by Western blot and immunodetection with the y7(jaii) antibody. This 
was shown not to be a cell-type specific effect as y7(2oi-275) transfected into tsA- 
201 cells was also undetectable. To examine if this lack of detection was a 
problem, such as low affinity, with the y 7 (Taii) antibody, a C-terminally HA tagged 
construct was also made. This construct was also not detectable with either the 
y 7 (Tail) antibody or an antibody raised against the HA epitope. However, 
expression of this construct was observed after concentration by 
immunoprecipitation with an anti-HA antibody and a band of expected size (11 
kDa) was detected (Fig. 6.5).
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Fig. 6.5. y7(2oi-275i_HA is only observable after concentration by 
immunoprecipitation. Extracts o f tsA-201 cells transfected with y7(2oi-275)_HA or 
untransfected controls were immunoprecipitated and expression o f y7(2oi-275)_HA  
detected with an anti-HA antibody.
Despite not being detectable by western blotting, when transiently 
transfected into C 0S7 cells and imaged by confocal microscopy y7(2oi-275) is 
detectable. y 7 (2oi-275) appears throughout the cytoplasm and occasionally also 
in the nucleus (Fig. 6.4.B). y7(20i-275) does not show the perinuclear localisation 
seen with y7 or the truncated y7 constructs.
Quantitative Western blotting experiments, as detailed above (Fig 6.3), 
were performed to investigate the effect of y7(20i-275) on expression of Cav2.2 
protein. Co-expression of y7(20i-275) with Cav2.2 resulted in a knockdown of 
Cav2.2 expression to 56% ± 25% (n=5) of Cav2.2 expressed with empty vector.
Electrophysiological studies were performed in collaboration to examine 
the effect of y7 on N-type current through Cav2.2 channels. To examine if 
removal of the C-terminal tail of y7 resulted in a reduction in N-type current y7 
and the truncated y7 constructs were used in a Xenopus oocyte expression 
system. These experiments were performed by Prof. A. Dolphin. Briefly, 
Cav2.2, the auxiliary subunits a28-2 and p1 b, and either y7, one of the truncated 
y7 constructs or empty pMT2 vector were injected into Xenopus oocytes. Three 
days post injection N-type current was recorded by two electrode voltage clamp.
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The results are summarised in Fig. 6.6. in which they are compared to 
the effect of y7 and the truncated y7 constructs on Cav2.2 protein expression in 
COS7 cells. The electrophysiological experiments correlate well with the 
previous Western blotting experiments with a correlation coefficient of 0.919. In 
these experiments y7 (2oi-275) significantly reduced N-type current though Cav2.2 
channels compared to control oocytes in which empty vector replaced a y7 
construct.
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Fig. 6.6. Correlation between the effect o f  f7 and the truncated f7 constructs on
^ I
Cay2.2 expression in COS7 cells and on their reduction o f Cay2.2 Ba currents in 
Xenopus oocytes. Quantitative western blotting experiments were compared to the
^ I
effect o f y7 and the truncated y l  on N-type Ba currents through Cay2.2 in Xenopus 
oocytes. Bars represent S.E.M. The straight line was obtained by linear regression, r = 
0.919.
Further to these experiments the effect of y7(1.2i7) and y7(20i-275) on N-type 
current through Cav2.2 was tested in the mammalian tsA-201 cell line. These 
experiments were performed by Dr J. Leroy. Briefly, y7 reduced N-type current 
through Cav2.2 channels and y7(1.217) did not. y7(20i.275) did not reduce N-type 
current. This was likely to be due to the low level of y7(20i-275) expression in tsA- 
201 cells.
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To investigate if the C-terminal tail of y7 would be able to suppress 
Cav2.2 expression when attached to another protein a further construct was 
made which contained the transmembrane domains of y2 and the C- terminal 
tail of y7 (y2TM y7Tail). Expression was confirmed by western blotting and 
immunodetection with the y7(Taii) antibody resulting in a band of the expected 
size (32 kDa) (Fig. 6.7). The effect of y2TMy7Tail, y2 and y7 on N-type current 
through Cav2.2 in tsA-201 cells was investigated by Dr J Leroy. Briefly y7 once 
again was shown to reduce N-type current. However, y2 and y2TM y7Tail did 
not.
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Fig. 6.7. Detection o f y2TMy7Tail in tsA-201 cells. Extracts o f tsA-201 cells 
transfected with y7 or y2TMy7Tail or untransfected controls were western blotted with 
the y7(Taii) antibody.
6.5. Discussion
T T
The results described here are in agreement with those published by 
Moss et al (174) in which suppression of expression by y7of GFP tagged- 
Cav2.2, but not Kv3.1b, was observed. The present results extend this finding 
by showing that the C-terminal tail of y7 plays a critical role in the suppression of 
Cav2.2 currents and expression. Removal of the C-terminal tail of y7 negates 
y7 suppression of Cav2.2 and expression of the C-terminal tail alone is enough 
to partially suppress Cav2.2 expression. This has been shown in both a 
mammalian cell line and in Xenopus oocytes by western blotting and 
electrophysiology respectively.
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It is possible that removal of the C-terminal tail of y7 results in a protein 
that is misfolded and non-functional. However, from the evidence that the C- 
terminal tail expressed alone is sufficient to suppress Cav2.2 expression, this 
would seem unlikely.
Although it is possible that the RXR domains in the C-terminal tail of y7 
are critical in the suppression of Cav2.2 expression by y7, this is not 
demonstrated by these experiments. Site-directed mutagenesis of the RXR 
domains would be required to determine if mutation of the RXR domains was 
sufficient to negate the suppression of Cav2.2 expression by y7. If the RXR 
domains were preventing y7 from progressing from the ER then one would 
expect a change in location, probably to the plasma membrane, for the 
truncated y7(1.2i7) construct. However, this was not seen. y7(1_2i7) showed the 
same subcellular distribution as full length y7. No y7 was localised to the 
plasma membrane and in non-permeablised cells it was not detectable with an 
antibody to a predicted extracellular loop. It is possible that the epitope for the 
extracellular antibody is somehow masked in non-permeablised cells. It is also 
possible that the four transmembrane structure, with intracellular N and C- 
termini and two extracellular loops, for y7 is incorrect. Alternative structures for 
PMP22, to which family y7 belongs, have been put forward (255). However, 
these structures would still put the y7 loop epitope on the extracellular side of 
the plasma membrane.
These experiments show that the last four amino acids, TSPC which are 
similar to the TTPV found in the TARPs, are unimportant in the suppression of 
Cav2.2 expression. The removal of these four amino acids did not prevent the 
suppression by yl of Cav2.2 expression in COS7 cells or the reduced N-type 
current through Cav2.2 channels n Xenopus oocyte expression systems. 
Mutation from TSPC to TTPV also resulted in suppression of Cav2.2 expression 
in COS7 cells. This however does not rule out that these four amino acids are 
important in another aspect of the function of yl. Indeed, they may well form a 
motif with similar functionality to the PDZ binding motif formed by TTPV in 
TARPS.
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Immunocytochemistry experiments showed that there were few cells that 
were strongly expressing y7(2oi-275), suggesting that the problem was due to 
poor expression of y7(20i-275)- As y7(2oi-275) is in the same vector as the other 
truncated constructs it would consequently have the same promoter. It was 
also ensured that there was a Kozak sequence (256) incorporated into the 
construct. The poor expression of y7(2oi-275) could be due to the composition of 
the C-terminal tail of y7. The C-terminal tail of y7 contains 29% proline, 
glutamate, serine and threonine. Proteins high in these amino acids have been 
shown to be rapidly degraded (257) and certain sequences of these amino 
acids are known as PEST sequences. Although prediction programmes do not 
pick a specific PEST sequence in the C-terminal tail it possible that the high 
percentage of these amino acids of y7(20i-275) leads to y7(20i-275) being quickly 
degraded. This is further supported by the observation that purified His-tagged 
y7(2oi-275) was found to be very quickly degraded. Also, after concentration by 
immunoprecipitation HA tagged y7(20i-275) was detectable by western blotting 
with an anti-HA antibody.
It is unknown why y2TMy7Tail did not reduce N-type current through 
Cav2.2 in tsA-201 cells. A possible explanation for this result could be that the 
construct may not fold in a way in which the C-terminus is available to or may 
be localised to a different cellular location where the C-terminus can not exert 
its effect.
In conclusion it would appear the C-terminal tail of y7 is necessary and 
sufficient for the suppression of CaV2.2 in overexpression systems.
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Chapter 7 -  y7 and its Association
With RNPs
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7.1. Introduction
7.1.1 Identification of Protein-Protein Interactions by Co- 
immunoprecipitation and Peptide Mass Fingerprinting
Identification of protein-protein interactions by proteomics methods is 
becoming increasingly popular. One method that has successfully identified 
novel protein interactions is by identification of proteins that co- 
immunoprecipitate with the protein of interest by peptide mass fingerprinting 
(258). Briefly the mix of proteins that have been immunoprecipitated are 
separated by 1D (SDS PAGE) or 2D electrophoresis (SDS PAGE followed by 
iso-electrofocusing).
A detailed description of the methodology of peptide mass fingerprinting 
will not be discussed here. Briefly, the proteins of interest are excised from the 
gel, washed and the cystine residues reduced and alkylated. The protein is 
then digested with trypsin and the resulting peptides are analysed by MALDI 
(Matrix-assisted Laser Desorption/Ionization) mass spectrometry. The masses 
of the tryptic peptides are determined and the resulting peptide map is queried 
against a non redundant sequence database containing all known protein 
sequences. The significance of the match between the peptide map obtained 
and the protein it is predicted to represent is then determined. One method of 
doing this is to assign a Mowse (molecular weight score) value using the 
Mowse algorithm (259).
7.2. Aims
The aims of the work described in this chapter were firstly try to and 
identify potential binding partners of y7 through co-immunoprecipitation and 
secondly to examine if one identified potential binding partner, hnRNP A2, 
interacts with a putative A2RE in Cav2.2 mRNA.
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7.3. Additional Methods
Experiments were performed as described in Chapter 2 with the following 
differences and additions.
7.3.1. Staining and Preparation of Proteins for Identification by Peptide 
Mass Fingerprinting
7.3.1.1. Silver Staining
Gels were stained using Silver Express® Silver Staining kit following the 
manufactures guidelines. Briefly, after running the gel proteins were fixed and 
sensitised to staining using the respective solutions from the kit. The gel was 
then thoroughly washed with ultra pure water before being incubated in 
developing solution until the desired intensity was achieved. The reaction was 
stopped by the addition of stopping solution and the gel was then once again 
thoroughly washed with ultra pure water. An image of the gel was then 
scanned and edited using Photoshop.
7.3.1.2 Coomassie Staining
Gels were stained using SimplyBlue™ SafeStain following the 
manufactures guidelines. Briefly, after running gels, they were thoroughly 
washed with ultra pure water. 20 ml of stain was then added and the gels were 
left to incubate at room temperature for one hour with constant shaking. The 
stain was then removed and replaced with 100 ml of water and incubated for a 
further hour. An additional 20 ml of a 20% NaCI (w/v) solution was added and 
incubated overnight at room temperature with gentle shaking. A second one 
hour wash with ultra pure water was performed before scanning or excision of 
bands.
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Samples that were sent for identification were run on 4-12% Bis-Tris gels 
and then stained with SimplyBlue™ SafeStain. To reduce possible 
contamination gel tanks were extensively washed before running gels and fresh 
buffers and containers were used throughout. Bands of interest were excised 
from the gel using a clean scalpel blade for each band. Gels were run, stained 
and bands excised in a laminar flow hood. Peptide mass fingerprinting was 
performed by the Proteomics and Peptide Facility at the MRC Clinical Science 
Centre, Imperial College. Details of the Mascot search engine can be found at 
http://matrixscience.com (260). Briefly, a high score represents a low 
probability that the match between the experimental data and the matched 
protein is random.
7.3.2. hnRNP A2 Binding Experiments
Experiments to investigate if the potential A2RE site in Cav2.2 mRNA 
bound hnRNP A2 were performed as described previously (261) with the 
exception that mouse brain, rather than rat brain, was used as a source of 
hnRNP A2. These experiments are briefly described below.
7.3.2.1. Biotinylated Oligonucleotides
5’-Biotinylated RNA oligonucleotides were purchased from Invitrogen and 
are detailed in the Appendix. A2RE and non-specific are identical in base 
composition as used previously (261). Cav2.2 corresponds to bases 1096-1116 
of mouse Cav2.2.
7.3.2.2. Protein Extraction
Brains were removed from adult male mice and washed extensively in 
ice cold PBS prior to homogenisation in extract buffer (20 mM HEPES, 0.65 M 
KCI, 2 mM EDTA, 1 mM MgCl2 2M glycerol 14.3 mM p-mercaptoethanol 8.7 mM 
Nonidet-p40, 12.1 mM deoxycholic acid and Complete™ protease inhibitors pH
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7.4). Samples were then centrifuged at 13,000xg for 15 minutes at 4°C. The 
supernatant was extracted and protein concentration estimated by BCA assay.
7.3.2.3. hnRNP A2 Binding Assay
0.5 mg of streptavidin-coated magnetic particles were incubated with 2 
pg of biotinylated RNA oligonucleotide in a solution of 10 mM Tris-HCI, 1mM 
EDTA and 100 mM NaCI, pH 7.5 for 10 minutes on ice. Beads were then 
washed twice for 5 minutes with 10 mM Tris-HCI to remove unbound RNA. 1 ml 
of binding buffer (10 mM HEPES, 3 mM MgC^, 40 mM NaCI, 5% (v/v) glycerol 
and 10 g/L Heparin, pH 7.5) containing 5 mg of mouse brain homogenate was 
added and left to incubate with constant shaking for 30 minutes at 4°C. The 
supernatant was then removed and three five minute washes performed with 
binding buffer.
Proteins were released by the addition of 200 pi of SDS sample buffer 
and heating to 65° C for 10 minutes. Beads were then removed before 
separation by SDS PAGE. 20 pi of each sample was run on a 4-12% Bis-Tris 
gel and western blotting and immunodetection with Anti-hnRNP A2 (1:200 
dilution) performed.
7.3.3. Co-lmmunoprecipitation of y7_HA From Transiently Transfected tsA- 
201 Cells.
y7_HA was co-immunoprecipitated from transiently transfected tsA-201 
cells as previously described for stably transfected PC 12 cells. 
Immunoprecipitated proteins were taken up in SDS buffer. Western blotting 
was performed with the Anti-hnRNP A/B at 1:1000 dilution.
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7.4. Results
7.4.1. The RNA Interacting Proteins, hnRNP A2, hnRNP A3 and the Rat 
Homologue of Pigpen Co-immunoprecipitate With y7_HA from Stably 
Transfected PC12 Cells
In an attempt to further understand the role of y7 it was decided to 
identify proteins with which it interacts endogenously. For this a PC 12 cell line 
was generated that stably expressed y7_HA (as detailed in Chapter 3). PC 12 
cells were chosen as they had previously been shown to endogenously express 
y7 and thus would be expected to also express the proteins with which y7 
interacts.
PC 12 cells stably transfected with y7_HA and untransfected PC 12 cells 
were harvested and proteins were immunoprecipitated with an anti-HA 
antibody. Immunoprecipitated proteins were taken up in loading buffer and 
separated by SDS PAGE. Proteins then were visualised by silver or coomassie 
staining. Proteins that were present in the y7_HA sample but not the 
untransfected control were considered to represent proteins which potentially 
interact with y7.
Fig.7.1. shows preliminary results in which low amounts of cells were 
used and the resulting gel silver stained gel. A number of additional proteins 
were immunoprecipitated from y7-HA expressing cells compared to 
untransfected cells. A diffuse band (red arrow) at around 34 kDa was thought 
to be y7_HA.
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Fig. 7.1. y7_HA and additional proteins can be immunoprecipitated from y7_HA 
stably transfected PCI2 cells. Immunoprecipitated proteins from y7_HA stably 
transfected and control untransfected PC 12 cells were separated by SDS PAGE and 
identified by silver staining. Red arrow indicates expected y7_HA. Black arrow 
indicates the doublet o f bands thought to correspond to hnRNP A2 and hnRNP A3 later 
identified by peptide mass fingerprinting.
However, the sensitivity of silver staining makes individual bands hard to 
distinguish. Furthermore, although MS protein analysis can be performed on 
very low levels of protein, which are only detectable by silver staining the use of 
a larger amount of protein reduces problems with potential contaminating 
proteins. Additionally silver staining that is compatible with peptide mass 
fingerprinting analysis is equally sensitive but results in higher background 
levels.
Repeating the above experiment but scaling up the amount of starting 
material increased the amount of immunoprecipitated protein to a level that 
could be detected by Coomassie staining (Fig 7.2). Bands corresponding to 
proteins which were present in the y7_HA transfected cells, but not in the
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untransfected cells, were excised under sterile conditions and taken for 
identification by peptide mass fingerprinting.
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Fig. 7.2. Immunoprecipitation o f  y7_HA and additional proteins from y7_HA stably 
transfected PCI2 cells. Immunoprecipitated proteins from y7_HA stably transfected 
and untransfected PC 12 cells (Control) were separated by SDS PAGE. I. Coomassie 
blue staining II. Western blotting w ith A nti-H A  antibody. Red arrows indicate y7_HA. 
Black arrows labelled 1,2 and 3 indicate bands excised from gel and identified by 
peptide mass fingerprinting. Representative o f two independent experiments.
Fig. 7.3., Fig. 7.4. and Fig. 7.5. show the results of peptide mass 
fingerprinting. Bands 3, 2 and 1 correspond to hnRNPA2, a mixture of hnRNP 
A2/B1 and hnRNP A3 and Pigpen, respectively.
Peptide mass fingerprinting identified the protein corresponding to the 
band of approximately 36 kDa (Band 3) to most likely be the RNA binding 
protein hnRNP A2/B1 (Fig 7.3). 12 peptides were successfully matched with 
34% of the protein covered. From this data it is not possible to determine if it is 
the A2 or B1 isoform of hnRNP. The apparent molecular weight of 36 kDa 
would suggest that it is the A2 isoform (predicted molecular weight 36 kDa) 
rather than the B1 isoform (predicted molecular weight 38 kDa). Also, none of 
the matched peptides falls within the addition 12 amino acids present in the B1 
isoform.
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P r o b a b il i ty  Based Mowse Score
II
Q91ZR9 Mass: 35957 Total score: 527 Peptides matched: 12
Heterogeneous nuclear ribonucleoprotein A2/B1Mus musculus (Mouse).
III
Sequence Coverage: 34%
1  MEREKEQFRK L F IG G L S F E T  TEESLRNY YE QWGKLTDCW MRDPASKRSR
5 1  GFGFVTFSSM  AEVDAAMAAR P H S ID G R W E  PKRAVAREES GKPGAHVTVK
1 0 1  KLFVGGIKED TEEHHLRDYF E E Y G K ID T IE  IIT D R Q SG K K  RGFGFVTFDD
1 5 1  HDPVDKIVLQ KYHTINGHNA EVRKALSRQE MQEVQSSRSG RGGNFGFGDS
2 0 1  RGGGGNFGPG PGSNFRGGSD GYGSGRGFGD GYNGYGGGPG GGNFGGSPGY
2 5 1  GGGRGGYGGG GPGYGNQGGG YGGGYDNYGG GNYGSGSYND FGNYNQQPSN
3 0 1  YGPMKSGNFG GSRNMGGPYG GGNYGPGGSG GSGGYGGRSR Y
Fig. 7.3. 36 kDa protein (Band 3) identified as hnRNP A2/B1. I. Probability based 
Mowse Score. Score is -10*Log(P), where P is the probability that the observed match 
is a random event. Individual ions scores > 52 (to the right o f the green hatched region) 
indicate identity or extensive homology (p<0.05). II. hnRNP A2 identified as the most 
probable match. III. Sequence coverage o f hnRNP A2. Matched peptides shown in 
bold red.
148
IP r o b a b i l i t y  B ased  H ouse S c o re
II
Mixture Total score: 172 Peptides matched: 24
Components (only one family m em ber shown for each component):
AAN76992 Mass: 37063 Total score: 97 Peptides matched: 14
A F463524 NID: - Mus musculus
Q 91ZR 9 Mass: 35957 Total score: 76 Peptides matched: 11
Heterogeneous nuclear ribonucleoprotein A 2/B 1.- Mus musculus (Mouse).
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Ill
Sequence Coverage of hnRNP A3: 38%
1 MEVKPPPGRP QPDSGRRRRR RGEEGHDPKE PEQLRKLFIG GLSFETTDDS
51 LREHFEKWGT LTDCW M RDP QTKRSRGFGF VTYSCVEEVD AAMCARPHKV
101 DGRW EPKRA VSREDSVKPG AH LTVK K IFV GGIKEDTEEY NLRDYFEKYG
151 K IETIEVM ED RQSGKKRGFA FVTFDDHDTV D K IW Q K Y H T INGHNCEVKK
201 ALSKQEMQSA GSQRGRGGGS GNFMGRGGNF GGGGGNFGRG GNFGGRGGYG
251 GGGGGSRGSY GGGDGGYNGF GGDGGNYGGG PGYSSRGGYG GGGPGYGNQG
301 GGYGGGGGGY DGYNEGGNFG GGNYGGGGNY NDFGNYSGQQ QSNYGPMKGG
351 SFG G R SSG SP YGGGYGSGGG SGGYGSRRF
juence Coverage of hnRNP A2/B1: 38%
l MEREKEQFRK L F IG G L S F E T TEESLRNYYE QWGKLTDCVV MRDPASKRSR
51 GFGFVTFSSM AEVDAAMAAR P H S ID G R W E PKRAVAREES GKPGAHVTVK
101 KLFVGGIKED TEEHHLRDYF E E Y G K ID T IE IITD R Q SG K K RGFGFVT FDD
151 HDFVDKIVLQ KYHTINGHNA EVRKALSRQE MQEVQSSRSG RGGNFGFGDS
201 RGGGGNFGPG PGSNFRGGSD GYGSGRGFGD GYNGYGGGPG GGNFGGSPGY
251 GGGRGGYGGG GPGYGNQGGG YGGGYDNYGG GNYGSGSYND FGNYNQQPSN
301 YGPMKSGNFG GSRNMGGPYG GGNYGPGGSG GSGGYGGRSR Y
Fig. 7.4. 37 kDa protein (Band 2) identified as mixture hnRNP A2/B1 and hnRNP 
A3. I. Probability based Mowse Score. Score is-10*Log(P), where P is the probability 
that the observed match is a random event. Protein scores greater than 74 (to the right 
o f the green hatched region) are significant (p<0.05). II. A mixture o f hnRNP A2/B1 
and hnRNP A3 are identified as the most probable matches. III. Sequence coverage o f 
hnRNP A2/B1 and hnRNP A3. Matched peptides shown in bold red.
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Probability Based Mowse Score
II
Q 8C FQ 9 Mass: 52570 Total score: 72 Peptides matched: 2
Similar to pigpen - Mus musculus (Mouse).
III
Sequence Coverage: 3%
1 MASNDYTQQA TQSYGAYPTQ PGQGYSQQSS QPYGQQSYSG YGQSADTSGY
51 GQSSYGSSYG QTQNSYGTQS APQGYGSTGG Y G SSQ SSQ SS YGQQSSYPGY
101 G QQ PAPSSTS G SYG G SSQ SS SYGQPQSGGY GQQSGYGGQQ QSYGQQQSSY
151 NPPQGYGQQN QYNSSSGGGG GGGGGNYGQD QSSMSGGGGG GGYGNQDQSG
201 GGGGGYGGGQ QDRGGRGRGG GGGYNRSSGG YEPRGRGGGR GGRGGMGGSD
251 RGGFNKFGGP RDQGSRHDSE Q D N SD N N T IF VQGLGENVTI ESVADYFKQI
301 GIIKTNKKTG QFMINLYTDR ETGKLKGEAT V SFD DPPSAK AAIDWFDGKE
351 FSGNPIKVSF ATRRADFNRG GGNGRGGRGR GGPMGRGGYG GGGSGGGGRG
401 GFPSGGGGGG GQQRAGDWKC PNPTCENMNF SWRNECNQCK APKPDGPGGG
451 PGGSHMGGNY GDDRRGRGGY DRGGYRGRGG DRGGFRGGRG GGDRGGFGPG
501 KMDSRGEHRQ DRRERPY
Fig. 7.5. 60 kDa protein (Band 1) identified as Pigpen. I. Probability based Mowse 
Score. Score is -10*Log(P), where P is the probability that the observed match is a 
random event. Individual ions scores > 45 indicate identity or extensive homology
(p<0.05). II. Pigpen identified as the most probable match. III. Sequence coverage o f 
Pigpen. Matched peptides shown in bold red.
Peptide mass fingerprinting identified the protein corresponding to the 
band of approximately 37 kDa (Band 2) to most likely be a mixture to two RNA 
binding proteins hnRNP A3 and hnRNP A2/B1 (Fig 7.4). 14 peptides were 
successfully matched for hnRNP A3 and 11 peptides fro hnRNP A2/B1 with 
38% of the protein covered in both cases
Peptide mass fingerprinting identified the protein corresponding to the 
band of approximately 60 kDa (Band 1) to most likely be the RNA binding 
protein Pigpen (Fig 7.5). 2 peptides were successfully matched covering 3% of 
the protein.
7.4.2. Endogenous hnRNP A2 Co-lmmunoprecipitate with y7_HA in 
Transiently Transfected tsA-201 cells
To confirm co-immunoprecipitation of hnRNP A2 tsA-201 cells were 
transiently transfected with y7_HA. Three days post transfection cells were 
harvested and y7_HA immunoprecipitated using an anti-HA antibody. Co- 
immunoprecipitation of hnRNP A2 was confirmed by western blotting with an 
anti-hnRNP A/B antibody (Fig. 7.6).
152
y7_HA -  + -  + -  + +
■■ . *• 35- -
35-
•
35-
'  t
Input ip Input IP
Anti-hnRNP A/B Anti-HA
Fig. 7.6. Endogenous hnRNP A2 co-immunoprecipitates with y7_HA in transiently 
transfected tsA-201 cells. tsA-201 cells were transiently transfected w ith y7_HA.
Three days post transfection y7_HA was immunoprecipitated using an anti-HA 
antibody. Proteins were separated by SDS PAGE and hnRNP A2 and y7_HA identified 
by western blotting w ith anti-hnRNP A/B and anti-HA antibodies, respectively. 
Representative o f four experiments.
Western blotting with an anti-hnRNP A/B antibody identified a single 
band of approximately 36 kDa from immunoprecipitated material from y7_HA 
transfected cells. From the apparent molecular weight it was thought to be 
hnRNP A2. No additional bands were seen in the y7_HA sample compared to 
the control untransfected sample in the input blots suggesting that there was no 
non-specific binding of the anti-hnRNP A/B antibody to y7_HA. A faint higher 
molecular weight band of approximately 37-38 kDa, which could correspond to 
the B1 isoform of hnRNP or hnRNP A3, was detectable in the input blot but not 
detected in the immunoprecipitated blot. No bands were detected in the 
immunoprecipitated blot from control, untransfected, tsA-201 cells, suggesting 
that hnRNP A2 does not bind non-specifically to the beads alone.
7.4.3. Cav2.2 mRNA Contains an A2RE element
Previous work by Ainger et al (262) had identified a potential A2RE site 
in Cav2.2 mRNA. To examine if this A2RE site could indeed bind hnRNP A2 a
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repeat of the original experiment performed by Hoek et al (261), to identify the 
A2RE, was performed using a ribonucleotide oligonucleotide corresponding to 
the potential A2RE in Cav2.2.
Mouse brain homogenate was incubated with biotinylated ribonucleotide 
oligonucleotides corresponding to the consensus A2RE site from MBP, the 
potential A2RE site in Cav2.2 and a scrambled non-specific sequence (identical 
to the non-specific sequence used by Hoek et al (261)). Streptavidin-coated 
magnetic beads were added and ribonucleotides and any bound proteins were 
separated using magnetic separators. As a further control a beads alone 
sample was used. Bound proteins were taken up in SDS sample buffer, 
separated by SDS PAGE and hnRNP A2 detected by western blotting with an 
anti-hnRNP A2 antibody (Fig 7.7).
hnRNP A2
Fig. 7.7. Cav2.2 contains an A2RE site. Biotinylated ribonucleotides corresponding to 
the consensus A2RE, the potential A2Re in Cay2.2 mRNA and a scrambled non­
specific sequence were incubated w ith mouse brain extract and bound proteins isolated 
using streptavidin coated paramagnetic beads. Proteins were separated by SDS PAGE 
and hnRNP A2 identified by western blotting with an anti-hnRNPA2 antibody.
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A strong band of approximately 36 kDa was pulled down with the 
biotinylated ribonucleotides corresponding to the A2RE site and the potential 
A2RE site in Cav2.2 mRNA, but not with the non-specific scrambled sequences 
or beads alone. A slightly higher molecular weight band was also pulled down, 
which could correspond to the B1 isoform of hnRNP A2/B1 or to hnRNP A3.
7.5. Discussion
7.5.1. Ribonucleoprotein Complexes and RNA Trafficking
To function correctly eukaryotic mRNA requires the association of RNA- 
binding proteins. These are collectively referred to as mRNA-protein complex 
proteins (mRNP proteins) or heterogeneous ribonucleoproteins (hnRNP 
proteins). These proteins have a range of roles including splicing, mRNA 
export, localisation, translation and stability (213). mRNPs bind to nascent 
transcripts and many remain bound until they reach the ribosomes, shuttling 
between the nucleus and the cytoplasm (263;264).
The mRNA for a range of proteins has been shown to be trafficked to 
discrete locations within the cell before translation takes place (265-268). This 
allows the cell to achieve high levels of protein expression at the site of mRNA 
localisation and allows the exclusion of protein from certain cellular domains. It 
is thought that the mRNAs are assembled into trafficking intermediates termed 
‘RNA granules’ (269). These granules contain multiple RNA molecules, 
trafficking factors and translation machinery components (270). Granules 
containing mRNAs that encode soluble proteins are retained within the 
cytoplasm, whereas those encoding membrane proteins are targeted to the ER. 
Other granules, such as those containing mRNA encoding myelin basic protein 
(MBP), are trafficked within the cell to where the protein is required. In the case 
of MBP in oligodendrocytes the mRNA granules are trafficked to the myelin 
compartment (271;272). The trafficking pathway of each granule is determined
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by specific cis-acting elements in the RNA cargo and cognate trans-acting 
factors in the cell (273).
7.5.2. Heterogeneous Nuclear Ribonucleoproteins
Heterogeneous nuclear ribonucleoproteins (hnRNPs) were first 
described as a group of chromatin-associated RNA-binding proteins (263). 
There are now more than 20 proteins that have been shown to be part of the 
hnRNP complex. These proteins have been shown to be involved in multiple 
functions including transcriptional regulation, telomere length maintenance, 
mRNA trafficking, splicing and mRNA stability (265;274-278).
hnRNP A2 was first identified by Brayer et al (279). It is a 36 kDa protein 
consisting of an N-terminal domain containing two RNA-binding domains and a 
C-terminal domain containing an RGG arginine/glycine rich motif (280;281). 
Tissue distribution analysis shows high levels of expression in the brain and 
testes with lower levels of expression in the liver, lung and heart. Within the 
cells it is located within the cell nucleus, but is also found in the cell body (261). 
The human orthologue was cloned by Biamonti et al (282) who showed it is 
encoded by 11 exons. An alternatively spliced variant, hnRNP B1, was also 
found which contained a 36 nucleotide mini-exon. This results in the addition of 
twelve amino acids near the N-terminus present in hnRNP B1 but not hnRNP 
A2 (280). The hnRNP B1 variant ranges between 2 to 5% of total hnRNP 
A2/B1 transcripts depending upon the tissue (283;284).
hnRNP A2 has been shown to be involved in the trafficking to mRNA. A 
21 nucleotide c/'s-acting sequence within the 3’-untranslated region of MBP 
mRNA was shown to be necessary and sufficient for mRNA trafficking in 
oligodendrocytes. Hoek et al showed that the cognate trans-acting factor to this 
cis-acting sequence was hnRNP A2 (261). This sequence was named the 
hnRNP A2 response element (A2RE). Munro et al went on to show that 
degenerate A2REs are present in other trafficked mRNAs, including activity- 
related cytoskeleton-associated protein (ARC) and the GABA receptor a  
subunit, also bound hnRNP A2 (285). Shan et al proposed that mRNA 
trafficking involving A2RE and hnRNP A2 takes place not only within
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oligodendrocytes but is also responsible for dendritic RNA localisation in 
neurons (286). They also showed trafficking by this mechanism involves 
microtubules. Potential A2REs have been found in a range of proteins that 
have been shown or are thought to be localised, among these is Cav2.2 
(262;268).
Proteomic techniques are becoming increasingly popular to find novel 
interactions between proteins. Using co-immunoprecipitation and subsequent 
identification by peptide mass fingerprinting three proteins were found that 
potentially interact with y7. All three of these proteins, hnRNP A2, hnRNP A3 
and Pigpen, are RNA interacting proteins.
The co-immunoprecipitation of hnRNP A2 was confirmed by its co- 
immunoprecipitation with y7_HA from tsA-201. Endogenous hnRNP A2 could 
be detected in tsA-201 cells and could also be detected in the 
immunoprecipitate of y7_HA transfected cells. However, no hnRNP A2 was 
detected in the immunoprecipitate of untransfected control cells. No additional 
bands were seen in lysate from y7_HA transfected tsA-201 cells compared to 
untransfected cells showing that the hnRNP A/B antibody does not non- 
specifically detect y7.
As the name would suggest hnRNP A3 is similar to hnRNP A2. It shows 
similar tissue distribution as hnRNP A2 and is also is mostly localised to the 
nucleus but can also be found in cytoplasmic granules. hnRNP A3 is a trans­
acting factor to the A2RE element. Furthermore it has been shown to interact 
directly with the A2RE and not just through association with hnRNP A2. It has 
been suggested that it may serve a similar role in RNA trafficking as hnRNP A2 
(287).
Pigpen is another putative RNA-binding protein (288). The human 
orthologue TLS (translocated in liposarcomas) is a 53 kDa protein which is also 
found in heterogeneous nuclear ribonucleoprotein complexes (289;290). It has 
been shown to interact with RNA polymerase II (291) and is involved in 
transcriptional activation (292).
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These three proteins can be found together in RNP complexes and it is 
possible that co-immunoprecipitation of one these proteins will result in the 
other proteins being co-immunoprecipitated also. It is also possible that y7 
could interact with a further unidentified protein or indeed RNA itself. Treatment 
with RNase would help to identify if there is direct interaction between these 
proteins and y7. In addition a yeast two-hybrid system could be used to confirm 
these results and find other proteins that interact with y7. However, interactions 
between transmembrane proteins are difficult to determine by this method.
Also, yeast two-hybrid is known to give many false positive results.
In the peptide mass fingerprinting experiments it is possible that the 
hnRNP A2, detected in band 2 was actually due to contamination of the sample 
from the lower hnRNP A2 band below. To overcome this better separation of 
proteins could have been achieved by using a higher percentage acrylamide gel 
or using MES instead of MOPS as the running buffer. Ideally 2D 
electrophoresis, in which proteins are separated by iso-electrofocusing prior to 
separation by SDS PAGE could have been used. This may have identified 
further proteins that had co-immunoprecipitated.
The experiments performed here show that the potential A2RE site in 
Cav2.2 does indeed bind hnRNP A2. As hnRNP A2 has previously been shown 
to be involved in the trafficking of mRNA in neurons (286) and Cav2.2 mRNA is 
trafficked in neurons (268) it is possible that the A2RE element and hnRNP A2 
are the cis-acting element and cognate trans-acting factors that result in Cav2.2 
mRNA localisation.
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Chapter 8 -  Discussion and Future
Work
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This study attempts to deduce more information about the role of the 
recently identified stargazin-like protein y7. It has been shown that the 
expression of the neuronal VDCC subunit Cav2.2 is suppressed by the co­
transfection of y7 in both Xenopus oocyte and mammalian cell overexpression 
systems. The work presented here attempts to further characterise y7. It 
identifies the region of y7 that is responsible for the suppression of Cav2.2 
expression and further investigates the mechanism by which this takes place. It 
also identifies a possible interaction between y7 and proteins involved in the 
trafficking of RNA.
8.1. y7 as a Auxiliary Subunit of Voltage-Dependent 
Calcium Channels
By homology the family of y subunits can be subdivided into three sub­
families. The first is comprised of y1 and y6; the second comprises y2, y3, y4 
and y8; and the third comprises y5 and y7. All of these proteins are part of the 
larger tetraspannin PMP-22/EMP/MP20/Claudin family.
It remains controversial if all, or indeed any, of the y subunits form part of 
a functional VDCC. The effects of y7 upon VDCC kinetics and voltage 
dependant properties are slight compared to a 25 and p subunits. In general y 
subunits downregulate calcium channel activity (293), although there is conflict 
between results from different groups. Other roles for y subunits have been 
elucidated (177,210) and it remains uncertain what physiological roles y 
subunits play. It could be argued that each of the sub-families, while sharing a 
degree of similarity to one another, serve different physiological roles.
Evidence for y subunits being involved in VDCC function is strongest for 
the first sub-family. y1 was initially identified by co-purification with Cav1.1 from 
skeletal muscle. In addition to this biochemical evidence several studies have 
shown y1 to have an effect on VDCC kinetics and voltage dependant properties 
(293). Recently both the long and short isoforms of y6 have been shown to
modulate Cav3.1 currents (187). Co-expression of the long isoform of y6 with
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Cav3.1 was shown to significantly decrease current density. However, this 
decrease must be due to a different mechanism than the suppression of Cav2.2 
by y7 as y6 expression did not affect the level of Cav3.1 mRNA or the amount of 
total Cav3.1 protein.
The second sub-family (y2, y3, y4 and y8) have been clearly shown to 
have a role in the trafficking of AMPA receptors. These have now been 
designated as TARPs (160; 177). In addition to their role in trafficking they have 
also recently been shown to be involved in the modulation of AMPA receptors. 
Along with their roles in AMPA receptor trafficking and function it remains 
possible that they may also interact with VDCCs. Several studies have found 
changes in VDCC kinetics when co-expressed with TARP’s. Also, Cav2.2 was 
found to co-precipitate with GluR1 and y2 and it has been proposed that they 
may form a complex in vivo (117).
Of the three families the third (y5, y7) is the least well categorised.
Overall there is little similarity between these proteins and the TARPs. The C- 
terminal regions of these proteins are much shorter (especially compared to y8) 
and lack a type I PDZ-binding motif important for TARP functionality. Tomita et 
al have showed that y5 is not a TARP and does not traffic AMPA receptors 
(177). y7, has been shown to suppress Ba2+ current through Cav2.2, and to a 
lesser extent Cav12 and Cav2.1 (174). However, this reduction in current is 
due to reduction in channel expression rather than modulation of the channel. 
Cav3.1 current and expression was shown to be unaffected by y7 expression 
(187). No work presented here supports the view that y7 is a subunit of VDCCs.
8.2. Structure and Cellular Distribution of y7
A shared motif between all y subunits is a predicted glycosylation site 
present in the 1st extracellular loop of the protein. Here it is shown that y7 is 
glycosylated at this site when expressed in tsA-201 cells. Mutation of the 
predicted site of glycosylation, asparagine at position 45 to alanine, resulted in 
y7 running on SDS-PAGE at the predicted molecular mass of 32 kDa. It
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remains to be ascertained if y7 is endogenously glycosylated and, if so, the 
composition of the carbohydrate residues. Also, the observation that a HA tag 
placed at the N-terminus of y7 was not detectable using a Anti-HA antibody 
despite the expression of the rest of the protein suggests there may be some 
modification of the N-terminus of the protein.
y7 does not share the same cellular distribution as the rest of the 
examined y subunits. Both the data presented here, and the experiments 
performed by Hansen et al (187), found y7 to be located intracellularly with no 
expression at the plasma membrane. Here we show that a CFP tagged y7 
construct in part co-localises with PDI, a marker of ER when stably transfected 
into PC 12 cells. However, co-localisation is incomplete suggesting expression 
in intracellular membranes other than those of ER. Removal of RXR domains, 
shown to be involved in ER retention of proteins and present in the C-terminus 
of y7, did not lead to it reaching the plasma membrane, suggesting that there 
must be other sequences within y7 that keep it intracellular.
Cell adhesion is one of the functions of the claudin family of proteins. y2 
has been shown to have retained the ability to induce cell aggregation when 
expressed in mouse L-fibroblasts, suggesting a role in cell adhesion (294). The 
lack of plasma membrane localisation would preclude such a role for y7.
In both this study and that of Hansen et al (187) the subcellular 
distribution of y7 was examined using mammalian cell over expression systems. 
The endogenous distribution of y7 in PC12 cells was more diffuse, but once 
again y7 was not detectable in the plasma membrane. In PC12 cells that were 
undergoing differentiation and had put out processes, y7 was often found at the 
end of these processes.
8.3. Suppression of Cav2.2 Expression by the Co­
expression of y7
Moss et al (174) had previously shown that the reduction of N-type 
current through Cav2.2 caused by the co-expression of y7 was not due to
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modulation of the channel but rather by a reduction in the expression of the 
channel. One of the aims of this study was to try to elucidate the mechanism by 
which the suppression of Cav2.2 expression occurs.
One hypothesis would be that the suppression of Cav2.2 expression by 
y7 was non-specific. Thus, the expression of any protein would also result in a 
reduction of Cav2.2 expression. Moss et al (174) used confocal microscopy to 
show that contrary to this hypothesis co-expression of y7, but not Kv3.1b 
reduced the expression of a GFP tagged Cav2.2 construct. This result was 
confirmed here by western blotting. y7 significantly reduced Cay2.2 expression 
when co-transfected in a mammalian cell expression system. However, co­
transfection of Kv3.1b had no significant effect on Cav2.2 expression.
To confirm that the suppression of Cav2.2 expression by y7 co­
transfection was not due to promoter competition a construct was designed that 
would produce y7 mRNA which would not be translated. Co-transfection of this 
construct with Cav2.2 did not affect N-type current through Cav2.2 channels.
Combined with the work performed by Moss et al (174) these 
experiments would suggest that the suppression of Cav2.2 by y7 is specific and 
not due to promoter competition. The suppression of Cav2.2 is also somewhat 
specific to y7 as co-transfection Kv3.1b, another transmembrane protein, does 
not suppress Cav2.2 expression. Furthermore, the lack of suppression of 
Cav2.2 by non-translated y7 mRNA suggests that it is not RNA-RNA interaction 
between y7 and Cav2.2 mRNA that is responsible for Cav2.2 expression.
An alternative hypothesis would be thaty7 expression would suppress 
the expression of any protein that was co-transfected with it. Moss et al (174) 
had used western blotting to show that another VDCC subunit, P1b was 
unaffected by y7 co-transfection. They also used confocal microscopy to show 
that Kv3.1b expression was unaltered by y7 co-transfection. Here, western 
blotting was used to confirm that co-expression of y7 did not alter Ky3.1b 
expression. Thus, y7 does not non-specifically suppress the expression of all 
proteins with which it is co-transfected.
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Previous work by Wei et al (180) indicated a possible interaction between 
p and y subunits. They found that the modulation of L-type current through 
Cav1.2 by y1 was p dependent, p subunits have also been shown to increase 
the expression ai subunits (109). Moss et al showed previously that y7 does 
not suppress p1b subunit expression. However, y7 may have prevented 
interaction between the p1b and Cav2.2 and thus prevented the increase in 
Cav2.2 expression due to p1b co-expression. This could not be examined 
electrophysiologically as the small size of the currents produced by Cav2.2 
when transfected into mammalian cells without p subunits would make the 
identification of a reduction, due to y7 co-transfection, difficult to determine. 
Changes in the amount of Cav2.2 protein could still be detected by western 
blotting even in the absence of p or a28. These experiments showed that 
Cav2.2 expression was still suppressed by y7 co-transfection and did not 
depend upon the presence of p or a28 subunits.
Raghib et al (237) reported that Cav2.2 expression could be suppressed 
by the co-transfection of truncated Cav2.2 constructs. Recently the mechanism 
of this suppression was shown to involve the ER stress pathways (238). ER 
stress has been shown to activate a series of pathways that result in the 
suppression of protein expression, giving the cell time to recover. In this study 
three markers of ER stress, the upregulation of CHOP, the upregulation of XBP 
and the editing of XBP, were examined. Using QPCR none of these markers 
was found to be upregulated by the expression of y7, or y7 and Cav2.2. This 
would suggest that ER stress is not involved in the suppression of Cav2.2 
expression. Furthermore it suggests that the mechanism of the suppression of 
Cav2.2 expression by y7 is different to the mechanism of the suppression of 
Cav2.2 by truncated Cav2.2 constructs.
During this study work performed by Dr K. Page showed that Cav2.2 
mRNA was reduced by the co-expression of y7 in mammalian cell expression 
system. In addition experiments performed by Prof A. Dolphin showed that in 
Xenopus oocytes, if synthetically synthesised Cav2.2 mRNA was used, rather 
than expressing Cav2.2 from a vector, y7 failed to suppress Cav2.2 expression
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and there was no significant difference in N-type current between control and y7 
co-injected oocytes. Furthermore, injection of RNasin, an inhibitor of RNases, 
was found to attenuate the suppression of Cav2.2 expression. These 
experiments would suggest that the suppression of Cav2.2 expression by y7 is 
due to a reduction in Cav2.2 mRNA. There are several possibilities as to why 
Cav2.2 mRNA is reduced including reduced synthesis and increased 
degradation of Cav2.2 mRNA.
Thus far suppression of Cav2.2 protein by y7 has only been identified in 
overexpression systems. Endogenous N-type current through Cav2.2 channels 
are unchanged when y7 is transfected in both SCG’s and PC 12 cells. This may 
be due to insufficient turnover of the endogenous channels to give an 
observable result. Investigation of endogenous mRNA level, rather than 
currents, may reveal a change thfere. It is also possible that Cav2.2 expression 
is only suppressed by co-expression of y7 when Cav2.2 is expressed from 
cDNA in a vector.
Here it is shown that the C-terminus of y7 is necessary and sufficient for 
the suppression of Cav2.2 expression. Both biochemically and biophysically 
expression of y7 without the C-terminus was shown to have no significant effect 
upon Cay2.2 expression. Additionally expression of the C-terminus alone was 
sufficient to cause suppression of Cav2.2 expression. The last four amino acids 
(TSPC), which resembles the type I PDZ binding motif which was found to be 
important in the function of TARPs, were found not to be involved in the 
suppression of Cav2.2 expression by y7. Also, removal of the glycosylation site 
present in y7 did not attenuate the suppression of Cay2.2 expression.
8.3. Interaction Between hnRNP A2 and y7
Immunoprecipitation of a HA tagged y7 construct from a stably 
transfected PC 12 cell line identified several proteins that potentially interact with 
y7. Subsequently three of these proteins were identified by peptide mass 
fingerprinting to be hnRNP A2, hnRNP A3 and Pigpen. Interestingly all three of 
these proteins are RNA binding proteins. Endogenous hnRNP A2 also co-
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immunoprecipitated the HA tagged y7 construct when it was transiently 
transfected into tsA-201 cells. This would suggest that the interaction between 
y7 and hnRNP A2 was not an artefact generated during the generation of the 
stable cell line.
It cannot be excluded that the interaction between y7 and hnRNP A2 is 
an artefact due to the use of an overexpression system. Ideally co- 
immunoprecipitation of endogenous y7 and hnRNP A2 could be obtained. 
Unfortunately however the antibodies for y7 and hnRNP A2 where found to be 
unsuitable for immunoprecipitation. It also has not yet been determined if there 
is a direct interaction between y7 and hnRNP A2. It is possible that the 
interaction was through either of the two other identified proteins or through 
some as yet unidentified protein. It is also possible that these proteins interact 
with each other through RNA. Incubation of the immunoprecipitated proteins 
with RNase would answer this question.
Of these three proteins, hnRNP A2, has been the most extensively 
studied. It is a 36 kDa protein that is found within the nucleus and also 
throughout the cell body (261). hnRNP A2 shares a similar tissue distribution 
with y7 (as identified by Chu et al (171)) with high levels of expression in the 
brain and testes (Fig 8.1).
hnRNP A2
Fig. 8.1 hnRNP A2 and y7 have similar expression profiles. Tissue distribution o f A) 
hnRNP A2 protein (red arrow) and B) y7 mRNA (blue arrow). Adapted from A. Hoek 
e ta l{261). B. Chu et al (171)
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hnRNP A2 has been shown to be a trans-acting factor that has a role in 
the trafficking of mRNA (261). The cognate cis-acting sequence is a 21 
nucleotide sequence known as the A2RE. In oligodendrocytes, A2RE/hnRNP 
A2 determinants are involved in at least four steps in the RNA trafficking 
pathway: (1) export from the nucleus to the cytoplasm, (2) granule assembly in 
the perikaryon, (3) transport along microtubules in the processes, and (4) 
translation activation in the myelin compartment (295). They have also been 
proposed to be responsible for dendritic RNA localisation in neurons of several 
mRNAs, including calcium-calmodulin-dependent protein kinase II alpha subunit 
and neurogranin mRNA (286;296).
Cav2.2 mRNA has previously been shown to be trafficked to the dendritic 
growth cones of cultured hippocampal neurons (268) and potential A2RE sites 
have been identified within it (262). Here it is shown that a potential A2RE site 
corresponding to bases 1096-1116 in mouse Cav2.2 mRNA is confirmed to bind 
hnRNP A2. Other potential A2REs are also present within Cav2.2 mRNA, 
however these have yet to be confirmed to bind hnRNP A2. These finding 
would suggest that the trafficking of Cav2.2 mRNA involves the A2RE/hnRNP 
A2 trafficking mechanism.
As mentioned previously the other two proteins identified were also RNA 
binding proteins. It is also possible that both these proteins are involved in the 
localisation of mRNA. hnRNP A3, like hnRNP A2 has been shown to be a 
fra/?s-acting factor to A2REs (287). In the same study hnRNP A3 was found to 
have a similar cellular distribution to hnRNP A2 and it was suggested that 
hnRNP A3 is also involved in RNA trafficking, although as of yet this has to be 
confirmed. Intriguingly the human orthologue of Pigpen (TLS) has been found 
to associate with NDMA receptors (297). Belly et al (298) reported that in 
hippocampal neurones TLS is largely excluded from the neuronal nucleus and 
is found in the cytosol and in somatodendritic particles with some co-localisation 
with NMDA receptor clusters. They proposed that TLS may contribute to 
steering, anchoring or regulating mRNAs at synaptic sites.
Members of the hnRNP family of proteins have been shown to be 
involved in RNA stability. hnRNP D acts to stabilise c-fos,
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granulocyte/macrophage colony-stimulating factor and p-adrenergic receptor 
mRNA (299-301). It has also been shown to destabilise c-myc mRNA (302). It 
has been proposed that the regulation of RNA metabolism is likely to involve a 
complex interplay between multiple RNA elements and trans-acting factors, 
including hnRNP A2.
Given the role of RNPs in RNA stability, the interaction between y7 and 
three RNP’s and that Cav2.2 mRNA is reduced by the co-expression of y7, it is 
tempting to hypothesise that the mechanism of suppression of Cay2.2 
expression by y7 involves one of the three RNPs identified. A simple 
hypothesis would be that overexpression of y7 sequesters the RNP which leads 
to Cav2.2 mRNA being destabilised. Alternatively overexpression of y7 may 
lead to upregulation of one of the RNPs which leads to Cav2.2 mRNA 
destabilisation. It is possible that the RNPs bound to Cav2.2 mRNA expressed 
from a vector are different from endogenous Cav2.2 mRNA, as many RNPs 
bind during the splicing process. This may in part explain the lack of effect of y7 
upon endogenous channels.
The TARPs have been shown to be involved in the trafficking of AMPA 
receptor. From homology it is possible that y7 would also be involved in 
trafficking. Here it is shown that y7 co-immunoprecipitates with three RNPs that 
have been proposed to be involved in the trafficking of mRNA. It is an intriguing 
possibility that y7 acts in a similar method to the TARPs, and is involved with 
guiding trafficked mRNA to its correct location within the cell.
As was described previously the C-terminus of y7 alone is sufficient to 
suppress expression of Cav2.2. Interestingly a BLASTp search found that there 
is homology between the C-terminus of y7 and the APOBEC-1 (Fig.8.2). While 
this is a low significance match, the protein it identifies is interesting. APOBEC1 
is the catalytic subunit of the apoB RNA-editing enzyme which edits 
apolipoprotein B mRNA. This protein has previously been shown to interact 
with hnRNP A2 (303) and another member of the hnRNP family hnRNP C1 
(304).
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Score = 32.0 bits (68), Expect = 4.1
Identities = 16/40 (40%), Positives = 20/40 (50%), Gaps = 18/40 (45%)
ISSDVSIQ-HTQ....... . . . . . . . .NYPPAI...... KYPDHL Y?
ISS V+IQ ET+ HYPP+ +YP HL
ISSGVnOIffUQEYCYCMPWPPSHEATORYP-Hl A P O B E C -1
Fig. 8.2. There is homology between the C-terminus o f y7 and APOBEC-1. A
BLASTp search for short, nearly exact matches to the C-terminus of y7 identified a 
region in APOBEC-1 as have the highest similarity (excluding other y subunits).
APOBEC-1 is a cytidine deaminase converting cytidine to uridine.
Related to APOBEC-1 (and sharing some similarity to the C-terminus of y7) are 
the adenosine deaminases acting on RNA (ADAR) family of proteins. These 
proteins convert adenosine residues into inosine (A to I) in mRNA. Interestingly 
one member of the ADAR family has been shown to be involved in the editing of 
GluR2 receptor mRNA (305). This results in the replacement of glutamine with 
arginine at position 607. Unedited Gin containing subunits readily tetramerize 
and traffic to synapses, whereas edited Arg containing subunits are largely 
unassembled and ER retained. Also, mRNA editing by ADARs has been 
suggested to be involved in mRNA stability (306).
While y7 is unlikely to directly involved in A to I editing (as it doesn’t not 
contain the catalytic site conserved in the ADAR family of proteins) it could be 
involved in recruiting ADARs or another RNA editing protein. There is already 
evidence of Cav a1 subunit mRNA being edited (307;308) and it is possible that 
y7 may recruit a protein that edits Cav2.2 mRNA, resulting in the Cav2.2 mRNA 
or protein being more unstable.
8.4. Future Work
8.4.1. Cellular Distribution of y7
The cellular distribution of y7 could be further investigated using electron 
microscopy and gold immunolabelling. This would identify if any y7 is present at
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the plasma membrane and also if it is present within any intracellular 
organelles. The endogenous expression of y7 in Purkinje cells would make 
them suitable to be used in these experiments.
8.4.2. Phosphorylation Sites of y7
In addition to the N-glycosylation site present in y7 there are also several 
potential phosphorylation sites. Phosphorylation of y2 has been shown to be 
important in its role as a TARP (203-205) and the phosphorylation of y7 may 
prove to be important also. Mutation of these sites to alanine, to mimic the non- 
phosphorylated site, and glutamate, to mimic the phosphorylated site, may 
reveal the importance of these site to the function of y7.
8.4.3. The Structure of y7
It is unlikely that a high-resolution structure of y7, or any of the y subunits, 
will be obtained soon. Members of the PMP family have thus far proved hard to 
purify and crystallise (309). If a model of any of the PMP family is identified 
then a model for the structure of y7 may be obtained by comparison.
8.4.4. y5
y5 has high similarity to y7 and is likely to serve similar functions. It would 
be interesting to examine if y5 has similar effects on Cav2.2 expression. 
Furthermore, y5 may interact with hnRNP A2, hnRNP A3 and Pigpen.
8.4.5. Interaction of y7 and RNPs
It is essential to further confirm the interaction between y7 and hnRNP 
A2, hnRNP A3 and Pigpen. One system that could be used is the yeast 2- 
hybrid system. This would require sub-cloning of the y7, hnRNP A2, hnRNP A3 
and Pigpen into vectors with a portion of a transcriptional activator of a reporter 
gene (e.g. (3-Gal or Lex A). This method will only identify a direct interaction 
between y7 and one of the RNPs. If the interaction between y7 and the RNPs
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requires a yet undetected protein then it will not be picked up by this system. A 
search for proteins that interact with y7 could be performed by using a library of 
proteins rather than testing direct interactions. Unfortunately previous attempts 
to use y7 for the yeast 2-hybrid system were unsuccessful as the vector 
autoactivated (Dr. F. Moss personal communication).
Endogenous interaction between y7 and hnRNP A2, hnRNP A3 and 
Pigpen could be identified by co-immunoprecipitation from mouse brain. Thus 
far however, the antibodies for y7, and hnRNP A2 were found to be unsuitable 
for this. It would also be interesting to investigate if y7 and any of the RNPs co- 
localise within the cells. This was attempted for hnRNP A2 and y7 in PC12. 
However, once again the antibodies for hnRNP A2 were unsuitable (hnRNP A2 
was not detectable above background). Antibodies for hnRNP A3 and Pigpen 
have yet to be tested.
It is hypothesised that the C-terminus of y7 is required for the interaction 
with the RNPs and it may be sufficient by itself to form these interactions. Co- 
immunoprecipitation could once again be used. However, the C-terminus of y7 
was found to express poorly in mammalian cells. Using a large amount of 
starting material may overcome this problem. In addition a His-tagged y7 
construct has been generated to express the C-terminus of y7 in a bacterial 
system. This can then be used to attempt to pull down interacting proteins from 
mouse brain. In addition, if purified hnRNP A2, hnRNP A3 and Pigpen can be 
obtained, then direct in vitro interaction between them and the C-terminus of y7 
can be tested.
8.4.6 y7 and RNA editing
It would be interesting to see if Cav2.2 mRNA is edited and, if so, if y7 is 
involved in this process. Traditionally RNA editing has been identified by 
sequencing genomic DNA and comparing the sequence to cDNA. This can be 
a time consuming process. However, improved, quicker methods of identifying 
RNA editing are now being used (310).
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8.4.7 y7 and RNA Trafficking
The interaction of y7 with proteins that have been shown to be involved in 
the trafficking of RNA points towards the intriguing possibility that y7 may also 
be involved in this process. As mentioned above, it would be interesting to 
perform experiments to see if y7 and any of the three RNPs co-localise in cells 
that have been shown to traffic RNA. In addition it would be interesting to see if 
suppression of y7 expression, using RNAi, alters RNA trafficking within these 
cells.
8.4.8. The Effect of y7 on Cav2.2 mRNA
It has been determined that the suppression of Cav2.2 by the co­
expression of y7 takes place at the level of RNA. The reduced amount of 
Cav2.2 mRNA could be due to a reduced level of expression or due to an 
increased rate of degradation. To examine this QPCR could be used to 
determine Cav2.2 mRNA half life of Cav2.2 in the presence and absence of y7.
A decreased half life would suggest that the co-expression of y7 leads to 
destabilisation of Cav2.2 mRNA. This has now been performed by Dr L. Ferron 
in our laboratory with the result that y7 doubles the rate of degradation of 
Cav2.2 mRNA.
As Cav2.2 mRNA has been found to be destabilised by y7 co-expression 
then it would be interesting to see if this effect could be attenuated by the 
further co-expression of one of the RNPs. Additionally, it would be interesting to 
investigate whether expression of any of the RNPs leads to a stabilisation or 
destabilisation of Cav2.2 mRNA. Furthermore, it would be interesting to see if 
there was a difference between Cav2.2 mRNA expressed from a vector and 
endogenously expressed Cav2.2 mRNA in the presence and absence of y7.
In summary there is little evidence that y7 forms part of a VDCC complex. 
However, it does affect Cay2.2 mRNA. Further work examining the relationship 
between y7 and Cav2.2 mRNA will hopefully elucidate y7 physiological roles.
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Appendix
A.1. Materials Used
A.1.1. Chemicals
4',6-diamidino-2-phenylindole (DAPI) Molecular Probes
Agarose Sigma
Amplicillin Sigma
Cholic Acid Sigma
Complete™ protease inhibitor cocktail Roche Diagnostics
dNTPs Invitrogen
EDTA Sigma
Ethidium bromide Sigma
FITC Invitrogen
Igepal Sigma
NaCI Sigma
Phosphate buffered saline (PBS) Sigma
Protein G Agarose Sigma
Sodium dodecyl sulphate (SDS) Sigma
TexasRed-phalloidin Invitrogen
Tris 7-9 Sigma
Triton-X 100 Sigma
Tween Sigma
VectorShield Vector Laboratories
A.1.2. Kits
BCA assay 
Big Dye Kit 
Gel extraction kit 
ECLPIus 
Maxiprep kit 
Miniprep kit 
PCR clean up kit 
RNeasy kit
Pierce
Applied Biosystems
Invitrogen
APB
Invitrogen
Invitrogen
Invitrogen
Qiagen
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SilverExpress Silver Stain Invitrogen
A.1.3. Tissue Culture Reagents
1% non-essential amino acids
Cell Line Nucleofector™ Kit V (Solution V)
Collagen (Type IV) Rat Tail
Dulbecco’s Modified Eagle’s Medium
Fetal bovine serum
FuGENE 6 transfection reagent
Geneporter transfection reagent
Geneticin
Horse Serum
Minimum Essential Medium
Nerve Growth Factor 7S fragment (murine,
natural)
Poly-L-lysine
Roswell Park Memorial Institute 1640 
medium
A.1.4. Equipment
Avant-3100 Sequencer 
DU 800 Spectrophotometer 
iCylcer
LSM 510 Microscope
Nucleofector device
PCR machine
Semi-dry transfer system
TCS SP confocal scanning laser microscope
Typhoon phosphoimager
Invitrogen
Amaxa GmbH
Sigma
Invitrogen
Invitrogen
Roche Diagnostics
Gene Therapy
Systems
Invitrogen
Invitrogen
Invitrogen
Invitrogen
Sigma
Invitrogen
Applied Biosystems 
Beckman Coulter 
BioRad 
Zeiss
Amaxa GmbH
Techne
BioRad
Leica
APB
A. 1.5. Enzymes
Calf Intestinal Alkaline Phosphatase (CIAP) Promega 
EcoRI Invitrogen
Moloney Murine Leukemia Virus Reverse 
Transcriptase (MMLVRT) Promega
Ncol Invitrogen
Pfu Stratgene
Pvul Invitrogen
RNase-free DNase Quigen
T4 ligase Promega
A.1.6. Miscellaneous
Library efficiency DH5a competent cells Invitrogen
iQ SYBR supermix BioRad
QIAshredder columns Qiagen
RNasin Promega
Random hexamer primers Promega
Polyvinylidene fluoride membrane (PVDF) BioRad
Bovine serum albumin (BSA) Sigma
Rainbow markers APB
Sigma high markers Sigma
Sigma low markers Sigma
4-12% Bis-Tris gels Invitrogen
A.1.6. Software
Beacon Designer Premier Biosoft
Chromas Technelysium Pty Ltd
ImageQuant Molecular Dynamics
Omiga Accelrys
Photoshop Adobe
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A.2. Antibodies
Anti^y7 (Loop). Rabbit polyclonal antibody. Raised against the peptide 
YPPAIKYPDHLHIS, which is in the expected extracellular loop of y7. Affinity 
purified against the peptide.
Anti-y7 Tail). Rabbit polyclonal antibody. Raised against the peptide 
VASEYFLEPEINLVTEN, which is in the expected cytoplasmic C-terminal tail of 
y7. Affinity purified against the peptide.
Anti-Cav2.2. Rabbit polyclonal antibody. Raised against the peptide identical 
to residues 846-861 within the ll-lll loop of rabbit brain Cav2.2 which is in the 
expected cytoplasmic ll/lll loop of Cav2.2. Affinity purified against the peptide.
Anti-Kv3.1b. Rabbit polyclonal antibody. Raised against the CKESPVIAKY 
MPTEAVRVT, corresponding to residues 567-585 of rat Kv3.1b. Purchased 
from Alomone labs.
High Affinity Anti-HA (Clone 3F10). Rat monoclonal antibody. Recognizes 
the HA peptide sequence (YPYDVDYA) derived from the hemagglutinin protein 
of human influenza virus. Purchased from Roche Diagnostics.
Anti-HA. Rabbit polyclonal antibody. Recognizes the HA peptide sequence 
(YPYDVDYA) derived from the hemagglutinin protein of human influenza virus. 
Purchased from Sigma.
Anti-Rabbit-HRP. Goat polyclonal antibody raised against rabbit IgG. 
Conjugated to horseradish peroxidase. Purchased from BioRad.
Anti-hnRNP A2/B1 (F16) Goat polyclonal antibody. Raised against a peptide 
mapping within an internal region of hnRNP A2/B1 of human origin. Purchased 
from Autogen Bioclear.
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Anti-hnRNP A/B (H200). Rabbit polyclonal antibody. Raised against amino 
acids 1-200 mapping at the N-terminus of hnRNP A1 of human origin. 
Purchased from Autogen Bioclear.
Anti-PDI (ab2792) Mouse monoclonal antibody. Raised against full length 
native protein (purified from rat). Purchased from Abeam
Anti-Rabbit IgG (Whole Molecule) Biotin Conjugate Goat polyclonal 
antibody. Raised against rabbit IgG. Purchased from Sigma.
Anti-Mouse IgG (Whole Molecule) Biotin Conjugate Goat polyclonal 
antibody. Raised against mouse IgG. Purchased from Sigma.
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A.3. Primers Used
All primers used were purchased from Invitrogen.
A.3.1. Primers Used for the Generation of Constructs
y7(1-238)
Forward 5’-GACGAATTCACCATGAGTCACTGCAG-3 
Reverse 5’-ATAGAATTCCTCAGCGCCACGCCTCGGGCT-3’
y7(i-27i)
Forward 5’-GACGAATT CACCAT GAGT CACT GCAG-3’
Reverse 5’-AGCGAATTCTCAGGAGATGTGCAGGTGGT-3’
y7(201-275)
Forward 5’-ACGAATTCATGACCAAGCGCTACG-3’
Reverse 5’-ACGAATTCAGCAGGGCGAGGTG-3’
y7_CFP
Forward 5’-GACGAATT CACCAT GAGT CACT GCAG-3’
Reverse 5’-ATAGGATCCGAGCAGGGCGAGGTGGAGA-3’
y7_HA
Forward 5’-ATAGGACGGTACCAGCAT GAGT CACT GCAGCA-3’
Reverse 5’-ATAGAATTCAAGCGTAGTCTGGGACGTCGTATGGGTAGC 
AGGGCGAGGT GGAGA-3’
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HA_y7
Forward 5’-TATGGTACCATGTACCCATACGACGTCCCAGACTACGCTAGT 
CACT GCAGCAGCCG-3’
Reverse 5’-TATGAATTCAGCAGGGCGAGGTGG-3’
(201-275) _ H A
Forward 5’-ACGGTACCATGACCAAGCGCTACG-3’
Reverse 5’-ATAGAATTCAAGCGTAGTCTGGGACGTCGTATGGGTAGCAG 
GGCGAGGT GGAGA-3’
y7_STOP
Forward 5’-TACGGTACCAGCAT GAGT CACT GAAGCA-3’
Reverse 5’-TAT GAATT CAGCAGGGCGAGGT GG-3’
y2TM y7Tail
Forward__1 5’-TAT GGTACCAT GGGGCT GTTT GAT CGAG-3’
Reverse_1 5’-GCGTAGCGCTTGGTGATAAACATGTGCAC-3’
Forward_2 5’-GTGCACATGTTTATCACCAAGCGCTACGC-3’
Reverse_2 5’-TAT GAATT CAGCAGGGCGAGGT GG-3’
y7_PDZ
Forward 5 ’-ATAGGACGGTACCAGCAT GAGT CACT GCAGCA-3’
Reverse 5 ’-TAAGTAGAATTCATACGGGGGTGGTGGAGATGTGCAGGT-3’
y7N45A
Forward 5’-AT AGGACGGTACCAGCAT GAGT CACT GCAGCA 
ACCGCAGGCCCAGACCAC-3’
Reverse 5’-GT GGT CT GGGCCT GCGGT -3’
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A.3.2. RT-PCR and QPCR Primers
A.3.2.1. QPCR primers 
C av2 .2 (Q p cR )
Forward 5-GGCAAGAAGGAGGCAGAG-3’ 
Reverse 5’-GCAGAAGCGACGGAGTAG-3’
Annealing temperature used: 53°C
Cay1 -2(qpcr)
Forward 5’-TCGCTCTGCCTCTCCATT-3’ 
Reverse 5’-TTCCACTACCGCCTCCTT-3’
Annealing temperature used: 53°C 
y7(QpcR)
Forward 5’-GAGAGTCTGCTTCTTTGC-3’ 
Reverse 5’-CACCAAGTT GAT CT CT GG-3’
Annealing temperature used: 56.7°C
CHOP
Forward 5’-GAAAGCAGCGCATGAAGG-3’ 
Reverse 5’-CCATTCGGTCAATCAGAGC-3’
Annealing temperature used: 61 °C
XBP edited
Forward 5’-GCCTTGTAGTTGAGAACCAG-3’
Reverse 5-GAGGT GCACGTAGT CT GAG-3’
Annealing temperature used: 56.7°C
XBP unedited
Forward 5’-GTAGTTGAGAACCAGGAG-3’
Reverse 5’-CTGGCCTCACTTCATTC-3’
Annealing temperature used: 61.1°C 
A.3.2.2. RT-PCR primers
(Rat)
Forward 5’-CACTCAGAAGGAGTACAGC-3’
Reverse 5’-CCGAAGGACAGAAAGG-3’
Y2(Rat)
Forward 5’-CACTTTCCCGAAGACG-3’
Reverse 5’-GACCACCCATGAAGAGC-3’
This primer pair was also used for QPCR. Annealing temperature used: 54°C
y4(Rat)
Forward 5’-GTGAGCTGTCCATGTACACG-3’
Reverse 5’-GGAAACCCTCCTTTAGGTCC-3’
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Y6(Rat)
Forward 5’-GAATCTCGGCTTGACTCC-3’ 
Reverse 5’-GAAT CT CGGCTT GACT CC-3’
Y7 (Rat)
Forward 5’-AT GAGT CACT GCAGCAGC-3’ 
Reverse 5’-TCAGCAGGGTGAAGTGGA-3’
Ac tin (Rat)
Forward 5’-ATGGATGACGATATCGCTGC-3’ 
Reverse 5’-CTAGAAGCATTTGCGGTGCA-3’
y7_STOP(RT)
Forward 5’-T GAGT CACT GAAGCA-3’
Reverse 5-AACTGGCCCGAGTAGT-3’
A.3.3. Biotinylated RNA Oligos
A2RE
5’-Biotin-GCCAAGGAGCCAGAGAGCAUG-3’
Cav2.2
5’-Biotin-GCCAAGGAGCGGGAGCGAGUC-3’
Non-specific
5’-Biotin-CAAGCACCGAACCCGCAACUG-3’
A.4. Companies
Accelrys, Cambridge, UK
Adobe, CA, USA
Alomone labs, Jerusalem, Israel
Amaxa GmbH, Koeln, Germany
Amersham Pharmacia Biotech (APB), Little Chalfont, UK
Applied Biosystems, CA, USA
Beckman Coulter, Bucks, UK
BioRad, Hercules, CA, USA
Carl Zeiss Ltd, Harts, UK
Clontech, CA, USA
ECACC, Salisbury, UK
Gene Therapy Systems, San Diego, CA, USA
Invitrogen Carlsbas CA, USA
Leica, Bucks, UK
Molecular Dynamics, Bucks, UK
Pierce, Northumberland, UK
Premier Biosoft, CA, USA
Qbiogene, Harefield, UK
Qiagen, Crawley, UK
Roche Diagnostics, Mannheim, Germany
Sigma, UK
Stratgene La Jolla, CA, USA 
Techne, Staffs, UK
Technelysium Pty Ltd, Tewantin, Australia 
Vector Laboratories, Burlingame, USA
A.4. Additional Experiments
A.4.1 Additional Methods
A.4.1.1. Immunohistochemistry
For detection of y7(Loop) antibody was used. Free-floating brain coronal 
sections (40[jm thick) from adult mice perfused with 4% paraformaldehyde were 
blocked for 1 hour at room temperature with PBS, 0.1% Triton X-100 and 10% 
goat serum. Sections were incubated overnight at 4°C with the affinity purified 
y7 loop antibody (0.8 pg.ml'1), the antibody adsorbed with its peptide (0.8 and 
17.5 pg.ml'1 respectively), or no primary antibody. The secondary antibody 
used was biotin-conjugated goat anti-rabbit followed by streptavidin-Horse 
Radish Peroxidase and reaction with diaminobenzidine for 15 min. Sections 
were mounted on poly-L-lysine-coated slides, dehydrated, cleared and mounted 
in DPX.
A.4.1.2. In situ Hybridization
Adult male mice were killed by cervical dislocation and the brains
removed and frozen on dry ice. Sagittal sections (14 pm thick) were cut with a
cryostat and mounted on poly-L-lysine-coated slides, fixed in 4%
paraformaldehyde for 5 min. at 4°C, washed for 1 min. in PBS, then treated for
5 minutes in 70% ethanol and stored in 90% ethanol at 4°C. An antisense
probe for y7 was prepared from the oligonucleotide 5'-
CGT CACCAAGTT GAT CT CT GGTT CAAGAAAGTACT CAGAAGC CAC-3' by 3'
end labelling with [35S]dATP. A sense probe was also generated from the
complementary sequence. For in situ hybridization, after drying at room
temperature each slide was incubated with 1pl of the radiolabelled probe (~1.5
x 108 d.p.m.) and 2pl of DTT in 100 pi of hybridization solution containing 50%
formamide, 4 x SSC, 25 mM Sodium phosphate (pH 7.0), 1 mM Sodium
pyrophosphate, 5 x Denhardt's solution, 200 mg.ml'1 denatured herring sperm
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DNA, 100 |jg.ml-1 polyadenylic acid and 10% (w/v) dextran sulphate in a humid 
chamber overnight at 42°C. Control slides with adjacent sections were labelled 
with the sense probe. The following day the slides were washed two times in 1 
x SSC at 55°C for 30 minutes followed by a sequence of 0.1 x SSC, 70% and 
95% ethanol at room temperature for 1 minute each. Slides were left to dry at 
room temperature for up to 2 hours and exposed to a X-ray film for about two 
weeks. For examination at higher power, slides were developed by immersion 
in photographic emulsion K5. After development, slides were viewed by dark 
field illumination.
A.4.1.3 Electrophysiology
Xenopus oocytes were prepared, injected and utilized for 
electrophysiology as previously described (311), with the following exceptions. 
Plasmid cDNAs for the different VDCC subunits ai, a28-2, p^ and other 
constructs such as y7 were mixed in equivalent weight ratios at 1 Mg.pi'1, unless 
otherwise stated, and 9 nl injected intranuclearly. The corresponding cRNAs 
were made by mMessage mMachine, diluted to 0.5 jjg.jjl'1, and 60 nl of the 
mixture injected intracytoplasmically.
When used, (~0.25 U in 30 nl) of recombinant RNAsin or its vehicle, was 
injected intracytoplasmically 2 hours before cDNA injection. The recording 
solution for Cay2.2 injected oocytes contained: 5 mM Ba(OH)2; 80 mM TEA-OH 
; 2 mM CsOH ; 5 mM HEPES (pH 7.4 with methanesulfonic acid). The 
Ba(OH)2 concentration was raised isotonically to 10 or 40 mM where stated.
Whole-cell patch-clamp recording using tsA-201 and PC12 cells was 
performed and analyzed as described (238;312), with 1 - 20 mM Ba2+as charge 
carrier and a holding potential of-100mV. Currents were measured 10 ms after 
the onset of the test pulse and the average over a 2 ms period was calculated 
and used for analysis. Xenopus oocyte recordings were performed as 
described (313). The Ba2+ concentration was 5 mM, unless stated. Data are 
expressed as mean ± S.E.M. and l-V plots were fit with a modified Boltzmann 
equation as described (313).
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A.4.1.1. Measurement of mRNA Levels
COS-7 cells were transfected with cDNA encoding y7 alone, y7 with 
Cav2.2 (ratio 1:2), or Cav2.2 alone using GenePorter. Cells were harvested 
after 48 hours. Total RNA was purified using the RNeasy kit. mRNA was then 
purified from 30 pg total RNA using Dynabeads. Samples were denatured, run 
on a 1 % formaldehyde gel and transferred onto positively-charged membranes 
by downward capillary action. RNA was cross-linked onto the membrane using 
UV.
DNA fragments were made using the following primers: Cav2.2, 5’ACT 
TCG TGG TAG TCC TCA and 5'GTC GCT TCT GCT CTT CTT GG; y7, 5’TTC 
TGA AGA CAG TGC GCA CG and 5TCA TTT GGA TGG ACA CGT CG. The 
probes were labelled with psoralen-biotin using the BrightStar labelling kit, 
stored at -80°C and denatured at 90°C for 10 min immediately before use. 
Membranes were prehybridized in UltraHyb buffer at 42°C for 6 h. and then 
hybridized with the biotinylated probe at 50°C overnight. After washing 
membranes in 0.5 x SSC (1 x SSC is 150 mM NaCI, 15 mM Na citrate pH 7 ),
0.1% SDS at 65°C, the BrightStar assay was carried out following kit 
instructions. Bands were detected using autoradiography. Data were analysed 
using ImageQuant after scanning autoradiographs.
For QPCR, plasmid cDNAs for CaV2.2, pib, 0126-2 , Kir2.1-AAA plus y7 or 
blank vector were injected intranuclearly into oocytes in the ratio 6 : 2 : 2 : 1 :3. 
After 72 h, individual oocytes were harvested following electrophysiological 
recording. RT and QPCR were performed as describe in general methods.
The following primers were used:
Cav2.2, 5’CTC TGC GCT TAC TGA GAA TC-3’ and 5’AAC AGG AAG 
AGC AGG AAG AG-3’
Kir2.1-AAA, 5’TGG GTG AGA AGG GAC AGA GGT A and 5’AGG AGA 
GCA CGA AGG CAA GAC-3’
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Pib, 5’CTT AAG GAA GGA GGC AGA GC-3’ and 5’GGA GAC GGA TTG 
TAG CCA AC-3’
18S, 5’TGA CTC AAC ACG GGA AAC CT-3’ and 5’AAT CGC TCC ACC 
AAC TAA GAA C-3’
Data were normalized for expression of 18S ribosomal RNA.
A.4.2. y7 Localisation
A
a— dendrite
Fig. A.I. Localisation o f  y7 mRNA and protein. A) In situ hybridization for 77 
mRNA in a sagittal section of mouse brain, using a 35S-y7 antisense 
oligonucleotide probe (i, iii) and a y7 sense control probe (ii, iv). Expression of 
y7 mRNA is widespread (i), with stronger expression in olfactory bulb (OB), 
cerebellum (Cb) and CA1, CA3 and dentate gyrus (DG) regions of the 
hippocampus. The localisation of y7 mRNA in the cerebellum was examined at 
higher power (iii) and showed strong expression in the Purkinje cell layer (PCL)
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and also in the granule cell layer (GL). Scale bars represent 1mm. B) 
Immunohistochemical localisation for y7 in mouse cerebellum, showing 
presence in individual Purkinje cells (left) and their dendrites (right), using the 
y7(Loop) antibody. Staining was lost with no primary antibody or with antibody 
preabsorbed to immunizing peptide (data not shown). Scale bar represents 50 
pm (left) and 10 pm (right).
A.4.3. Electrophysiological Data for y7 Constructs
A
con
y7 (1 -217)
con
y7 -Stop
y7-N 45 A
| 40 pA 
50 msec
y7 (1-217)
y7 -Stop
* *
y7-N45A
B
-30
-25-
tr  -20-
Q .t  _15'J 
- 1 0 -
-5-
0
gamma7CFP
40 pA
CTRL
50 msec
Fig.A.2. The effect o f  y7constructs on Cay2.2 current expressed in tsA-201 cells. 
A)Upper panel: representative traces of Ba2+ currents induced by co-
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transfection of Cav2.2, p1b and ct25-2with pMT2 as control (con), compared to 
y7 (left), y7(1.2i7) (center left), y7_STOP (center right) and y7(N45A) (right). 
Currents were elicited by depolarisation to +5 mV from a holding potential of -  
100 mV. Calibration bars refer to all traces. Lower panel: mean inhibition of 
Ba2+ currents (expressed as % of control ± S.E.M.) induced by co-expression of 
Cav2.2 with y7 (black bar, n=21), y7(i_2i7) (white bar, n=15), y7_STOP (hatched 
bar, n=28) ory7(N45A) (grey bar, n=10). Statistical significance ** p<0.01 
Student's t test. B) Left. Value of the peak of barium current recorded at 0 mV 
for Cav2.2 (white bar n=10) and for Cav2.2 + y7 (grey n=12). Right: 
Representative traces of Ba2+ currents induced by co-transfection of Cav2.2, 
p1b and a25-2with pMT2 as control (CTRL), compared to y7_CFP.
A.4.4. Electrophysiological Data for PC12 Cells
20 -i
A
U . - 2 0 -  
Q .% -40- - 1 5 -
- 2 0 -
-60-
- 2 5 -
-80- mV - 3 0 -
20-20 0 40 6040-40 -20 0 20
mV
control* Y7 0  control* Y7  □
Fig.A.3. Effect o f  fJ  expression on endogenous and transient transfection induced 
N-type calcium current in PC12 cells. A) l-V relationship of N-type Ba2+ currents 
induced by transfection of Cav2.2 cDNA (control, ■, n=44) or Cav2.2 plus y7(y7, 
o, n=21).into undifferentiated PC12 cells. B) l-V relationship of endogenous N- 
type Ba2+ currents in differentiated PC12 cells, (control, ■, n = 18) ory7(y7,n, n = 
12)
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A.4.5. Suppression of Cav2.2 Expression by y7 Takes Place at the RNA 
Level
A Cav2 . 2  -  +
y7 + +
Cav2.2 —|
y7 —|
+
+
+
+
— 1— 1
(5) (3)
l— f — I
Probe: Cav2.2 y7
B
C  CO 
O 00 
CO (/> 1- Q) O
cu N
S i
03
O
120 
'  100 
80 
60 
40 
20 
0
Cav2.2
y?
(14)
QPCR
* *
(16)
f
+
+
/V « . A. 4. E ffect o f y7 on Cav2.2 mRNA levA: Northern blots were prepared
using mRNA isolated from COS-7 cells expressing y7 alone (left), y7 plus' \
Cav2.2 (middle) or Cav2.2 alone (right) and hybridized with a biotinylated probe
against the l-ll loop of Cav2.2 (top). The blot was stripped and re-probed for 77
■
(bottom). Right, histogram showing data analysed using ImageQuant. Amount 
of Cav2.2 (open bar) or y7 (grey bar) is shown as a percentage of control, either 
Cav2.2 or y7 alone. Numbers of separate experiments are given in 
parentheses. ** p< 0.01 B: Cav2.2, p1b, a28-2were expressed in oocytes in the 
absence (open bar) or presence (grey bar) of y7. QPCR was used to detect
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Cav2.2 in individual oocytes. Numbers of samples are given in parentheses. **
p<0.01.
control + v7
0.5 uA
25 ms
0 .0 - ■ control
- 0 . 1 -
(0co
-0.3-
-0.4-
-40 -20 0 20 40
C a ^ 2 /y 7 }
"^ RNAsin
C a £ 2 /y 7 J
mV
control o
C  25
control RNAsin
Fig. A.5. Lack of effect o f y7 on Cay2.2 expressed from mRNA. A) Cav2.2 was 
expressed from cytoplasmic injection of mRNA, following y7, p1b and a 28-2 
intranuclear injection of cDNA. The peak lBa is shown in 10 mM Ba2+, relative to 
control for n= 17 control cells, and n= 29 in the presence of 7 7 . B) Example 
currents from -30 to +30 mV for the two conditions shown in B. C) Cav2.2, pi b, 
a 28-2 and y7 were all injected as mRNA. The current-voltage relationship is 
shown for n= 38 controls (■) and n = 35 (o) in the additional presence of y7.
Data are fit by a modified Boltzmann function, with V5o,act of -3.6 and -2.3 mV 
respectively and Gmax of 9.8 and 8.2 pS, respectively. D) Current-voltage 
relationship for cells injected into the cytoplasm with either RNAsin (•, o) or its 
vehicle (■, □) prior to intranuclear cDNA injection of Cav2.2 / p1b/cc2S-2 (•, ■,
n=50, 25) or Cav2.2 / p1b /a28-2 /y7 (o, □, n =40, 26). Data are fit by a modified 
Boltzmann function, with Vso.act of -10.2 (•), -8.9 (■), -6.3 (o) and -1.6 (□) mV, 
respectively and Gmax of 33.3 (•), 38.3 (■), 30.1 (o) and 8.9 (□) pS, respectively. 
E) Percentage inhibition by y7 of lea at 0 mV in the presence of either vehicle or 
RNAsin. ** p< 0.01.
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